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The pituitary gonadotrophin releasing hormone (GnRH) receptor regulates
reproduction by activation of Gq/11 proteins. In contrast, GnRH receptors at
extrapituitary sites induce anti-proliferative effects that do not correlate with Gq/11
activation. We propose that the two endogenous ligands, GnRH I and GnRH II, and
certain antagonists selectively activate distinct signalling pathways by stabilisation of
distinct active conformations of the GnRH receptor, a concept termed ligand-induced
selective signalling (LiSS). This dissertation has investigated LiSS at the GnRH
receptor using several approaches.
The sequences of GnRH I and II differ in positions 5, 7 and 8. I investigated the
interaction of position 5 of GnRH I and GnRH II with Tyr6.58 of the receptor.
Compared with the Leu and Ala mutants, the Tyr6.58Phe mutant had higher affinity for
native GnRHs, but not Ala5-substituted GnRHs, suggesting that Tyr5 of GnRH I and
His5 of GnRH II interact with Tyr6.58 by aromatic interactions. Our molecular models
show that GnRHs interact with distinct rotamer conformations of Tyr6.58. This is
supported by the Tyr6.58Leu receptor, which makes compensatory interactions that
improve binding affinity and receptor activation for GnRH II, but not GnRH I,
compared with the Tyr6.58Ala receptor. Together these results suggest that GnRHs
stabilise distinct receptor active conformations.
To identify the most proximal signalling proteins that mediate GnRH receptor-
dependent anti-proliferative effects, I established a range of [35S]GTPS binding
assays. I confirmed that the GnRH receptor activates Gq/11, but in contrast to previous
proposals, my results show that the GnRH receptor cannot directly activate Gi. I
subsequently identified a novel GnRH receptor signalling partner, the SH2 domain-
containing phosphatase 2 (SHP-2). I propose that SHP-2 mediates the anti-
proliferative effects of the receptor. I show that the SHP-2 pathway is activated
independently of Gq/11 and suggest that signalling occurs by a direct interaction of
SHP-2 and src with the GnRH receptor. Furthermore, this pathway is activated by a
classical Gq/11 antagonist or by Gq/11-uncoupled GnRH receptor mutants.
My results provide convincing evidence supporting LiSS at the GnRH receptor and
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1.1 Physiological and therapeutic roles of GnRHs and GnRH analogues
The GnRH receptor plays a central role in the regulation of mammalian reproduction
(Cheng and Leung, 2005; Millar et al., 2004). Its ligand, GnRH I, is produced by
proteolytic cleavage of a precursor polypeptide in the hypothalamus and is released in a
pulsatile manner into the hypophyseal portal blood stream. This facilitates transport of
the decapeptide to GnRH receptors expressed on gonadotrope cells in the anterior
pituitary, initiating GnRH receptor activation (Cheng and Leung, 2005; Millar et al.,
2004). GnRH receptor activation mediates the biosynthesis and secretion of luteinising
hormone (LH) and follicle-stimulating hormone (FSH) which subsequently regulate
steroidogenesis and gametogenesis at the gonads (Cheng and Leung, 2005; Millar et al.,
2004).
Consistent with this role, mutations of the human GnRH receptor are associated with
hypogonadotrophic hypogonadism (HH), a disease characterised by absent or
incomplete pubertal development and infertility (Karges et al., 2003). In the case of
partial loss-of-function mutations, administration of high pulsatile doses of exogenous
GnRH analogues can be used to alleviate this condition (Karges et al., 2003). GnRH
agonists and antagonists are also used in the treatment of disorders initiated and/or
exacerbated by sex steroids, including precocious puberty, endometriosis, fibroids and
sex steroid-dependent cancers of the breast, ovary, prostate and endometrium (Casper,
1991; Maria Comaru-Schally and Schally, 1997). The therapeutic effect of GnRH
analogues on these sex steroid-dependent disorders is the indirect result of
downregulation (agonists) or competitive inhibition (antagonists) of the GnRH receptor
and its signalling, which thereby inhibits the downstream release of sex steroids from the
gonads (Casper, 1991; Herbst, 2003).
In addition to GnRH I, there is a second endogenous ligand for the GnRH receptor in
humans, GnRH II. GnRH I is the decapeptide, pGlu1-His2-Trp3-Ser4-Tyr5-Gly6-Leu7-
Arg8-Pro9-Gly10.NH2 whereas GnRH II differs by three amino acids and has the
substitutions His5, Trp7 and Tyr8. Interestingly, GnRH II exhibits 100% conservation
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but as yet elusive, function (Pawson et al., 2003). In some mammalian species, a second
receptor, the type II GnRH receptor, is proposed to mediate the signalling of this ligand
(Millar, 2003). However, in humans, a frame-shift mutation results in the generation of a
premature stop codon in the putative type II receptor transcript, preventing expression of
a full length type II receptor (Faurholm et al., 2001). Nevertheless, the human type I
receptor binds both GnRH I and GnRH II with high affinity. Thus the type I receptor is
proposed to mediate the physiological effects of both ligands in humans (Millar, 2003;
Pawson and McNeilly, 2005).
GnRH I and GnRH II exhibit distinct and overlapping expression profiles in diverse
tissues (Cheng and Leung, 2005; Hapgood et al., 2005). As discussed, GnRH I is
essential in the control of the hypothalamic-pituitary-gonadal axis. In contrast, GnRH II
is suggested to play a role in the regulation of sexual behaviour in some mammalian
species (Barnett et al., 2006; Kauffman and Rissman, 2004; Kauffman et al., 2005).
Nevertheless, GnRHs have been implicated in the regulation of a number of other
functions within the neuronal, immune and reproductive systems in both physiological
and pathophysiological settings (summarised in Table 1.1). For example, GnRHs are
suggested to play a role in immune cell development and neuronal migration, in addition
to effects on other aspects of reproduction, such as enhancing fertilisation and
implantation. In the pathophysiological context, GnRH analogues have been shown to
directly inhibit the proliferation of reproductive cancers, independently of the sex steroid
dependence of the cancer. Many of these above-mentioned functions have been
suggested by ex vivo data following administration of exogenous GnRHs and the
physiological relevance and differential effects of the two peptides require further
investigation.
The functional diversity and widespread expression of the GnRH receptor and its ligands
highlight some important features of this receptor. Firstly, this single receptor, not only
binds to, but is also required to transduce signalling to distinct pathways activated by the
two structurally distinct ligands, GnRH I and GnRH II. Secondly, the pharmacological
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pituitary (Table 1.1 and the references therein). An understanding of the molecular
functioning of the GnRH receptor is paramount to address the mechanism whereby this
receptor achieves this intricate feat. Here, I review the current understanding of GnRH
receptor ligand binding, receptor activation and downstream signalling within the
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Table 1.1. Established and putative roles of the GnRH receptor in mammals









Control of LH and FSH
biosynthesis and release
Gq/11, Gs, PKA, PKC, MAPK activation
and calcium release
GnRH I (Cheng and Leung, 2005;
Pawson and McNeilly,
2005; Rispoli and Nett,
2005)
Ovary Effects on steroidogenesis,
luteinisation, luteolysis and
atresia
Induction of apoptosis and upregulated
expression of plasminogen activator,
MMP-2, membrane type I MMP and
prostaglandin endoperoxide synthase II
GnRH I and
GnRH II










(Cheng and Leung, 2005;
Chou et al., 2003a; Chou
et al., 2003b; Chou et al.,
2003c; Chou et al., 2002)





(Rama and Rao, 2001)
Sperm Enhanced sperm-oocyte
interactions/fertilisation
NIS GnRH I (Morales, 1998)
Brain Regulation of sexual behaviour NIS GnRH II (not
GnRH I)
(Barnett et al., 2006;
Kauffman and Rissman,
2004; Kauffman et al.,
2005)





NIS GnRH I (Tanriverdi et al., 2003)
Immune cells Stimulation of immune
response
Increased IL2R and IFN-expression GnRH I (Tanriverdi et al., 2003)
Immune cells (T cells) Adhesion, chemotaxis and
homing of T cells
Upregulated expression of the laminin




(Chen et al., 2002)
Brain (neuronal cells) Migration and differentiation Gi activation and actin remodelling





(Navratil et al., 2007;
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Signalling involved * GnRH I
/GnRH II
Reference(s)





(Chen et al., 2005; Huang
et al., 2001)
Melanoma cells Inhibition of proliferation NIS GnRH I
analogue
(Zoladex)
(Moretti et al., 2002)
Reproductive and
cancerous tissues of the
breast, ovary, prostate,
endometrium and uterus
Inhibition of proliferation and
induction of apoptosis‡
Gi, PTP and SAPK activation. Inhibition
of RTK signalling (EGF and IGF-I
receptors). Various gene transcription
profiles altered (eg. c-fos). Inhibition of







2003; Kraus et al., 2006;
Limonta et al., 2003)
NIS- no information supplied specific for signalling.
* key, rather than comprehensive, signalling represented here.
† precise signalling here is cell-context dependent.
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1.2 Introduction to GPCRs and G proteins
The GnRH receptor is a member of the GPCR superfamily. GPCRs are cell surface
proteins that recognise a vast array of extracellular signals ranging from photons, ions,
nucleotides, lipids and biogenic amines, to peptides and larger proteins (Schlyer and
Horuk, 2006). They thus regulate a multitude of physiological functions and are
important therapeutic intervention points for numerous illnesses. Indeed, over 30% of all
current drugs in clinical use target GPCRs (Jacoby et al., 2006; Schlyer and Horuk,
2006). In this section, an overview of GPCR structure, signalling and trafficking is
provided.
1.2.1 Outline of GPCR structure, classification and numbering system
Despite the ability of GPCRs to bind structurally diverse ligands, these proteins are
thought to share a common structural architecture. This conserved topology consists of
seven transmembrane (7TM) domains linked by three extracellular (ECL) and three
intracellular (ICL) loops. Furthermore, an extr cellular N-terminal and an intracellular
C-terminal domain are present (Fig.1.1).
Analysis of amino acid sequence homology and conserved structural characteristics has
allowed classification of GPCRs into 5 main families, the rhodopsin, glutamate,
adhesion, frizzled/taste and secretin families (Fredriksson et al., 2003). The rhodopsin
family of GPCRs is the largest and the GnRH receptor falls within this category. The
conserved structural characteristics of this family are discussed in more detail in section
1.3.
Based on the highly conserved residues within this family, a numbering system for
identification of a specific residue within the GPCR structure has been devised. This
system, the Ballesteros and Weinstein numbering system, assigns the most highly
conserved residue in each TM domain the arbitrary number of 50, in addition to the TM
number (Ballesteros and Weinstein, 1995). For example, the most conserved residue in
TM6 is a proline residue and is referred to as Pro6.50. The positions of other amino acids
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relative to this pivotal residue within the TM domain. This numbering system will be
used in this review.
1.2.2 GPCR synthesis and trafficking
The predominant pathway for GPCR synthesis and trafficking in the cell involves the
following cycle (Ferguson, 2001; Marchese et al., 2003; Moore et al., 2007; Reiter and
Lefkowitz, 2006; Tan et al., 2004), which is summarised in Fig.1.2. GPCRs are
synthesised, folded and assembled in the endoplasmic reticulum (ER) of the cell
(Duvernay et al., 2005). Thereafter, they undergo additional post-translational
modifications (such as glycosylation) as they migrate from the ER, through the golgi, to
the plasma membrane, where the mature GPCR is finally delivered (Duvernay et al.,
2005). There are a number of factors that modulate the GPCR export process. These
may include receptor dimerisation and interactions with other proteins, including ER
chaperones and accessory proteins, which assist in receptor folding or alter receptor
conformation thereby aiding or altering receptor trafficking to the plasma membrane
(Duvernay et al., 2005; Tan et al., 2004). Defects in this pathway, resulting from GPCR
mutations which prevent their correct folding and export from the ER, cause a number of
diseases, such as retinitis pigmentosa, diabetes insipidus and HH (Tan et al., 2004;
Ulloa-Aguirre et al., 2004). In the case of GnRH receptor mutations causing HH, cell-
permeable non-peptide antagonists (such as IN3) have been shown to rescue expression
by acting as a pharmacological chaperone to assist the folding, assembly and routing of
the mutant receptor (Ulloa-Aguirre et al., 2004). Once rescued, many of these receptors
are able to bind GnRH analogues and evoke cell signalling at levels comparable with the
wildtype receptor suggesting that the major defect of these mutations results from
impaired trafficking of the receptor to the membrane (Ulloa-Aguirre et al., 2004).
At the plasma membrane, the GPCR is correctly positioned for interaction with its
ligand at the extracellular surface as well as with GTP-binding (G) proteins and
additional interacting proteins at the intracellular surface. Agonist interaction with the
receptor induces a conformational change in receptor structure which facilitates
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facilitates the sequential binding of G protein-coupled receptor kinases (GRKs) and -
arrestins which initiate rapid desensitisation of GPCRs (Moore et al., 2007; Reiter and
Lefkowitz, 2006). GRKs bind to the receptor first and phosphorylate serine and
threonine residues within ICL3 and the C-terminal tail of the receptor (Moore et al.,
2007; Reiter and Lefkowitz, 2006). -arrestins are subsequently recruited and bind to the
phosphorylated GPCR sterically uncoupling the receptor from G protein interaction and
activation (Moore et al., 2007; Reiter and Lefkowitz, 2006). Arrestin binding also
facilitates interaction of the receptor with the internalisation machinery of the cell which
enables internalisation of the GPCR via clathrin-coated pits (CCPs) and can initiate a
second wave of GPCR-mediated signalling (Marchese et al., 2003; Moore et al., 2007;
Reiter and Lefkowitz, 2006; von Zastrow, 2003). Internalised GPCRs are subsequently
sorted via a recycling pathway back to the plasma membrane or trafficked to lysosomes
where the receptor is degraded (Marchese et al., 2003; Moore et al., 2007; von Zastrow,
2003).
1.2.3 Overview of GPCR signalling
As their name suggests, a central element of GPCR signalling involves activation of
heterotrimeric G proteins, which consist of a heterotrimeric complex of G, Gand G
subunits (Cabrera-Vera et al., 2003; McCudden et al., 2005). Gand Ghave lipid
modifications that anchor the heterotrimer to the plasma membrane facilitating their
interactions with GPCRs (Cabrera-Vera et al., 2003; Wedegaertner et al., 1995).
Receptor-mediated G protein activation involves the following sequence of events
(summarised in Fig.1.3). In the inactive state, the Gsubunit of the heterotrimeric
complex is bound to a GDP molecule. Upon agonist activation, GPCRs undergo
conformational changes that, in turn, induce conformational alterations in the G
subunit, promoting the release of GDP and its subsequent association with GTP
(Birnbaumer, 2007; Cabrera-Vera et al., 2003; McCudden et al., 2005). In the traditional
model of G protein activation, the G subunit dissociates from G, freeing both
functional units for regulation of various intracellular effectors (McCudden et al., 2005;
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absolutely required for activation of the G protein. Thus a second model (the
“clamshel” model) exists where G protein activation involves rearrangement, rather
than dissociation, of the G protein subunits facilitating exposure of domains necessary
for effector activation (Bunemann et al., 2003; Robishaw and Berlot, 2004). G protein
inactivation results from the intrinsic GTPase activity of the G subunit, which
promotes the hydrolysis of GTP to GDP. This facilitates the termination of Gand G
signalling, either by their reassociation or by conformational changes that obscure
effector interaction sites on the heterotrimeric protein (Cabrera-Vera et al., 2003;
Robishaw and Berlot, 2004).
In addition to its intrinsic GTPase activity, G protein signalling is regulated by a number
of factors (Birnbaumer, 2007). Firstly, interaction with effectors enhances the GTPase
activity of the G protein. Furthermore, a dedicated family of proteins, the regulators of G
protein signalling (RGS) proteins, have been identified. These proteins have been shown
to augment the kinetics of activation and deactivation of G proteins (Birnbaumer, 2007;
McCudden et al., 2005). Finally, covalent modifications of G proteins (including
acylation or phosphorylation) alter the signalling capacity of G proteins (Chen and
Manning, 2001).
Currently, 16 different G, 5 Gand 12 Ggenes have been identified in humans
(Cabrera-Vera et al., 2003; McCudden et al., 2005). Furthermore, G proteins can be
divided into four major classes based on the sequence homology of the Gsubunit,
namely Gs, Gi/o, Gq/11 and G12/13 (Cabrera-Vera et al., 2003; McCudden et al., 2005). The
Gand Gfunctional signalling units interact with a number of different intracellular
effectors (summarised in Table 1.2 and 1.3 respectively) (Birnbaumer, 2007; Cabrera-
Vera et al., 2003).
GPCRs and G proteins are not exclusive partners. G proteins can be activated by other
non-GPCR proteins. Emerging evidence suggests that another family of receptors, the
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2004; Shan et al., 2006b). Furthermore, non-receptor activators of G protein
signalling/AGS proteins can activate G proteins independently of receptors (Cabrera-
Vera et al., 2003; Cismowski, 2006; McCudden et al., 2005). Conversely, GPCRs do not
only interact with and activate G proteins. Emerging evidence has revealed that GPCRs
can activate a number of heterotrimeric G protein-independent signalling pathways
(Brady and Limbird, 2002; Hall and Lefkowitz, 2002). For example, GPCRs have been
shown to regulate monomeric G proteins (Bhattacharya et al., 2004). GPCRs also enter
protein tyrosine phosphorylation cascades independently of heterotrimeric G proteins by
direct interaction with Janus kinases (JAKs) (Ali et al., 2000), src family kinases (Cao et
al., 2000) and RTKs (Pyne et al., 2003). Additionally, GPCR binding of GRKs, -
arrestins and several other scaffolding proteins can initiate downstream signalling (Hall
and Lefkowitz, 2002). Thus these heterotrimeric G protein-independent signalling events
increase the diverse signalling capacity of GPCRs.
1.2.4 Summary
GPCRs share a common overall structure, pathways of trafficking in the cell and
mechanisms of signalling. In the following sections, our current understanding regarding
GnRH receptor structure and signalling will be discussed. However, where necessary,
information from pioneering studies with other rhodopsin family GPCRs, such as the
prototypical rhodopsin and 2-adrenergic receptors, will be used to understand and
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Figure 1.1. Overall topology of the GPCR superfamily. Members of the GPCR superfamily have a
conserved structure consisting of seven transmembrane (7TM)-spanning regions linked by three
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Figure 1.2. GPCR biosynthesis (A) and trafficking (B). A, GPCRs are synthesised, folded and
assembled in the ER. They undergo post-translational modifications while migrating through the ER and
the golgi and the resulting mature GPCR is delivered to the plasma membrane. Incorrectly folded GPCRs
are retained in the ER, but cell-permeable small molecule antagonists (pharmacoperones) can be used to
rescue expression by serving as a template to enable correct folding and routing of the receptor. Figure
adapted from Conn et al. (Conn et al., 2007). B, Agonist-induced receptor activation facilitates G protein
activation and signalling (1). The receptor is then phosphorylated by GRKs creating docking sites for
arrestins (2). Arrestin binding enables receptor internalisation by clathrin-coated pits (CCPs) and can
initiate a second wave of signalling (3-4). Internalised GPCRs are sorted for degradation or recycling to
the plasma membrane (4-5). Figure adapted from Moore et al. (Moore et al., 2007).
A
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Figure 1.3. The G protein activation cycle. In the inactive state, the Gsubunit of the G protein is
bound to a GDP molecule and is associated with the Gsubunits. Agonist-induced GPCR activation or
constitutive GPCR activity induces a conformational change in the G protein which results in the release
of the GDP molecule and the uptake of GTP. This facilitates dissociation of the Gsubunit from G
enabling interaction with and activation of their respective effector molecules. The intrinsic GTPase
activity of the Gsubunit facilitates GTP hydrolysis to GDP, inactivation of the G protein and thus
reassociation of the heterotrimeric G protein complex. Recent evidence suggests that G protein activation
may not necessarily require dissociation of the G and Gsubunits, but may instead involve
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Table 1.2. Effectors of the Gsubunits of the heterotrimeric G proteins.





Gi Gi (Gi1, Gi2, Gi3) AC






Go, Gi2 Ca2+ channels
Gi/o Rap1 GAP degradation
Gt (Gt1, Gt2) cGMP-PDE
Gi, Go, Gz Bind GRIN 1 and 2
Gg Unknown
Gq Gq, G11, G14, G15, G16 PLCs
Gq Btk







Adapted from information in previous reviews (Albert and Robillard, 2002; Birnbaumer, 2007; Cabrera-
Vera et al., 2003). † Gs and Go each have two splice variants, Gs(S) and Gs(L) and GoA and GoB
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AC II, IV and VII
K+ channels (including GIRK1, 2, 4)
Ca2+ channels
Binds and activates GRKs
PI3K





Dynamin I GTPase activity
Gacts as a scaffold for Shc and Shc MAPK complex
Raf-1 protein kinase sequesters G
Ras exchange factor
Gsequesters KSR-1
transcription of the Glucocorticoid receptor in the nucleus
Table is adapted from previous reviews (Birnbaumer, 2007; Cabrera-Vera et al., 2003).
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1.3 GnRH receptor structure
Knowledge of a GPCR’sstructure is useful in understanding the mechanisms of ligand
binding and receptor activation. This information can be used to refine computational
models of the receptor, allowing the user to dock ligands to experimentally-identified
ligand binding sites and thereby predict novel receptor sites where additional ligand-
receptor interactions may occur. Computational models are also useful in ligand design
and can facilitate identification of lead compounds for high throughput drug screening
assays (Fanelli and De Benedetti, 2005).
GPCRs are thought to share a similar three-dimensional structure consisting of a bundle
of 7 transmembrane spanning-alpha helices orientated roughly perpendicular to the
plasma membrane (Filipek et al., 2003b; Yeagle and Albert, 2007), connected by 3 ICLs
and 3 ECLs and with an N- and C-terminal domain. The proposal that GPCRs share a
common structural architecture, particularly in the TM domains, is based on the
conservation of key structurally relevant sequences within the rhodopsin family GPCRs
(despite the low overall sequence homology) and the common requirement of these
receptors to interact with and activate a small subset of highly homologous G proteins
(Baldwin, 1993; Ballesteros et al., 2001b; Mirzadegan et al., 2003). This proposal has
facilitated the creation of successful computational models of GPCRs, as discussed
below.
Previously, the relative orientation of residues within the 7TM bundle of GPCRs was
determined by sequence analysis of the size, hydrophobicity and global sequence
conservation of residues within the helices of GPCRs (Baldwin, 1993; Ballesteros and
Weinstein, 1995). Specifically, residues that are hydrophobic, but not restricted in size
and exhibit low sequence conservation were predicted to face outwards towards the lipid
bilayer (Baldwin, 1993; Ballesteros and Weinstein, 1995). Conversely, conserved and/or
hydrophilic residues, which exhibit size restrictions, were predicted to face into the TM
bundle and participate in interhelical interactions (Baldwin, 1993; Ballesteros and
Weinstein, 1995). Models of GPCR structure built ab initio using these principles,










Chapter 1: Literature Review
18
biophysical experiments, were essentially consistent with the crystal structure of
rhodopsin that emerged subsequently (Ballesteros et al., 2001b; Fanelli and De
Benedetti, 2005; Yeagle and Albert, 2007). The elucidation of the crystal structure of
rhodopsin provided the first direct structural information regarding the inactive state of a
GPCR (Li et al., 2004; Okada et al., 2004; Palczewski et al., 2000). The fact that it was
consistent with the previous predictions supported the premise upon which these data
were based; specifically that rhodopsin family GPCRs have a similar overall structure.
Thus the high resolution structural data obtained from the crystal structure of the
rhodopsin provides the best information to date to accurately model the 7TM domains of
other GPCRs in the family (Fanelli and De Benedetti, 2005).
Due to the difficulty of crystallisation, molecular models of the GnRH receptor have
been built by homology modelling based on the crystal structure of rhodopsin (Betz et
al., 2006; Lu et al., 2007; Lu et al., 2005; Soderhall et al., 2005). These models provide
useful information regarding proposed inter- and intramolecular interactions, which can
then be tested by mutagenesis. The mutagenesis results can then be used to refine the
model. In this section, information regarding the crystal structure of rhodopsin is
presented and compared with the primary sequence and experimental data specific to the
GnRH receptor. An annotated sequence alignment of rhodopsin and the GnRH receptor
is presented in Figure 1.4.
1.3.1 The 7TM region
The crystal structure of rhodopsin reveals that the 7TM helices are arranged in an anti-
clockwise direction, when viewed from the extracellular surface (see Fig. 1.5). While
they are orientated roughly perpendicular to the membrane, many of the helices are
tilted, appearing to bend or lean over the neighbouring helix. A number of residues, such
as prolines, disrupt the regularity of the helices, inducing kinks within the TM segments
(see Fig 1.5). These structural kinks and irregularities change the trajectory of the TM
helices, creating a flask-like-shaped structure from a protein that would otherwise have
resembled a barrel. The advantages of this structure are inherent in its function as it
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binding, an intracellular region for interaction with intracellular effectors and a mid-
region which provides a means of transduction between the two (Madabushi et al.,
2004). Furthermore, this conformation facilitates a number of important interhelical
interactions. For example, TM3, while not significantly kinked, is tilted from the
membrane normal by ~30o. It thus changes its position within the 7TM bundle by
traversing from its inception point between TM2 and TM4 at the extracellular surface of
the molecule to its termination point at the intracellular surface in close proximity to
TM5. This facilitates intramolecular interactions between TM3 and five other helices
(TM2, TM4, TM5, TM6 and TM7), suggesting an important directive role for this helix
in receptor activation (Filipek et al., 2003a).
Sequence alignments of the TM domains of rhodopsin and the GnRH receptor (and
indeed other rhodopsin family GPCRs) reveal relatively low homology (see Fig.1.4).
However, it is suggested that rhodopsin family GPCRs can, in fact, adopt a similar
structure to rhodopsin, despite this low over ll sequence identity, by a mechanism
known as structural mimicry (Ballesteros et al., 2001b). The basis for this phenomenon
is that structural features induced by a particular residue(s) can be recreated by another
set of structurally distinct amino acids allowing the receptor to diverge sufficiently to
achieve ligand and signalling selectivity while retaining a conserved and efficient
functionally-relevant fold for G protein activation. An example of this can be observed
in rhodopsin where a kink in TM2, usually associated with the presence of a proline
residue, is induced by a set of two glycine and two threonine residues (Palczewski et al.,
2000). Analysis of the sequence alignment of rhodopsin and the GnRH receptor in TM2
reveals a proline residue in the GnRH receptor in an analogous position to this Gly-Gly-
X-Thr-Thr motif in rhodopsin, thus indicating that this proline may induce a similar kink
in TM2 of the GnRH receptor. The GnRH receptor also possesses the highly conserved
proline residues within its sequence, notably Pro5.50, Pro6.50 and Pro7.50.
Despite their relatively low sequence homology, the TM domains are the most highly
conserved region amongst GPCRs, unlike the extra- and intracellular domains which are
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homology (Mirzadegan et al., 2003). These are Asn1.50; Leu2.46; Asp/Asn2.50; Cys3.25;
Glu/Asp3.49; Arg3.50; Trp4.50; Phe6.44; Trp/Phe6.48; Pro6.50, Pro7.50 and Tyr7.53 (Fanelli and
De Benedetti, 2005; Mirzadegan et al., 2003). Conceivably, some of these residues
participate in key structural motifs that direct the overall receptor fold, such as the
proline residues (which were discussed above) as well as Cys3.25 which forms part of a
highly conserved disulfide bridge (see section 1.3.2). The other residues have been
identified as playing a role in creation of important intramolecular and interhelical
interactions, identified by mutagenesis studies in many rhodopsin family GPCRs as well
as in the crystal structure of rhodopsin (Filipek et al., 2003a; Lu et al., 2002). The
presence of these highly conserved residues, which direct receptor structure by
facilitating key interhelical interactions, provides further support for the similar overall
configuration of rhodopsin family GPCRs. Notably, Glu/Asp3.49 and Arg3.50 form part of
the E/DRY motif and the Pro7.50 and Tyr7.53 residues form part of the D/NPxxY motif.
These highly conserved motifs are hallmarks of the rhodopsin family GPCRs and play
key roles in receptor activation and will be revisited in more detail in section 1.4.
In the crystal structure of rhodopsin, one set of interactions observed in this inactive
state involves a hydrogen bonding network between residues Asn1.50, Asp2.50 and Asn7.49.
The Asp2.50 and Asn7.49 interact via a water molecule (Li et al., 2004; Okada et al., 2004;
Palczewski, 2006). Interestingly, this interaction was predicted prior to the crystal
structure, following the observation that these highly conserved residues are reciprocally
mutated in the G RH receptor (Zhou et al., 1994). In other words, in the GnRH receptor,
position 2.50 is an Asn while position 7.49 is occupied by an Asp. Further
experimentation involving site-directed mutagenesis of the GnRH receptor revealed that
when Asn2.50 was mutated to an Asp in the GnRH receptor, receptor expression was
abolished suggesting disruption of an important stabilising intramolecular interaction
(Flanagan et al., 1999; Zhou et al., 1994). Consistent with this, when both Asn2.50 and
Asp7.49 were reciprocally mutated recreating the configuration in other GPCRs, GnRH
receptor expression and high affinity agonist and antagonist binding were recovered
(Flanagan et al., 1999; Zhou et al., 1994). This provides support for the proposal that an
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compared with rhodopsin. This has enabled successful implementation of homology
modelling of the 7TM domains of the GnRH receptor, based on the crystal structure of
rhodopsin (Betz et al., 2006; Lu et al., 2007; Lu et al., 2005; Soderhall et al., 2005).
1.3.2 The extracellular domains
Sequence alignment of rhodopsin and the GnRH receptor’s extracellular domain
(consisting of the N-terminus and ECL1, ECL2 and ECL3) reveal that they are highly
divergent (Fig.1.4). Indeed, this domain is the most dissimilar region within rhodopsin
family GPCRs, reflecting the requirement of these proteins to interact with a range of
structurally distinct ligands (Mirzadegan et al., 2003). In rhodopsin, the extracellular
domain forms a compact structure (Li et al., 2004; Okada et al., 2004; Palczewski et al.,
2000). ECL1 and ECL3 form short loops and the ECL2 and N-terminal domains form a
layered roof of two -hairpins (composed of 4 -sheets) arranged over the centre of the
7TM helical bundle (see Fig.1.5). ECL2 forms the innermost -hairpin and rests within
the transmembrane helices. It has often been referred to as a plug/lid and has been
suggested to play a role in preventing rapid dissociation of rhodopsin’s ligand (Filipek et
al., 2003a; Palczewski, 2006; Sakmar, 2002). Experiments by Sakmar and colleagues
suggest a major role of ECL2 in rhodopsin in the regulation of receptor activation
(Sakmar, 2002). Consistent with the latter role, site-directed mutagenesis of two residues
in ECL2 of the GnRH receptor were able to convert an antagonist to an agonist, as
measured by inositol phosphate (IP) signalling, suggesting that this region may play a
similar role in the GnRH receptor (Ott et al., 2002). In rhodopsin, the -hairpin of ECL2
is stabilised by a disulfide bridge linking ECL2 to the top of TM3 (Palczewski, 2006;
Sakmar, 2002). This disulfide bridge is highly conserved amongst rhodopsin family
GPCRs (Mirzadegan et al., 2003) and is also observed in the GnRH receptor (Cook and
Eidne, 1997). While retaining cell surface expression, site-directed mutagenesis of the
relevant cysteine residues in the GnRH receptor revealed the absolute requirement of
this structural motif in ligand binding and receptor activation of this receptor (Cook and
Eidne, 1997). However, despite these similarities, it seems unlikely that the extracellular
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ECL2 observed in rhodopsin obscures the GnRH binding pocket. Indeed, computational
docking of the GnRHreceptor’s decapeptide ligands requires a significant displacement
of ECL2 and the N-terminal domain.
Other features of the GnRH receptor extracellular domain include a second set of
cysteine residues which form a disulfide bridge between the N-terminal domain and
ECL2, which is not observed in rhodopsin (Cook and Eidne, 1997). The precise
functional role of this bridge is unknown as mutagenesis did not significantly affect cell
surface expression, ligand binding or receptor activation (Cook and Eidne, 1997).
However, its presence is suggestive of a different conformation of the GnRH receptor’s
extracellular domain compared with rhodopsin. In addition, the GnRH receptor’s N-
terminal domain is decorated with glycosylation. The number of glycosylation sites for
the GnRH receptor depends on the species and is correlated with increasing receptor
expression, but doesn’t significantly alter ligand binding affinity or receptor activation
(Davidson et al., 1995; Millar et al., 2004). This is consistent with the presence and
outward facing arangement of these carbohydrate moieties in rhodopsin’s crystal 
structure (Li et al., 2004; Okada et al., 2004; Palczewski et al., 2000). While detailed
site-directed mutagenesis data and biochemical and biophysical analyses can provide
valuable information to model this region of the receptor, only a high resolution
structure of the receptor will enable determination of the structure conclusively.
1.3.3 The ligand binding pocket
In the inactive state, the ligand for rhodopsin is the small molecule, 11-cis-retinal. It is
covalently bound to the receptor at Lys7.43 in TM7 by a shiff base linkage, placing it
deep within the crevice of the TM bundle (Fig.1.5) (Filipek et al., 2003a). A number of
residues in rhodopsin in the 7TM domains and ECL2 of rhodopsin make direct contacts
with retinal (Filipek et al., 2003a; Li et al., 2004). Another key contact residue is Glu3.28
in TM3, which is suggested to stabilise the inactive conformation of the chromophore by
acting as a counterion for the protonated shiff base (Filipek et al., 2003a; Yeagle and
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Trp6.48 and Tyr6.51, make important interactions with the -ionone ring of the 11-cis-
retinal (Li et al., 2004; Palczewski, 2006; Yeagle and Albert, 2007).
Unlike rhodopsin’s ligand, GnRH I and GnRH II decapeptides are much larger, thus 
preventing their insertion deep within the transmembrane domains and necessitating a
different binding mode. The high affinity conformation of these ligands requires the
peptide to assume a II’-type turn involving positions 5-8 of the ligand (Barran et al.,
2005; Millar et al., 2004). In this conformation, the peptide resembles a horse-shoe
shape where the N- and C-termini are in close proximity and is optimal for ligand-
receptor interactions (Millar et al., 2004). This suggested conformation is supported by
the recent Nuclear Magnetic Resonance (NMR) structure for GnRH I (deposited in the
Protein Data Bank with the pdb code 1YY1).
Due to the absence of crystal structure information for the GnRH receptor, knowledge of
ligand-receptor interactions is mainly obtained from site-directed mutagenesis of the
GnRH receptor and computational modelling (Millar et al., 2004; Sealfon et al., 1997).
Site-directed mutagenesis of the GnRH receptor followed by ligand binding assays to
assess ligand binding affinity has enabled identification of potential ligand interaction
sites. However, this data must be interpreted with caution, because the mutation of a
receptor residue which decreases ligand binding affinity does not necessarily reflect the
loss of a direct ligand-receptor interaction site (Sealfon et al., 1997). Mutation of
residues in the receptor can indirectly affect ligand binding by disrupting intramolecular
interactions that are involved in configuration of the ligand binding pocket (Fromme et
al., 2004; Sealfon et al., 1997). This caveat underlines the necessity for verification of
potential ligand-receptor interaction sites identified by site-directed mutagenesis of the
receptor. Thus if a receptor mutation is identified as decreasing affinity for the ligand, its
role in direct ligand interactions should be assessed by concurrent alteration of the
ligand. Thus if the ligand and receptor residue interact, substitutions in the ligand that
prevent this interaction should result in analogue which has similar affinity at the
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be analysed further by computational modelling to assess the validity of the suggested
interaction, in the context of previously identified interactions. While the best method to
assess ligand binding affinity involves the use of ligand binding assays, mutations which
induce very low affinity can prevent the accurate use of this technique. However, in
cases where the mutant receptors have comparable cell surface expression relative to the
wildtype receptor, the measurement of second messenger generation, such as IP3, can be
used (Mamputha et al., 2007). In addition, the introduction of conservative mutations
may minimise the structural disruption caused by mutation of the specific residue and
substitution with smaller amino acids, like alanine, can avoid the introduction of novel
intramolecular interactions.
Combining the results of site-directed mutagenesis of the GnRH receptor in competition
binding and functional assays with homology modelling of the GnRH receptor based on
the crystal structure of rhodopsin (Lu et al., 2007; Stewart et al., 2007), a number of
interactions between GnRH I and the human GnRH receptor have been identified (see
Fig.1.6A). In the following section, the experimental and computational evidence to
support them is described. This is presented in sequential order of the residues in the
ligand and their proposed interactions with the receptor. Interactions, where additional
supporting experimental evidence is required, are highlighted.
1.3.3.1 pGlu1 forms a H-bond with Asn5.39
The mutation of Asn5.39 to Ala induces a decrease in affinity for GnRH I compared with
the wildtype receptor, as was inferred by a decrease in potency (Hoffmann et al., 2000).
This decrease was smaller when measured at the Asn5.39Gln receptor, which has a
conservative mutation at this position (Hoffmann et al., 2000). This suggests that the
side chain of Asn5.39 is important for GnRH I binding and that this function can be
partially recapitulated with a glutamine side chain. The authors used molecular
modelling to suggest an interaction of the Asn5.39 side chain with the backbone ketone
group of His2 (Hoffmann et al., 2000). However, subsequent refinements of the GnRH
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with pGlu1 (Millar et al., 2004). Experiments with pGlu1-substituted GnRH analogues
are required to confirm this proposed interaction.
1.3.3.2 His2 interacts with Asp2.61 and Lys3.32
The role of Lys3.32 in GnRH I binding and the nature of the interaction was suggested
following a series of mutations of Lys3.32 to Arg, Gln and Leu (Zhou et al., 1995). These
receptor mutations provide an indication of the nature of the ligand-receptor interaction
by analysis of their side chain characteristics. The wildtype receptor has a lysine residue
which has the capacity to act as a hydrogen bond donor and has a positive charge which
facilitates ionic interactions. Mutation to Arg is conservative and thus the residue retains
these interaction capabilities. Consistent with this, the Lys3.32Arg receptor retained high
affinity binding and produced functional responses comparable with the wildtype
receptor. However, mutation to Gln, which retains the ability to form H-bonds, but lacks
the positive charge, abolished detectable ligand binding and the receptor produced a
functional response with a much higher EC50 v lue. This suggests that the charge of Lys
is important for high affinity binding. Finally, mutation to Leu, which eliminates both
the charge and H-bonding capacity of the residue, resulted in a receptor unable to
produce a functional response, suggesting that a charge-strengthened hydrogen bond
donor is required at this position in the receptor in order to facilitate high affinity
binding of GnRH I. The authors postulate that this interaction may occur with His2 or
Trp3 of GnRH I, but subsequent experiments with modified ligands to confirm the
proposed interactions, were not performed.
The involvement of Lys3.32 in ligand binding was elucidated further in a subsequent
paper that identified and investigated the role of Asp2.61 in the binding of GnRH I.
Mutation of Asp2.61 to the conserved Glu (which has the same charge, but an increased
side chain length) and then to an uncharged residue Asn/Ala/Val resulted in a successive
decrease in affinity for GnRH I (Flanagan et al., 2000). These data suggest that both the
charge and the position of the Asp side chain are required for high affinity GnRH I
binding. In contrast with the wildtype receptor, the Asp2.61 mutant receptors exhibited a
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suggesting that Asp2.61 interacts with His2 of GnRH I (Flanagan et al., 2000). Further
analysis of a series of substitutions in position 2 of the ligand, as well as calculation of
the fold changes in affinity, indicated that the -NH group of His2 forms a H-bond with
Asp2.61. However, this interaction did not explain the loss of affinity of all peptides
(irrespective of ligand modifications) at the Asp2.61Val receptor compared with the
Asp2.61Glu receptor (Flanagan et al., 2000). Compared with the Glu mutation, the Val
mutation lacks negative charge. This suggests that this charge at this position in the
receptor is required in formation of interactions that facilitate creation of the ligand
binding pocket or is involved in an interaction with the backbone of the peptide.
Computational modelling revealed a potential ionic interaction with Lys3.32. This
interaction is proposed to facilitate Lys3.32 side chain interactions with the ligand
(Flanagan et al., 2000). Our current molecular model suggests that the Lys3.32 interaction
is with His2, but this requires experimental support.
1.3.3.3 Trp3 and Ser4 interactions
Studies involving mutation of Trp6.48 to Ser in the rat GnRH receptor showed a small
(~2-3-fold) decrease in affinity for GnRH I compared with the wildtype receptor
(Chauvin et al., 2000; Chauvin et al., 2001). The authors suggested that this residue was
important in the binding of GnRH I (Chauvin et al., 2000; Chauvin et al., 2001). We
have subsequently mutated this residue in the human GnRH receptor. This mutation
induced a large decrease in receptor expression (Coetsee et al., 2006). However,
following rescue of receptor expression using the small molecule antagonist IN3 (Lu et
al., 2005), no decrease in affinity for GnRH I or GnRH II was observed at the Trp6.48-
mutated receptors compared with the wildtype receptor (Coetsee et al., 2006). This is
consistent with a previous observation that Trp6.48 was not involved in GnRH I binding
(Betz et al., 2006). The position of Trp3 in our current molecular model suggests that it
may make interactions with ECL2.
The interactions between Ser4 and the GnRH receptor have not been experimentally
determined and the role of this residue awaits further investigation. The presence of this
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substitutions are not well-tolerated suggests that it may play a role or facilitate the
configuration of the high affinity ligand conformation (Millar et al., 2004; Sealfon et al.,
1997).
1.3.3.4 Tyr5 interacts with Tyr6.58
Several groups have mutated Tyr6.58 and observed large decreases in affinity for GnRH I
(Betz et al., 2006; Hovelmann et al., 2002). Molecular modelling revealed that this
interaction could be with Tyr5 (Hovelmann et al., 2002), but this interaction requires
experimental support. In chapter 2, using Tyr6.58-mutated receptors and position 5-
substituted GnRH I and GnRH II analogues, I investigate the validity and nature of this
proposed interaction.
1.3.3.5 Gly6 and Leu7 interactions
Receptor interactions with Gly6 are not well-established. However, the importance of a
flexible residue or D-amino acid in this position for high affinity binding suggests that
this residue contributes to the II’-type turn required for ligand-receptor interactions
(Barran et al., 2005). Experimentally identified receptor interactions with Leu7 are still
required.
1.3.3.6 Arg8 interacts with Asp7.32
Mutation of Asp7.32 to Asn decreased affinity of the receptor for GnRH I compared with
the wildtype receptor, but had no effect on the affinity for Arg8-substituted ligands
(Fromme et al., 2001). This suggests that Asp7.32 forms an ionic interaction with Arg8 of
GnRH I. However, further experimental data revealed this interaction to be more
complex. Firstly, the reduction in binding affinity for GnRH I observed at the Asp7.32-
mutated receptor was much smaller than the loss expected for disruption of an
electrostatic interaction (Fromme et al., 2001). Furthermore, conformationally
constrained ligands, such as those with D-amino acids in position 6, do not exhibit
selectivity for Asp7.32 and have similar affinities at the mutant and wildtype receptors
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transient ligand-receptor interaction which facilitates creation of the high-affinity
conformation of GnRH I.
1.3.3.7 Pro9 and the C-terminal glycinamide form interactions with Arg1.35 and Asn2.65
The interaction of Arg1.35 and Asn2.65 (in TM1 and TM2 respectively) with the C-
terminal glycinamide of the native GnRH peptide has been suggested using GnRH
analogues where the glycinamide is substituted with an ethylamide. In both the
Arg1.35Ala and Asn2.65Ala mutant receptors, the observed decrease in affinity
(Arg1.35Ala) or potency (Asn2.65Ala) compared with the wildtype receptor was smaller
for the ethylamide-substituted peptides than for native GnRH I (Davidson et al., 1996;
Hoffmann et al., 2000; Stewart et al., 2007). The authors suggest that Arg1.35 and Asn2.65
interact with the C-terminal glycinamide via H-bonds (Davidson et al., 1996; Hoffmann
et al., 2000; Stewart et al., 2007). However, the large decreases in affinity/potency of
GnRH I at the two mutant receptors compared with the wildtype receptor are not
accountable for by the loss of a single H-bond interaction. Indeed, computational
modelling suggests that Arg1.35 and Asn2.65 form part of a hydrogen bonding network
that links TM1, TM2 and TM7 and may thereby contribute to receptor structure and
stabilisation of the ligand binding pocket (Stewart et al., 2007). Furthermore, Arg1.35 may
make an additional H-bond with the carbonyl oxygen of Pro9 of the GnRH peptide
(Stewart et al., 2007).
1.3.3.8 Binding of GnRH II
The ligand-receptor binding residues for GnRH II are less well-defined (Millar et al.,
2004). However, a number of interaction sites are suggested to overlap with the GnRH I
binding sites (see Fig.1.6B). These include Asp2.61, Asn2.65, Lys3.32 and Arg1.35 (Davidson
et al., 1996; Flanagan et al., 2000; Millar et al., 2004; Stewart et al., 2007). Nevertheless,
an important observation is that mutation of Asp7.32 does not affect the binding of GnRH
II (which has a tyrosine in position 8) (Fromme et al., 2001). This suggests that Asp7.32
confers selectivity for GnRH I by interaction with Arg8. Thus Tyr8 of GnRH II is
proposed to make differential interactions with the receptor (Lu et al., 2005).
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GnRH II faces away from Asp7.32, consistent with the proposal that position 8 of GnRH
II makes differential interactions with the receptor (see Fig.1.6B).
1.3.3.9 Conservation of analogous ligand binding sites compared with other GPCRs
Interestingly, a number of residues at the equivalent positions of the GnRH receptor
binding sites are also involved in ligand binding in other GPCRs (Millar et al., 2004).
An example is Lys3.32, which is at the equivalent position of Asp3.32 in the monoamine
receptors, which is important for interaction with the positively charged bioamine
headgroups (Shi and Javitch, 2002) and of Ala3.32 in rhodopsin, which is also an
interaction site for 11-cis-retinal (Millar et al., 2004; Palczewski et al., 2000). This
indicates that certain GPCR ligand binding sites have been retained to some extent
during evolution, but the amino acids have been changed to mirror the chemical nature
of the cognate ligands.
1.3.4 The intracellular domains
The intracellular domains of GPCRs consist of three intracellular loops and a C-terminal
tail. Crystallisation of rhodopsin has revealed a high degree of flexibility within these
regions (Li et al., 2004; Okada et al., 2004; Palczewski, 2006; Palczewski et al., 2000).
This is consistent with other experimental evidence suggesting these regions undergo
conformational changes following receptor activation (Yeagle and Albert, 2007) and
reflects the requirement of these domains to interact with and activate different classes
of G proteins and other signalling molecules (Wong, 2003). In the crystallised inactive
state of rhodopsin the intracellular loops form random structures that outline the
periphery of the receptor (Li et al., 2004; Okada et al., 2004; Palczewski, 2006;
Palczewski et al., 2000). In contrast, the C-terminal tail forms an eighth alpha helix
which lies parallel to the membrane.
Considering the high sequence divergence of rhodopsin and the GnRH receptor in the
intracellular loops and the interaction of the receptors with different G protein subtypes,
it is difficult to predict the degree of structural similarity between the two proteins
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the crystal structure of rhodopsin questions the utility of such a comparison.
Nevertheless, a noteworthy observation is the complete absence of a C-terminal tail in
the GnRH receptor. This evolutionary alteration in the GnRH receptor is likely to reflect
refinement of the receptor for its own specialised signalling (Pawson et al., 1998).
Indeed, it has been hypothesised that, because this modification prevents the rapid
desensitisation and internalisation of the GnRH receptor, it assists the prolonged LH
surge induced by the GnRH receptor, which is required for ovulation in mammals
(Pawson et al., 1998).
1.3.5 Insights from the recent crystallisation of the 2-adrenergic receptor
Current GnRH receptor molecular models are based on the crystal structure of rhodopsin
(Betz et al., 2006; Lu et al., 2007; Lu et al., 2005; Soderhall et al., 2005). However, as
discussed above, the differences in ligand binding and signalling mediated by the two
receptors make it particularly difficult to model the extracellular and intracellular
domains of the GnRH receptor based on rhodopsin and limits the utility of these models.
Recently, a crystal structure of a second rhodopsin family GPCR, the 2-adrenergic
receptor (2-AR), was obtained (Cherezov et al., 2007; Rasmussen et al., 2007;
Rosenbaum et al., 2007). In order to achieve crystals, the structural flexibility of the 2-
AR was reduced by complexing the receptor with an antibody to ICL3 (Rasmussen et
al., 2007) or by insertion of T4-lysozyme (T4L) in place of ICL3 (Cherezov et al., 2007;
Rosenbaum et al., 2007), in combination with the presence of the high affinity partial
inverse agonist, carazolol. The antibody-GPCR complex only allowed resolution of the
intracellular region of the receptor, but the 2-AR-T4L was better resolved. This
structure is similar to rhodopsin, but exhibits a few important differences. Firstly, the
extracellular segments of the TM domains are angled away from the centre of the TM
bundle creating a more open conformation at this region of the receptor compared with
rhodopsin (Cherezov et al., 2007). Furthermore, unlike ECL2 of rhodopsin, which forms
a -hairpin and is inserted into the TM bundle, ECL2 of the 2-AR-T4L forms an
unexpected short helical segment and is more exposed to the solvent, a conformation
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site (Cherezov et al., 2007). This open configuration of the extracellular region of the 2-
AR is likely to reflect the requirement of this receptor to interact diffusible ligands,
which contrasts with the covalently bound ligand at rhodopsin. This is consistent with
the observation, mentioned above, that docking of the GnRH receptor’s difusible 
peptide ligands to the computational models of the receptor requires significant
displacement of ECL2. A second important difference is that TM3 is further away from
TM6 in the 2-AR-T4L structure compared with rhodopsin, preventing an interaction
known as the “ionic lock” (see section 1.4.3.4), which is proposed to constrain the 
receptor in the inactive state. This difference may explain the high basal activity of the
2-AR, which is not completely reduced in the presence of carazolol. This contrasts with
the absence of basal activity observed at both rhodopsin and the GnRH receptor. The
differences observed between rhodopsin and the 2-AR highlight that, while homology
modelling is a useful tool for identification of putative ligand-receptor and
intramolecular interactions, GPCRs have subtle structural alterations that reflect
specialisation of the receptor for the binding of different ligands and differential
signalling requirements. Thus predicted interactions proposed from homology models
require experimental validation, which can be used to refine and thus improve the
models.
1.3.6 Summary
The current predicted structure of the GnRH receptor relies heavily on information
gained from the crystallisation of another rhodopsin family GPCR, rhodopsin. These
receptors share important highly conserved structural motifs that are likely to direct a
similar overall fold for the two receptors (Ballesteros et al., 2001b). These motifs
include the highly conserved proline residues and residues of the conserved E/DRY and
D/NPxxY motifs (Mirzadegan et al., 2003). However, it is clear that the GnRH receptor
has a subtly distinct structure compared with rhodopsin, necessary for its own
specialised signalling functions. This is observed by the absence of the C-terminal tail
and reciprocal change of the Asp and Asn residues in positions 2.50 and 7.49 in the
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homology models of the GnRH receptor based on the structure of rhodopsin should be
subject to refinements which incorporate experimental data specific to the GnRH
receptor. Nevertheless, the validity and predictive power of GnRH receptor models,
based on the structure of rhodopsin, have been obtained from experimental evidence that
supports the proposed interactions extrapolated from the models (Millar et al., 2004). An
important underlying implication of the conserved structure of rhodopsin family GPCRs
is that they undergo a common mechanism of activation. In the following section, the
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Human GnRH R M A N S A S P E Q N Q N H C S A I N N S I P L M Q G N L P T L T
Bovine Rhod M N G T E G P N F Y V P F S N K T G V V R S P F E A P Q Y Y L A E P























































Human GnRH R L S G K I R V T V T F F L F L L S A T F N A S F L L K L Q K W T Q K K E K G K K L S R
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Human GnRH R M K L L L K H L T L A N L L E T L I V M P L D G M W N I T V Q W Y A G
Bovine Rhod L N Y I L L N L A V A D L F M V F G G F T T T L Y T S L H G Y F V F G








































































































Human GnRHR E L L C K V L S Y L K L F S M Y A P A F M M V V I S L D R S L A I T R P L A L K S N S
Bovine Rhod P T G C N L E G F F A T L G G E I A L W S L V V L A I E R Y V V V C K P M S N F R F G E N




























































































Human GnRHR K V G Q S M V G L A W I L S S V F A G P Q L Y I F R M I H L A D S S G Q T K V F S Q C V T H C S F S
Bovine Rhod N H A I M G V A F T W V M A L A C A A P P L V G W S R Y I P E G M Q C S C G I D Y Y T P H
























































































































Human GnRHR Q W W H Q A F Y N F F T F S C L F I I P L F I M L I C N A K I I F T L T R V L H Q D P H E L Q L N Q S K
Bovine Rhod E E T N N E S F V I Y M F V V H F I I P L I V I F F C Y G Q L V F T V K E A A A Q Q Q E S
































































































































Human GnRHR N N I P R A R L K T L K M T V A F A T S F T V C W T P Y Y V L G I W Y W F D P E M L N R L S D
Bovine Rhod A T T Q K A E K E V T R M V I I M V I A F L I C W L P Y A G V A F Y I F T H Q G S D F G P








































































































Human GnRHR P V N H F F F L F A F L N P C F D P L I Y G Y F S L
Bovine Rhod I F M T I P A F F A K T S A V Y N P V I Y I M M N K
Human GnRHR
Bovine Rhod Q F R N C M V T T L C C G K N P L G D D E A S T T V S K T E T S Q V A P A
Figure 1.4. Sequence alignment of the human GnRH receptor and bovine rhodopsin. Residues highlighted in yellow represent approximate TM regions.
Blue highlighted residues are the most highly conserved residues in each TM domain. Cysteines in red represent residues that form disulfide bridges (see
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Figure 1.5. Crystal structure of bovine rhodopsin. The crystal structure of rhodopsin is represented in
ribbon (A) and schematic (B) forms, as viewed from within the plane of the membrane. TM numbering (in
Roman numerals), glycosylation and palmitoylation modifications are indicated. Rhodopsin’s ligand, 11-
cis-retinal, is represented in grey. The schematic figure allows easier identification of the four -sheets
formed by the N-terminal and ECL2 regions, which form a layered roof over the centre of the TM
domains. Rhodopsin’s structure as viewed from the intracelular (C) and extracelular (D) surfaces arealso
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Figure 1.6. Ligand docking models of the human GnRH receptor. A, GnRH I docked at the GnRH receptor. GnRH I is proposed to make the
following interactions: PGlu1 interacts with Asn5.39; His2 interacts with Asp2.61 and Lys3.32; Tyr5 interacts with Tyr6.58; Arg8 interacts with Asp7.32; Pro9
and the C-terminal glycinamide interact with Arg1.35 and Asn2.65. B, GnRH II docked at the GnRH receptor. GnRH II is proposed to make the following
interactions: His2 interacts with Asp2.61 and Lys3.32; Pro9 and the C-terminal glycinamide interact with Arg1.35. Asp7.32 confers specificity for GnRH I
and does not contribute to GnRH II binding. The molecular models of the GnRH receptor are based on homology modelling of rhodopsin (1U19). The
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1.4 GnRH receptor activation
1.4.1 Theoretical models of GPCR activation: the Ternary Complex Model
Important early experiments that shaped our understanding of GPCR activation were
incorporated into theoretical models which are useful to explain and predict receptor
behaviour. One of the earliest models was termed the ternary complex model (TCM)
(De Lean et al., 1980). This model states that receptors exist in an equilibrium of two
agonist affinity states, a high affinity and low affinity state. The model proposes that the
high affinity state of the receptor is the result of a ternary complex association of the
agonist, receptor and G protein whereas the low affinity state is characterised by the
absence of G proteins in the complex. Alterations in any of the three components of the
ternary complex shift the equilibrium of the two receptor agonist affinity states,
according to the laws of mass action. This model is useful in understanding the
importance of receptor-G protein interactions in receptor pharmacology and provides an
explanation for the observed differences in the pharmacological profile and constitutive
activity of a receptor in different tissues where the relative receptor: G protein ratios
may vary.
The discovery that mutation of specific residues in a receptor could induce constitutive
activity and resulted in a high affinity agonist binding state of the receptor, without the
presence of G proteins, was not consistent with the TCM. Thus the TCM was refined
and denoted the extended ternary complex model (ETCM) (Samama et al., 1993). In this
model, the two states, characterised by differences in agonist binding affinity, were
termed R and R*, where R represents the low affinity inactive receptor conformation
and R* represents the high affinity active (G protein-activating) receptor conformation.
An isomerisation constant, J, was introduced which provides a measure of the proportion
of receptors in R and R* and is influenced by the inherent ability of the receptor to
change conformation. Receptor mutations that induce constitutive activity are proposed
to ease the transition of receptors from R to R* thereby shifting the equilibrium of
receptors to a higher proportion in the active conformation. In this model, agonists bind
with higher affinity to R* shifting the equilibrium of receptors towards the active
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with higher affinity to R altering the receptor conformational equilibrium in favour of
the inactive conformation and decreasing basal receptor activity. Neutral antagonists
bind with equal affinity to both R and R* and thus do not change the receptor
equilibrium and do not produce a ligand-induced functional signalling response.
Emerging experimental evidence has revealed some limitations of the ETCM (Kenakin,
2002), which will be discussed in more detail in section 1.5.6. However, this model
highlights an important aspect of receptor activation. Specifically, that receptor
activation requires a conformational transition from an inactive to an active
conformation. This transition is associated with a specific energetic barrier that can be
lowered by mutation-induced disruption of receptor intramolecular constraining
interactions (Kobilka, 2007). The identification of a role for a number of highly
conserved motifs in receptor activation has led to the proposal of a common mechanism
of activation utilised by all rhodopsin family GPCRs (Karnik et al., 2003; Schwartz et
al., 2006). Thus much of the current understanding of GnRH receptor activation is
inferred from experiments with other rhodopsin family GPCRs, such as rhodopsin and
the 2-AR. In this section, key early experiments and recent innovative work providing
insight into GPCR activation are outlined. Wherever possible, experimental evidence
specific to the GnRH receptor is provided.
1.4.2 Conformational changes associated with receptor activation
Experimental evidence and analysis of conserved structural motifs suggests that GPCRs
undergo similar structural rearrangements upon activation (Karnik et al., 2003; Schwartz
et al., 2006). These conformational changes associated with receptor activation are
proposed to involve an outward movement of TM6 relative to TM3 and an outward
movement of TM7, at the cytoplasmic end of the receptor (see Fig.1.7) (Gether, 2000;
Karnik et al., 2003; Lu et al., 2002; Okada et al., 2001; Schwartz et al., 2006). This
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These conformational changes are suggested by various biophysical and biochemical
experiments in several GPCRs (Meng and Bourne, 2001). Site-directed spin-labelling
(SDSL) studies with rhodopsin suggest that light activation induces an outward
rotational movement of TM6 relative to TM3 at the intracellular end of the receptor
(Farrens et al., 1996). A similar conformational rearrangement upon receptor activation
was detected in the 2-AR using environmentally sensitive fluorophores (Ghanouni et
al., 2001b; Kobilka, 2002). The absolute requirement of this conformational change for
receptor activation is underlined by the inability of receptors with disulfide bridges or
engineered metal-ion binding sites between the intracellular ends of TM3 and TM6 to
induce G protein activation (Cai et al., 1999; Meng and Bourne, 2001; Sheikh et al.,
1999).
Furthermore, SDSL and activation-dependent generation of intramolecular disulfide
bridges suggest an outward movement of TM7 upon receptor activation (Yang et al.,
1996; Yu et al., 1999). Additional evidence for TM7 exposure at the intracellular end of
the receptor upon receptor activation is provided by the activation state-dependent
binding of an antibody to a TM7 epitope including a portion of the NPxxY motif
(Abdulaev and Ridge, 1998).
Thus receptor activation involves an outward rotational movement of TM6 and to a
lesser degree the outward movement of TM7, relative to TM3, at the intracellular
surface of the receptor (Lu et al., 2002; Palczewski, 2006; Schwartz et al., 2006). The
outward motion of TM6 and TM7 at the intracellular end of the TM bundle is coupled
with an inward movement of these helices towards TM3 at the extracellular surface of
the membrane. This was demonstrated by the creation of a metal ion binding site
between residues at the extracellular end of TM3, TM6 and TM7 that induced receptor
activation (Elling et al., 2006). Consultation of the crystal structure of the inactive state
of rhodopsin revealed that a metal ion binding site could not be accommodated by these
residues without an inward movement of TM6 and TM7. The authors propose a model
of receptor activation where proline residues within the helices act as hinges for the
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2006; Schwartz et al., 2006). However, the magnitude of the helical rearrangements
predicted by biochemical and biophysical experiments may have been overestimated as
a recent photoactivated crystal structure of rhodopsin revealed only minor
conformational changes (Salom et al., 2006).
1.4.3 Highly conserved GPCR residues or motifs facilitate receptor activation
A number of highly conserved GPCR residues and motifs assist in mediating the
receptor conformational changes outlined above. These residues include several highly
conserved proline residues and the D/NPxxY, E/DRY and CWxP motifs (Gether, 2000;
Schwartz et al., 2006) (see Fig.1.8).
1.4.3.1 The conserved prolines Pro6.50 and Pro7.50
Proline residues have a significant influence on receptor structure as they induce
disruptions within the 7TM helices and are often associated with a bend or kink at that
region within the helix (Ballesteros et al., 2001b). Thus these residues play an important
role in directing the overall receptor structure (see section 1.3). Two proline residues in
TM6 and TM7, Pro6.50 and Pro7.50, are highly conserved amongst GPCRs (Mirzadegan et
al., 2003). Furthermore, the essential role of these proline residues is illustrated by the
disruption of receptor folding and function when they are mutated in a number of
receptors (Sansom and Weinstein, 2000). In addition to the important effects on receptor
folding, proline residues are proposed to act as flexible hinges that facilitate the
conformational changes associated with receptor activation, particularly the movement
of TM6 and TM7 (Elling et al., 2006; Sansom and Weinstein, 2000; Schwartz et al.,
2006). The presence of the highly conserved prolines within the GnRH receptor
sequence suggests that the GnRH receptor structure is compatible with this proposed
mechanism of activation (see Fig.1.4).
1.4.3.2 The CWxP motif and the rotamer toggle switch
Movement of the proline hinges is modulated by intramolecular and interhelical
interactions of the residues above and below the relevant prolines in the helix. Cys6.47,
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family GPCRs (Mirzadegan et al., 2003; Schwartz et al., 2006). In the 2-AR, mutation
of Cys6.47 to Ser, which has a similar distribution of side chain rotamer configurations in
the helix, demonstrates receptor behaviour comparable with the wildtype receptor (Shi et
al., 2002). However, mutation of Cys6.47 to Thr, for which the population of side chain
configurations in the helix differs, results in a receptor that exhibits constitutive activity.
This suggests that the rotamer configuration of the Cys6.47 side chain plays an important
role in receptor activation (Shi et al., 2002). Furthermore, the biased monte carlo
technique of conformational memories indicates that the rotamer conformation of Cys6.47
is coupled with that of Trp6.48 and Phe6.52. The co-ordinated position of these highly
conserved residues is proposed to modulate the angle of the TM6 proline kink and thus
the movement of TM6, suggesting that these residues form part of a rotamer toggle
switch which facilitates receptor activation (Schwartz et al., 2006; Shi et al., 2002).
Nuclear Magnetic Resonance (NMR) experiments suggest that Trp6.48 also undergoes a
shift in orientation upon light activation of rhodopsin which is consistent with the
rotamer toggle switch proposed in the 2-AR (Crocker et al., 2006). Furthermore, Trp6.48
is implicated in the regulation of receptor activation in several other GPCRs (Joubert et
al., 2002; Lu et al., 2004; Marie et al., 2001). Thus this proposed mechanism activation
switch may be more broadly applicable to the rhodopsin family GPCRs (Singh et al.,
2002).
In the GnRH receptor, mutation of Trp6.48 to Ser or Ala and Cys6.47 to Tyr or Ala resulted
in significantly decreased receptor expression levels (Chauvin et al., 2000; Chauvin et
al., 2001; Janovick et al., 2002; Lu et al., 2007). This result suggests that these residues
participate in important intramolecular interactions that stabilise receptor structure and
facilitate the correct folding of the GnRH receptor. Following rescue of Trp6.48- and
Cys6.47-mutated receptor expression with the small molecule antagonist IN3, IP
signalling could be detected (Janovick et al., 2002; Lu et al., 2007). Constitutive activity
was not observed, but the absence of complete data for the calculation of signalling
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of these residues in receptor activation (Janovick et al., 2002; Lu et al., 2007).
Nevertheless, an interesting observation is that the Cys6.47Ala and Cys6.47Tyr mutant
receptors had increased affinity for GnRH II, but not GnRH I. As Cys6.47 is not a direct
GnRH II binding site, this suggests that Cys6.47 mutation alters the ligand binding pocket
by receptor conformational changes (Lu et al., 2007). This suggests that Cys6.47 is also
spatially positioned in the GnRH receptor to contribute to receptor conformational or
structural rearrangements, which is consistent with the toggle switch model.
1.4.3.3 The D/NPxxY motif
A second set of highly conserved residues cluster around Pro7.50 and form the D/NPxxY
motif. The Asp/Asn7.49 and Tyr7.53 on either side of the proline are proposed to
participate in distinct sets of intramolecular interactions that modulate the angle of the
proline kink in TM7 and thus TM7 movement upon receptor activation (He et al., 2001;
Sansom and Weinstein, 2000).
Asp/Asn7.49 of the D/NPxxY motif is proposed to undergo a conformational
rearrangement and participate in discrete intramolecular interactions in the inactive and
active states of the receptor. In the inactive conformation of rhodopsin, Asn7.49 forms
part of a hydrogen bonding network with Asn1.50 and Asp2.50 which connects TM1, TM2
and TM7 (Li et al., 2004; Palczewski et al., 2000). Asp2.50 is central to this interactive
network, interacting with Asn1.50 by direct hydrogen bonding and with Asn7.49 via a
bridging water molecule. Asn7.49 also participates in interactions with residues in H6 in
the inactive state which may be relevant to receptor activation (Li et al., 2004; Okada et
al., 2004; Urizar et al., 2005). In the thyrotropin receptor (TSHR), mutation-induced
disruption of an interaction between Asn7.49 and Thr6.43 and Asp6.44 in H6 induces
constitutive activity (Urizar et al., 2005). The crystal structure of rhodopsin reveals an
analogous interaction is present in rhodopsin and thus this may represent a more general
mechanism for GPCR activation (Urizar et al., 2005).
Due to the low resolution of the active MetaII crystal structure of rhodopsin, the










Chapter 1: Literature Review
42
2006). However, site-directed mutagenesis experiments and molecular modelling in the
TSHR and the Histamine H1 receptor suggest that Asn7.49 may interact directly with
Asp2.50 and a second ionic counterpart that could be Arg3.50 of the DRY motif in the
active state of GPCRs (Bakker et al., 2008; Urizar et al., 2005).
The GnRH receptor has undergone a reciprocal mutation at positions 2.50 and 7.49
(Flanagan et al., 1999; Zhou et al., 1994). As discussed in section 1.3.1, analysis of the
effects of mutations at these positions on GnRH receptor expression and ligand binding
affinity suggest that a similar set of interactions between Asn1.50 and Asn2.50 and Asp7.49
occur in the inactive conformation of the GnRH receptor (Flanagan et al., 1999; Zhou et
al., 1994). Mutation of Asp7.49 to Ala in the GnRH receptor resulted in a coupling
efficiency of 0.7% of the wildtype receptor value, as measured by IP assays (Flanagan et
al., 1999). This reveals that Asp7.49 also plays a critical role in receptor activation of the
GnRH receptor. Interestingly, when the configuration of the 2.50 and 7.49 residues
observed in the GnRH receptor was introduced into the TSHR, the TSHR exhibited
decreased constitutive activity (Urizar et al., 2005). Thus perhaps this feature facilitates
a more constrained inactive receptor conformation in the GnRH receptor.
The side chain of Tyr7.53, on the other side of the proline kink, participates in a different
set of intramolecular interactions. In the inactive state of rhodopsin, Tyr7.53 forms an
intramolecular constraining interaction with Phe7.60 in H8. Mutation-induced disruption
of this interaction in rhodopsin results in MetaII formation (Fritze et al., 2003). The
suggestion that these residues participate in a constraining intramolecular interaction in
the inactive state of the receptor is strengthened by the observation that a disulfide bond
created between Tyr7.53 and Phe7.60 prevented MetaII formation (Fritze et al., 2003).
Tyr7.53 may also play a role in stabilising the active conformation of GPCRs. Mutation of
Tyr7.53 in the 5HT2C serotonin receptor displayed diverse phenotypes, ranging from
uncoupled to high constitutive activity, depending on the nature of the side chain
substitution at that position (Prioleau et al., 2002). This suggests that Tyr7.53 may be
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Despite the absence of H8, mutation of Tyr7.53 to Ala in the GnRH receptor abolished G
protein activation, as measured by IP assays (Arora et al., 1996). This suggests that
Tyr7.53 is also important for GnRH receptor activation. Additionally, Tyr7.53 to Ala
mutation in the GnRH receptor differentially affects the binding of GnRH I and GnRH II
(Lu et al., 2005). As the cytoplasmic position of Tyr7.53 prevents its direct interaction
with GnRH II, this effect is more likely due to the ability of this residue to modulate
receptor conformation, as observed with the Cys6.47 mutation.
1.4.3.4 The E/DRY motif and the ionic lock
The highly conserved E/DRY motif is a key element of GPCR activation (Flanagan,
2005; Gether, 2000; Okada et al., 2001; Rovati et al., 2007). In the crystal structure of
inactive rhodopsin, Arg3.50 interacts with the neighbouring Glu3.49 and Glu6.30 positioned
in ICL3 below TM6 (Li et al., 2004; Okada et al., 2004; Palczewski, 2006). A charge
neutralising mutation of Glu3.49 to Gln induces increased constitutive activity at opsin,
the form of rhodopsin which lacks the presence of the inverse agonist 11-cis-retinal
(Acharya and Karnik, 1996). Additionally, SDSL experiments reveal that this mutation
results in helical rearrangements that are associated with rhodopsin activation (Kim et
al., 1997). Similarly, in the 2-AR, receptor mutants with charge-neutralising mutations
of Asp3.49 or Glu6.30 exhibited constitutive receptor activity (Ballesteros et al., 2001a).
Using methanethiosulfonate (MTSEA) assays which assessed the accessibility of
Cys6.47, it was possible to infer that these Asp3.49 or Glu6.30 mutations also induced
conformational rearrangements in the helices of the 2-AR (Ballesteros et al., 2001a).
This led to the proposal that the network of interactions involving the triad, Arg3.50,
Asp3.49 and Glu6.30, constitute an “ionic lock” or constraining interaction that prevents 
helical movement and GPCR activation (Ballesteros et al., 2001a).
While Asp3.49 and Arg3.50 are highly conserved amongst rhodopsin family GPCRs,
Glu6.30 is not (Mirzadegan et al., 2003). Nevertheless, mutation of Asp3.49 and Arg3.50
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GPCRs, suggesting that they have a conserved function in the regulation of receptor
activation (Flanagan, 2005; Rovati et al., 2007). In the GnRH receptor, mutation of
Asp3.49 to Asn resulted in an enhancement of receptor signalling efficiency, suggesting
that this mutation disrupts a constraining interaction (Ballesteros et al., 1998).
Computational molecular modelling of the GnRH receptor supports the feasibility that
this constraining interaction consists of Asp3.49 and Arg3.50 (Ballesteros et al., 1998).
In addition to interactions that constrain the inactive conformation of the receptor,
Arg3.50 is also implicated in stabilising the active state of GPCRs. In the active state,
Arg3.50 is proposed to interact with Asp2.50 and Asn7.49 (Bakker et al., 2008; Urizar et al.,
2005). This interaction is also predicted to occur in the active state of the GnRH receptor
(Ballesteros et al., 1998). This suggestion is consistent with the observation that
mutations of both Arg3.50 and Asp7.49 in the GnRH receptor significantly compromise
receptor activation, as measured by IP signalling (Arora et al., 1997; Flanagan et al.,
1999).
Tyr3.51 in the E/DRY motif is the least conserved residue of this motif in rhodopsin
family GPCRs (Mirzadegan et al., 2003; Rovati et al., 2007). Indeed, Tyr3.51 mutation in
a range of GPCRs is associated with either the absence or only minor affects on receptor
signalling suggesting that this conserved residue is not required for receptor activation
(Rovati et al., 2007). The GnRH receptor has a serine at position 3.51 and thus exhibits a
DRS, as opposed to the typical DRY, motif. Mutation of Ser3.51 to Ala in the GnRH
receptor did not affect IP signalling, consistent with the suggestion that this residue does
not contribute to receptor activation (Arora et al., 1997).
1.4.4 Summary
An underlying implication of the conserved structure of GPCRs is a common
mechanism of activation (Karnik et al., 2003; Schwartz et al., 2006). GPCR activation is
proposed to involve the disruption of a set of constraining intramolecular interactions or
molecular switches, which facilitates receptor helical rearrangements, particularly of
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the formation of a new set of intramolecular interactions that stabilise the active state of
the receptor. The conformational transition involved in receptor activation is guided by a
set of key highly conserved residues, including the CWxP, D/NPxxY and E/DRY motifs
and facilitated by the presence of highly conserved proline residues, Pro6.50 and Pro7.50,
which act as hinges for the conformational changes (Karnik et al., 2003; Schwartz et al.,
2006). Analysis of the effects of mutation of these key residues in the GnRH receptor on
receptor activation are consistent with the suggestion that this proposed mechanism of
activation is utilised by the GnRH receptor. Nevertheless, currently, no mutation of the
GnRH receptor has been sufficient to induce constitutive activity (Lu et al., 2007; Millar
et al., 2004; Myburgh et al., 1998b). This may reflect an increased set of constraining
interactions in the GnRH receptor and/or that the GnRH receptor requires the directive
action of new intramolecular interactions in order to attain the active state rather than
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Figure 1.7. GPCR conformational changes induced upon receptor activation. Proposed
conformational changes that GPCRs undergo upon receptor activation as viewed from within the plane of
the membrane (A) and from the extracellular surface (B). GPCRs are proposed to undergo a
conformational change upon receptor activation involving an outward rotational movement of TM6, and
to a lesser degree TM7, relative to TM3 at the intracellular end of the receptor. This is coupled with an
inward movement of these helices at the extracelular end of the TM domains. This “see-saw” movement 
is facilitated by proline residues (highlighted with yellow dashed circles), which act as hinges for this
mechanical event about the indicated pivot points (represented with yellow balls). The rotamer
conformation of Trp6.48 (indicated in grey in B) of the CWxP motif facilitates these movements by the
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Figure 1.8. Highly conserv d GPCR motifs facilitating receptor activation mapped onto the GnRH
receptor sequence. This figure is a two-dimensional representation of the human GnRH receptor showing
the TM domains connected by the ECLs and ICLs. The most highly conserved residue in each TM domain
is indicated in yellow. Highly conserved residues important for receptor activation, specifically the DRS,
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1.5 Ligand-induced receptor activation and signalling
1.5.1 Agonist binding induces receptor activation
As described above, receptor activation involves the disruption of key intramolecular
interactions that facilitate receptor conformational changes. Thus the question arises:
how does agonist binding induce receptor activation? Due to the unusual covalent
linkage of rhodopsin’s ligand within the receptor, this model system is less suitable to
understand the complex process of agonist binding at the GnRH receptor. Thus
experimental data describing the binding of diffusible agonists at the 2-AR will be
discussed in this section. This information and experimental work specific to the GnRH
receptor are incorporated into a hypothesis regarding the probable process of agonist
binding at the GnRH receptor.
Current thinking is that agonists perform two functions that facilitate receptor activation
(Kobilka, 2007; Kobilka and Deupi, 2007). Firstly, agonists facilitate the disruption of
intramolecular interactions or molecular switches that constrain the receptor in the
inactive state. Experimental evidence for this role of agonists is provided by a method
that was able to measure disruption of the intramolecular interactions constituting the
ionic lock and the rotamer toggle switch in the 2-AR (Yao et al., 2006). Specifically, it
was shown that disruption of these two intramolecular switches correlated with ligand
efficacy, where full agonists disrupted both switches while antagonists did not disturb
either set of interactions (Yao et al., 2006).
The second role of ligands is that they create a bridge between opposing helices that
stabilises the active conformation of the receptor (Kobilka and Deupi, 2007). As
discussed, the proposed receptor conformational changes involve a see-saw motion of
the 7TM helices where the extracellular ends move inward (coupled with an outward
motion of the intracellular ends) (Schwartz et al., 2006). Experimental support for this
role was provided following creation of a metal ion binding site in the 2-AR by
mutation of specific residues in TM3, TM6 and TM7. This mutant receptor could be
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active position of the extracellular ends of the TM helices (Elling et al., 2006). Thus
agonist-induced receptor activation involves the disruption of intramolecular interactions
which promotes formation of the active conformation of the receptor that is stabilised by
the bridging action of the agonist (Kobilka and Deupi, 2007).
The energetic feasibility of the conformational transition from inactive to active receptor
is facilitated by the formation of a new set of favourable interactions between the agonist
and receptor. It is suggested that these agonist-receptor interactions form by a sequential
multi-step process. Initial agonist-receptor contacts are proposed to facilitate receptor
conformational changes that enable subsequent agonist-receptor interactions to occur.
This is supported by evidence that agonist-receptor contacts at one end of the 2-AR
synergistically contribute to the binding of agonist-receptor contacts at a remote region
of the receptor (Del Carmine et al., 2004). 2-AR agonists comprise two domains, a
catechol ring and a tail, which are proposed to bind to opposing helices within the 2-
AR. Three serine residues (Ser5.42, Ser5.43 and Ser5.46) in TM5 contribute to the binding
of functional groups on the catechol ring. The loss in binding affinity at receptors with
mutations of these serine residues was smaller when there were less functional groups in
the catechol tail (Del Carmine et al., 2004). Considering the limited flexibility of the
small molecule catecholamine agonist, the authors concluded that this synergism is the
result of receptor conformational changes initiated by preceding agonist-receptor
interactions which thereby facilitate the formation of subsequent agonist-receptor
contacts (Del Carmine et al., 2004). Thus agonist binding is suggested to occur by an
induced-fit mechanism. Furthermore, the sequential nature of the agonist binding
process suggests that multiple intermediate receptor conformations should be formed.
Indeed, using a 2-AR which is fluorescently labelled to assess receptor conformational
changes in real time, the presence of consecutive distinct receptor active conformations
in response to agonists is observed (Swaminath et al., 2004).
Agonist binding at the GnRH receptor is expected to follow a similar multi-step pattern.
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conformations, the larger, more flexible GnRH peptides add additional complexity to the
agonist binding process at the GnRH receptor. While information on the mechanism of
GnRH I binding is limited, a few key observations allow postulation of the mechanism
of binding. Firstly, analysis of GnRH I-receptor contacts (see section 1.3) reveals that
the GnRH I C-terminal residues, Arg8, Pro9 and the Gly10NH2, interact predominantly
with TM1, TM2 and extracellular surface of the receptor at Asp7.32 in ECL3 (see
Fig.1.9). Substitutions at these positions in the ligand decrease ligand binding affinity
revealing an important role for the C-terminal residues in receptor binding (Millar et al.,
2004; Sealfon et al., 1997). Furthermore, the interaction of Arg8 with Asp7.32 is proposed
to represent a transient interaction that facilitates configuration of the II’-type turn of
GnRH I (Fromme et al., 2001). In contrast, the N-terminal residues of GnRH I, pGlu1,
His2 and Trp3 are proposed to interact mainly with receptor residues within TM3 and
TM5 (see Fig.1.9). Mutations of the proposed receptor contact residues for this N-
terminal region of the ligand have illustrated an important role for these residues in
GnRH receptor activation (Millar et al., 2004; Sealfon et al., 1997). Furthermore,
substitutions of these N-terminal residues with D-amino acids result in the generation of
GnRH receptor antagonists (Sealfon et al., 1997). This is consistent with the observed
role of agonist contacts with TM3, TM5 and TM6 in 2-AR activation (Swaminath et al.,
2004). Consolidating these experimental observations, I propose the following simplistic
scheme for the binding of GnRH I to the GnRH receptor. The C-terminal region of
GnRH I makes initial contacts with the receptor, serving to anchor the ligand to the
receptor and promoting formation of the high affinity conformation of the ligand. This
facilitates the insertion of the N-terminal region of GnRH I into the 7TM helices for
interaction with TM3 and TM5. The binding of GnRH II is likely to follow a similar
pattern considering the conserved nature of the N- and C-termini. However, its
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1.5.2 Intermediate receptor conformations induced upon agonist binding have
functional relevance
The sequential mechanism of agonist binding predicts an important aspect of receptor
structure and behaviour. Specifically, that GPCRs do not simply switch between two
conformations, the inactive and active state, but rather that receptors can assume
multiple conformations. Interestingly, some of the multiple intermediate receptor
conformations initiated by agonist binding may have distinct functional significance and
this results in initiation of different downstream signalling pathways which are activated
in a sequential manner.
An experimental illustration is provided by analysis of agonist-induced 2-AR
conformational changes in real time using fluorescence microscopy (Swaminath et al.,
2004). In response to the agonist, norepinephrine (NE), two conformational components
were observed at the receptor, a set of rapid conformational changes followed by a set of
slower conformational changes. In contrast, the agonist dopamine (DA), which differs
from NE by a single hydroxyl group, induced only rapid conformational changes at the
receptor. Analysis of the differences in signalling properties of the two agonists revealed
that, while DA is strongly coupled to G protein signalling, its capacity to mediate
receptor internalisation is significantly compromised compared with NE (Swaminath et
al., 2004). The authors propose that NE functional groups bind to the receptor in a
sequential manner inducing a series of receptor conformational intermediates. The first
set of rapid conformational changes induces a conformation that facilitates G protein
activation. This is followed by a second set of conformational changes initiated by the
hydroxyl group which distinguishes it from DA. This set of conformational changes has
a high energetic barrier and thus occurs at a slower rate and results in a conformation
that facilitates receptor internalisation (Swaminath et al., 2004). Thus NE initiates a
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1.5.3 Ligand-induced selective signalling (LiSS)
The work described above highlights an important aspect of agonist-induced receptor
activation, notably, that agonist structure has the capacity to direct the conformation of
the receptor and thus select the downstream signalling pathway(s) activated. In the
above example, DA was only able to activate G protein signalling. However, NE, which
has an additional hydroxyl group, was able to initiate activation of both G protein and
internalisation pathways. This suggests that compared with DA, NE stabilises a different
subset of receptor conformations that can be recognised by both G proteins and the
internalisation machinery of the cell.
The concept of LiSS refers to the ability of structurally distinct ligands to induce
different conformations at the same receptor that thereby determine the capacity of the
receptor to signal to different downstream signalling pathways (see Fig.1.10). There are
a number of terms used to denote this concept including agonist-directed trafficking and
functional selectivity (Kenakin, 1995; Kenakin, 2001; Kenakin, 2003; Urban et al.,
2007). In this review, it will be referred to as LiSS as this term considers the role of the
ligand in the selection of the signalling pathway, but is not biased by historical
classifications of ligands as agonists or antagonists (Millar et al., 2004; Millar et al.,
2008). This is important, because, as discussed below, certain ligands previously
classified as antagonists of a particular G protein signalling pathway, have demonstrated
the capacity to activate other signalling pathways.
There are several predictions from LiSS that can be investigated experimentally and thus
provide evidence for its existence (Perez and Karnik, 2005; Urban et al., 2007). The first
is that structurally distinct ligands facilitate induction of different receptor
conformations. This feature of LiSS is supported by investigations using experimental
techniques that directly probe the receptor conformation (Ghanouni et al., 2001a).
Indeed, two agonists of the 2-AR, isoproterenol and DA, induced different fluorescence
lifetime distributions of the fluorescently-labelled 2-AR, reflecting their capacity for
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ability of different ligands to induce different receptor conformations is also inferred
from studies describing the differential capacity of structurally distinct ligands to disturb
the rotamer toggle switch and ionic lock (Swaminath et al., 2005; Yao et al., 2006).
A second prediction of LiSS is that different receptor conformations have differential
capacities to activate downstream signalling pathways. Thus receptor mutations that
disrupt intramolecular interactions, and thus alter the receptor’s conformation, may alter 
the signalling capacity of the receptor at one signalling pathway, but not another.
Furthermore, different ligands, which stabilise distinct receptor conformations, should
exhibit reversals of potencies at different downstream signalling pathways within the
same experimental or cellular context.
Several examples examining G protein signalling pathways of GPCRs support these
described features of LiSS. Examples involve identification of the reversal or change in
the relative efficacy of ligands at different G protein pathways. In the 5-HT2C serotonin
receptor, which couples to both the Gq and Gi protein classes, a group of agonists with
comparable abilities to activate Gq, displayed differences in their abilities to activate Gi
signalling (Cussac et al., 2002). Furthermore, a Cys3.35Phe mutation in the 1b-AR
resulted in constitutive activation of the Gq signalling pathway, but without constitutive
activation of Gi signalling, a second pathway activated by this receptor (Perez et al.,
1996). Further support for the selectivity of this mutation-induced conformation was
provided by the observation that it increased the affinity and potency of one set of
structurally similar ligands, the phenethylamines, but had no affect on the affinity or
potency of the structurally distinct imidazolines (Perez et al., 1996). Interestingly,
different ligands can even facilitate selective interaction of the receptor with different G
proteins of the same class, as was observed with the Gi family of G proteins at the CB1
cannabinoid receptor (Mukhopadhyay and Howlett, 2005).
The signal selectivity of distinct receptor active conformations is not confined to
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an inverse agonist of Gs signalling at the receptor, paradoxically acts as an agonist in
inducing a non-G protein-mediated event involving upregulation of the MAPK pathway
(Baker et al., 2003). Additionally, distinct receptor conformations are able to
differentially select for signalling and desensitisation events, such as receptor
phosphorylation and internalisation. An example includes a bradykinin receptor, which
has a mutation within the 7TM domain, that was constitutively phosphorylated and
internalised, but did not activate Gq (Kalatskaya et al., 2004). Furthermore, a ligand of
the angiotensin AT1A receptor induced desensitisation-associated receptor
phosphorylation, but was unable to facilitate receptor internalisation, revealing that
distinct conformational states mediate these pathways (Thomas et al., 2000).
1.5.4 LiSS and multiple active conformations of the GnRH receptor
There are two sets of experimental data consistent with the ability of the GnRH receptor
to exhibit LiSS. The first involves the observation of reversal of ligand efficacies at
distinct GnRH receptor signalling pathways. While GnRH II has a ten-fold lower
potency at Gq signalling compared with GnRH I, it exhibits an increased potency in
mediating anti-proliferative signalling at the GnRH receptor (Enomoto and Park, 2004;
Grundker and Emons, 2003; Millar et al., 2008). Additionally, ligands previously
classified as antagonists due to their inability to activate Gq signalling, are reported to
induce Gi activation and anti-proliferative signalling at the GnRH receptor (Maudsley et
al., 2004; Yano et al., 1994).
Further experimental evidence consistent with LiSS at the GnRH receptor shows that
mutations of the receptor can selectively increase the binding affinity and/or potency of
the receptor for distinct ligands. This was demonstrated following alanine substitution of
Met3.43, Met5.54, Phe6.40, Phe6.44 and Ile7.52 in TM3, TM5, TM6 and TM7 of the GnRH
receptor. Mutation of each of these residues individually, specifically increased the
affinities of the mutant receptors for GnRH II, but did not affect the affinities for GnRH
I (Lu et al., 2005). As these residues are proposed not to form direct binding contacts
with GnRH II, these data suggest that GnRH I and GnRH II preferentially stabilise
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in the TM domain of the GnRH receptor and is not a direct ligand binding site, increased
the affinity and efficacy of GnRH I decapeptides with substitutions of Arg8 with Gln,
Trp or Ser, without significantly altering native GnRH I binding affinity and efficacy
(Lu et al., 2007). These results are consistent with the ability of structurally distinct
GnRH ligands to bind to and induce different receptor conformations at the GnRH
receptor.
1.5.5 Ligand-independent factors that alter receptor conformation
LiSS considers the effects of the extracellular ligand on GPCR structure which induces
long-range changes in receptor structure thereby altering the conformation of the
intracellular domain of the receptor and thus intracellular signalling. Conversely, GPCR
interactions with intracellular proteins, which alter the conformation of the receptor, can
change the observed affinity at the extracellular ligand binding pocket (Nelson and
Challiss, 2007). Evidence for ligand-independent modulation of receptor conformation is
considered in this section.
The earliest evidence that interaction of GPCRs with intracellular proteins altered
receptor conformation followed the observation that GPCR affinity was affected by the
presence or absence of G proteins (De Lean et al., 1980). High agonist binding affinity
was observed at receptors coupled to G proteins whereas uncoupling of the receptor
from G proteins by addition of GTP analogues resulted in a low affinity receptor
conformation. Other factors that have been observed to influence receptor conformation
include phosphorylation of the intracellular domains of the receptor, receptor
dimerisation, interactions with accessory proteins (such as receptor activity-modifying
proteins (RAMPs) and scaffolding proteins) and localisation of the receptor in the
specialised membrane microdomains, namely lipid rafts (Chini and Parenti, 2004;
McLatchie et al., 1998; Nelson and Challiss, 2007; Terrillon and Bouvier, 2004). A
consequence of the ability of the intracellular milieu to influence receptor conformation
is that, as a result of differential expression of proteins in different cells, GPCRs may
exhibit differential binding and signalling profiles depending on the tissue in which the
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and signalling profile of a receptor in different cells involves differential splicing and
editing of the receptor and distinct post-translational modifications (such as
palmitoylation and phosphorylation) (McGrew et al., 2004; Nelson and Challiss, 2007).
The GnRH receptor exhibits cell-context dependent signalling (Dobkin-Bekman et al.,
2006). Indeed, the large tissue-specific differences in GnRH receptor signalling led
researchers to suggest that a second form of the GnRH receptor is expressed by splice
variants or otherwise (Enomoto et al., 2004). However, other data argue against the
existence of such variants (Grundker et al., 2001). Nevertheless, there is evidence to
suggest that the GnRH receptor is subject to a number of the factors discussed above.
For example, there have been several reports to indicate that phosphorylation of the
GnRH receptor is able to alter ligand binding (Caunt et al., 2004; Liebow et al., 1991).
Furthermore, there are several lines of evidence to suggest that the GnRH receptor forms
homodimeric complexes (Cheung and Hearn, 2003; Cheung and Hearn, 2005). The
GnRH receptor may also interact with a protein, denoted GnRH II reliquum, which is
translated from a short mRNA transcript initiated from the cytoplasmic end of TM5 to
the carboxyl terminus of the putative type II GnRH receptor gene (Pawson et al., 2005).
This protein affects expression of the type I GnRH receptor (Pawson et al., 2005).
However, the full effects of this protein on the GnRH receptor function, such as
induction of differential signalling, require further elucidation. These data highlight the
importance of cellular context when documenting the pharmacological and signalling
profile of ligands at a particular receptor.
1.5.6 Revisiting the concept of efficacy and theoretical models for receptor activation
Features of LiSS have necessitated revisiting some of the classical pharmacological
terms and theoretical models of receptor activation. One example is the concept of
efficacy. Historically, efficacy of a ligand provided a measure of ligand-induced
production of downstream second messenger molecules relative to the maximal response
observed in the relevant tissue (Kenakin, 2002; Kenakin, 2003). However, the emerging
complexity of GPCR behaviour requires the inclusion of responses such as receptor
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activation of multiple G proteins, into the term efficacy (Kenakin, 2002). Within this
framework a ligand can demonstrate efficacy at one pathway while having no, or
negative efficacy (inverse agonism) at another functional response. This allows for the
ability of, for example, antagonists at G protein signalling pathways to have a measure
of efficacy at induction of internalisation pathways.
The utility of the ETCM is limited as it cannot explain the observation of reversal of
ligand efficacy (Kenakin, 2003). Furthermore, this model considers only the dynamic
interactions of the ligand, receptor and a single G protein type (Kenakin, 2004).
However, many GPCRs activate multiple G proteins as well as non-G protein interaction
partners that induce functional responses at GPCRs. An alternative model to describe
receptor behaviour is the probabilistic model (Kenakin, 2004). This model states that in
the absence of ligand, instead of existing in two conformations, the inactive and active
states, the receptor exists in a number of distinct conformations. Ligand binding, as well
as the presence of other factors that bind to the receptor and alter its conformation,
change the distribution of receptor conformations increasing the probability of a receptor
being in one subset of conformations and decreasing it in others. The subset of receptor
conformations stabilised by the ligand determines the set of signalling pathways
activated by that receptor (see Fig.1.11). Thus this model can incorporate many different
facets of GPCR behaviour and is useful to explain data observed in the complex tissue
environments (Kenakin, 2004).
1.5.7 Molecular basis for distinct receptor conformations
Historically, receptors were viewed as switches which can simply be turned on and off.
However, the existence of LiSS suggests that the receptor is instead made up of a series
of functional domains/molecular switches, each with the capacity to alter the
conformation of a specific microdomain within the receptor’s structure. Diferent 
agonists are able to disrupt a specific subset of these functional domains and this
determines the conformation and signalling capacity induced by the ligand (Yao et al.,
2006). These functional domains include the highly conserved intramolecular
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rotamer toggle switch, the ionic lock and the NPxxY motif (Weinstein, 2005; Yao et al.,
2006). However, there are likely to be additional receptor-specific functional domains
specialised for the signalling of the relevant GPCR. The molecular mechanisms
underlying LiSS are poorly understood and future research efforts should address LiSS
on two levels. Firstly, it is important to be able to translate ligand interactions into the
disruption of particular functional domains within the receptor structure. Secondly, the
disruption of specific permutations of the functional domains/intramolecular interactions
needs to be related to the activation of downstream signalling pathways. An example of
the coupling of a functional domain to a downstream signalling pathway is the proposal
that the NPxxY motif, which makes intramolecular interactions with helix 8, regulates
the interaction with and activation of proteins that interact with the C-terminal tail of
GPCRs, such as PDZ domain-containing proteins (Weinstein, 2005).
1.5.8 Summary
Understanding the ability of ligands to selectively stabilise distinct receptor
conformations and thus direct the activation of the downstream signalling pathways has
important therapeutic implications as it presents the possibility that GPCR ligands/drugs
can be tailored to induce activation of a desired signalling pathway, but not activation of
other signalling pathways that may be associated with side-effects. To attain this level of
utility, understanding LiSS requires investigation from several experimental vantage
points (Urban et al., 2007). Firstly, it is important to delineate how structurally distinct
ligands interact with the receptor to induce different receptor conformations that have
selective signalling capacity. Secondly, it is necessary to be able to relate distinct
receptor conformations to the specific functional downstream responses activated.
Finally, at the most distal level, the role of receptor downstream signalling must be
placed in the context of the tissue and organism.
An interest in understanding the molecular mechanisms facilitating LiSS at the GnRH
receptor represents the underlying motivation and central theme for the work in this
dissertation. In chapter 2, I present an investigation of the ability of Tyr5 and His5 of
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of the distinct receptor conformations and differential signalling induced by GnRH I and
GnRH II, delineation of the similar and contrasting ligand-receptor interaction sites of
these two ligands will provide insight into LiSS at the GnRH receptor. In the subsequent
chapters, I present investigations into the ability of the GnRH receptor to signal to
diverse downstream signalling pathways. In chapter 3, the capacity of the GnRH
receptor to interact with multiple G proteins, specifically Gq and Gi, is explored.
Subsequently, in chapter 4, a novel G protein-independent signalling pathway involving
activation of the SH2 domain-containing phosphatase 2 (SHP-2) by the GnRH receptor
is presented. Exploring the functional motifs of the GnRH receptor required to activate
downstream signalling pathways will contribute to the understanding of the molecular
mechanism whereby the GnRH receptor mediates such diverse physiological effects (see
Table 1.1). Ultimately, insight into LiSS at the GnRH receptor may assist in the
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Figure 1.9. Schematic representation of GnRH I binding to the GnRH receptor TM domains. GnRH
I is proposed to make the following interactions: PGlu1 (1) interacts with Asn5.39; His2 (2) interacts with
Asp2.61 and Lys3.32; Tyr5 (5) interacts with Tyr6.58; Arg8 (8) interacts with Asp7.32; Pro9 and the C-terminal
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Figure 1.10. The concept of ligand-induced selective signalling (LiSS). A, Historically, GPCRs (R)
were viewed as “on-off switches”, where many structuraly distinct ligands (L1-L4) bind to the same
receptor type and induce activation of a single downstream signalling pathway (SP1) by stabilising a single
receptor active conformation. B, However, recent evidence suggests that GPCRs can activate multiple
downstream pathways (SP1-SP3) independently of each other. These signalling pathways may represent
multiple G protein signalling pathways, G protein-independent signalling or even initiation of receptor
desensitisation and internalisation. LiSS refers to the ability of different ligands to facilitate differential
activation of the downstream signalling pathways by stabilisation of distinct active conformations of the
receptor, which differ in their capacity to interact with downstream signalling molecules. In the above
example, preferential coupling of the different ligands is indicated by larger arrows. Figure is adapted
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Figure 1.11. Probabilistic theory of GPCR activation. In the probabilistic theory, GPCRs exist in a
range of receptor conformations. Each receptor-mediated biological event, such as G protein coupling,
receptor phosphorylation, internalisation and non-G protein signalling, is facilitated by a specific ensemble
of receptor conformations that may overlap with other receptor-mediated activities. In the resting state,
GPCRs occur in a subset of conformations indicated as the reference state that is usually associated with
little pharmacological activity. However, a small percentage of the receptor conformations in the reference
state may overlap with, for example, the G protein coupling conformation, thus giving rise to constitutive
activity (grey shaded area) as indicated in the example above. Ligand binding or accessory proteins alter
the distribution of receptor conformations thereby changing the biological activities induced by the






































































Chapter 1: Literature Review
63
1.6 GnRH receptor signalling
GnRH receptor signalling has been studied extensively and is the subject of several
reviews (Caunt et al., 2006; Dobkin-Bekman et al., 2006; Kraus et al., 2001; Kraus et al.,
2006; Naor et al., 2000; Naor et al., 1998; Pawson and McNeilly, 2005). However, a
comprehensive account of these signalling pathways is beyond the scope of this review.
Instead, I focus on two signalling pathways investigated in this thesis, which are
suggested to facilitate the anti-proliferative and proapoptopic signalling of GnRH
receptor, specifically coupling of the receptor to the alternative G protein family, Gi, and
activation of protein tyrosine phosphatase (PTP) signalling (Imai et al., 1996a; Maudsley
et al., 2004). Thus, in the final section of this review, multiple G protein signalling and
activation of the SH2-domain containing phosphatases (SHPs) by GPCRs are discussed.
1.6.1 Activation of multiple G proteins by the GnRH receptor is proposed to enable
signalling to distinct downstream pathways
Historically, GPCRs were thought to mediate activation of downstream signalling
pathways by coupling exclusively to one G protein class. However, recent evidence has
revealed that a single GPCR can couple to multiple G protein classes with distinct
downstream signalling effects (Hermans, 2003; Kukkonen, 2004). Furthermore, as
discussed above, structurally distinct ligands can induce different conformations at the
same receptor, which differ in their ability to activate different classes of G proteins
(Akam et al., 2001; Gazi et al., 2003; Perez and Karnik, 2005; Reversi et al., 2005;
Urban et al., 2007). Thus some ligands may be able to activate a single G protein class,
while others may activate two G protein families with differing efficacies.
The GnRH receptor is able to induce anti-proliferative and proapoptopic signalling in
reproductive cancer cells (Grundker and Emons, 2003; Grundker et al., 2001; Kraus et
al., 2006; Maiti et al., 2005; Maudsley et al., 2004). However, activation of this pathway
does not correlate with classical GnRH receptor signalling in the pituitary, which
involves activation of the Gq/11 family of G proteins (Grundker and Emons, 2003; Millar
et al., 2008). This has led to the proposal that the anti-proliferative effects of the GnRH
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Millar et al., 2008; Stanislaus et al., 1998b). Indeed, there is evidence to suggest that the
Gi family of G proteins is involved in GnRH receptor anti-proliferative signalling
(Grundker et al., 2001; Imai et al., 2006; Limonta et al., 1999). However, the ability of
the GnRH receptor to couple directly to Gi is still a matter of debate (Grosse et al.,
2000). In this section, GPCR-G protein coupling is critically discussed with emphasis on
data specific to GnRH receptor-G protein coupling. As the GnRH receptor is also
proposed to couple to Gs, evidence to support this interaction is also presented.
1.6.1.1 Determination of GPCR-G protein coupling preferences
Determination and classification of the G protein classes activated by a GPCR are often
inferred from the second messenger systems activated by the receptor, which are specific
to that G protein type (see Table 1.2). Activation of Gq results in activation of
phospholipase C (PLC), which hydrolyses phosphatidylinositol 4,5-bisphosphate
(PIP2), thereby generating the second messengers, inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). In contrast, Gs and Gi have opposing effects on adenylate cyclase
(AC), where Gs is stimulatory and Gi is inhibitory, resulting in respective generation or
inhibition of the second messenger cAMP. Thus if GPCR activation results in generation
of IP3, accumulation of cAMP or reduction in cAMP production, the GPCR is frequently
classified as a Gq-, Gs- or Gi-coupled receptor respectively. However, the effectors,
PLCand adenylate cyclase, can be indirectly regulated by alternative G protein classes.
For example, Gsubunits dissociated from activated Gsubunits, such as Gs and Gi,
are able to activate PLC(Table 1.3). Additionally, Ca2+ ions are able to differentially
activate or inhibit certain isoforms of AC (Birnbaumer, 2007). Ca2+ ions released from
intracellular stores following IP3 generation may result in effects on AC in response to a
Gq-coupled GPCR. Thus designation of the G protein class activated by a GPCR, based
on analysis of the observed regulation of second messenger systems, can result in
erroneous conclusions.
Another mechanism used to infer GPCR-mediated G protein activation involves the use
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cholera toxin (CTX) facilitates ADP-ribosylation of Gs proteins inducing the constitutive
activation of Gs. If CTX is able to induce a similar cellular response as that of the
GPCR, some researchers conclude that the GPCR is able to activate Gs. However, as
discussed above, this may not be accurate as other G protein subtypes may mediate an
increase in cAMP. Another toxin, pertussis toxin (PTX) induces ADP-ribosylation and
inactivation of the Gi family of G proteins and can thus be used to suggest activation of
this G protein subtype in response to a GPCR (Cabrera-Vera et al., 2003). However, the
ability of GPCRs to transactivate RTKs, which can activate G proteins, suggests that use
of this toxin is also not able to prove conclusively that a specific G protein class is
coupled to a GPCR (Kreuzer et al., 2004; Shan et al., 2006a).
The use of second messengers and toxins to determine the G protein coupling preference
of a GPCR is therefore problematic. Thus in order to conclusively deduce the G protein
activated by a GPCR, the most proximal step of the receptor-stimulated G protein
activation pathway should be assessed. The activation of a G protein by a GPCR
involves the exchange of a GDP molecule for GTP on the G protein (see section 1.2).
Arguably one of the best methods to a capture this activation event is the [35S]GTPS
binding assay, which uses a radioactive non-hydrolysable GTP analogue to label
activated G proteins (Harrison and Traynor, 2003; Lazareno, 1999; Milligan, 2003;
Weiland and Jakobs, 1994). This method is performed in membranes eliminating cross-
talk that would be observed in the intact cell and can quantitatively measure activation
of a specific G protein class.
1.6.1.2 The GnRH receptor is proposed to couple to multiple classes of heterotrimeric
G proteins
Numerous studies suggest that the GnRH receptor couples to multiple G protein classes,
including Gq, Gs and Gi. Table 1.4 provides a list of the G proteins that the GnRH
receptor is proposed to activate, the experimental method used to suggest which G
protein class is involved and the downstream signalling affected by activation/inhibition
of the relevant G protein. The majority of these studies rely on second messenger
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proteins. Only two studies measured either a direct GnRH receptor-G protein interaction
or receptor-stimulated exchange of GDP for GTP (see Table 1.4). The first study showed
cross-linking of Gq and Gi to the GnRH receptor (Grundker et al., 2001). However, this
interaction was only investigated in the absence of agonist. Thus the specificity of the
interaction and the ability of the GnRH receptor to activate the G proteins (which would
be expected to induce receptor-G protein dissociation and thus decrease the quantity of
G proteins cross-linked to the receptor) was not assessed. The second study captured
GnRH receptor-catalysed G protein activation by measuring the binding of a non-
hydrolysable GTP analogue, [-32P]GTP azidoanilide, to the G proteins in the presence
or absence of agonist (Grosse et al., 2000). The assay was performed in membranes
which eliminated the possibility of signal cross-talk. Investigation of GnRH receptor-
induced photolabelling of Gq, Gs, Gi, G12 and G13 with [-32P]GTP azidoanilide revealed
that only Gq was activated in response to GnRH I (Grosse et al., 2000). However, this
contrasts with other, albeit less direct methods, that suggest that Gs and Gi specifically,
rather than their downstream second messengers, are indeed involved in GnRH receptor
signalling. For example, Gs and Gi proteins undergo agonist-stimulated palmitoylation
and release from the plasma membrane following GnRH receptor activation
(Krsmanovic et al., 2003; Stanislaus et al., 1998c). Furthermore, the ability of GnRH
receptor agonists to antagonise PTX-catalysed ADP ribosylation of Gi in a dose-
dependent manner suggests that Gi is activated downstream of the GnRH receptor
(Grundker et al., 2001; Limonta et al., 1999). Thus, the ability of the GnRH receptor to
couple to Gs and Gi is still a matter of debate.
1.6.1.3 Receptor determinants of receptor-G protein coupling
Due to the low sequence homology of the ICLs of GPCRs, efforts to designate the G
protein coupling preference of a receptor based on analysis of the primary sequence have
proved largely unsuccessful (Wess, 1998). Instead, similar to the paradigm in the 7TM
domain, the ICLs of GPCRs are proposed to share a similar conformation, rather than
sequence homology, that facilitates G protein recognition and activation (Wong, 2003).
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receptor conformation which facilitates G protein activation is suggested to be an
amphiphilic -helical structure with hydrophobic and cationic residues on opposing
sides of the helix (Wong, 2003). This structure is suggested to activate all G protein
classes, including Gi/o, Gs and Gq proteins (Wong, 2003). This has led to the hypothesis
that ICLs constitute two functional domains, an activation domain that interacts with and
activates the G protein and a selectivity domain that restricts access to the activation
domain to a specific G protein subtype (Wong, 2003).
Analysis of the functional domains of the ICLs of GPCRs that are important for G
protein activation have revealed the importance of ICL2 and the N- and C-terminal
regions of ICL3 (Wess, 1998). This is supported by ICL-swapping experiments that
enabled recipient GPCRs to activate the G protein class of the donor receptor (Wess,
1998). In contrast, consensus interpretation of the roles of ICL1 and the C-terminal tail
suggest that they are predominantly involved in regulating the selectivity and efficiency
of the receptor-G protein interaction (Wess, 1998). However, the importance of these
domains varies among different GPCRs (Wess, 1998).
In the GnRH receptor, residues in ICL1, ICL2 and ICL3 are proposed to mediate
receptor-G protein specificity. ICL1 of the GnRH receptor exhibits two basic residues at
its N-terminal end and a BBxxB (where B is a basic amino acid and x is any residue)
motif at the C-terminal end of the loop (see Fig.1.8). This motif is suggested to facilitate
Gs and Gi coupli g in other ICLs of the GPCR family (Arora et al., 1998). Site-directed
mutagenesis of residues within ICL1 of the GnRH receptor severely compromised
cAMP accumulation, but did not affect IP signalling in COS-7 cells (Arora et al., 1998).
This suggests that the cAMP and IP signalling pathways can be activated independently
of each other and that ICL1 may facilitate selective coupling to Gs proteins. Mutation of
residues in ICL2 has revealed the importance of this loop in IP signalling and thereby
suggested a role for ICL2 in Gq coupling (Arora et al., 1997; Arora et al., 1995;
Ballesteros et al., 1998). Furthermore, other experimental data suggest that ICL3 is also
important for Gq and Gs coupling. For example, mutation of Ala6.29 (at the C-terminal
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that ICL3 facilitates Gq coupling (Myburgh et al., 1998a). Furthermore, overexpression
of GnRH receptor ICL3 peptides in GGH3 cells resulted in inhibition of GnRH receptor-
induced IP signalling and cAMP production, suggesting that this loop facilitates both Gs
and Gq coupling (Ulloa-Aguirre et al., 1998). However, the ability of ICL3 of the Gq-
coupled M1 muscarinic receptor to mediate inhibition of GnRH-induced cAMP
accumulation questions the specificity of this experimental approach (Ulloa-Aguirre et
al., 1998). In summary, ICL1 and ICL3 are proposed to facilitate Gs coupling, while
ICL2 and ICL3 are suggested to enable Gq coupling by the GnRH receptor. To date, no
domains have been implicated in GnRH receptor activation of Gi.
1.6.1.4 Other determinants of receptor-G protein coupling
In addition to selectivity imposed by the sequence of the GPCR, there are a number of
other factors that regulate the selectivity of the receptor-G protein interaction (Albert
and Robillard, 2002; Wess, 1998). The most obvious of these are the determinants
inherent in the G protein sequence. The C-terminal amino acids of the Gprotein are
critically involved in receptor selectivity (Oldham and Hamm, 2006; Slessareva et al.,
2003; Wess, 1998). Furthermore, other regions of G, such as the N-terminus, the 4/6
loop, the N/1 loop, the 2/4 loop and the 3/5 loop are also suggested to regulate
interaction with the receptor, but may be specific to the G protein class involved
(Oldham and Hamm, 2006; Slessareva et al., 2003). In addition to G, the subtype
composition of the Gsubunit is also proposed to modulate receptor-G protein
selectivity (Albert and Robillard, 2002; Oldham and Hamm, 2006). Other factors that
affect receptor-G protein coupling specificity include G protein expression levels,
modifications of the receptor (such as phosphorylation), interactions of RGS proteins
with the G protein and interactions of scaffolding proteins with the receptor (Albert and
Robillard, 2002). Thus the G protein selectivity observed at a particular GPCR may be
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1.6.1.5 Summary
The GnRH receptor is suggested to exhibit promiscuous coupling to Gq, Gs and Gi
(Table 1.4). However, the use of second messenger systems to designate these coupling
preferences and conflicting reports which suggest that the GnRH receptor only couples
to Gq (Grosse et al., 2000), highlight the necessity to investigate GnRH receptor
coupling using techniques that directly measure receptor-stimulated G protein activation.
Furthermore, the influence of ligand structure on these distinct signalling pathways and
the receptor domains required for preferential G protein coupling are not well-defined.
The importance of investigating these pathways is underscored by proposals suggesting
that the activation of multiple G proteins may facilitate the diverse physiological effects
of the GnRH receptor (Millar et al., 2008; Stanislaus et al., 1998b). As I am interested in
the anti-proliferative and proapoptopic effects of the GnRH receptor in reproductive
cancers, I chose to focus on Gi activation, as this G protein is proposed to mediate these
effects (Limonta et al., 1999; Maudsley et al., 2004). Additionally, the molecular
mechanisms underlying the proposed interaction between the GnRH receptor and Gi are
poorly understood. To address this, in chapter 3, I set up the [35S]GTPS binding assay
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Table 1.4. Investigation of multiple G protein coupling of the GnRH receptor
G
protein(s)
Cell type Method used to infer G protein involvement Direct
method
Reference




Dose-dependent protection of Gi from ADP-ribosylation by PTX in the
presence of increasing concentrations of a GnRH agonist. PTX inhibits PTP
activity.
No (Imai et al.,
1996b)
Gi LNCaP and DU145
prostate cancer cells
Ability to decrease forskolin-stimulated cAMP responses. GnRH agonist




Gi Ovarian cancer cell line PTX inhibits ERK activation. No (Kimura et al.,
1999)
Gi Prostate cancer JEG-3 and
BPH-1 cells
Inhibition of cAMP. No (Maudsley et
al., 2004)
Gi, Gq Ishikawa, Hec-1A
endometrial cancer cells
and EFO-21 and EFO-27
ovarian cancer cells
Cross-linking experiments indicate GnRH receptor coupling to Gq and Gi.
PTP activity and EGF-induced c-fos expression are PTX-sensitive. GnRH
agonist antagonises PTX-catalysed ADP ribosylation of Gi.
Yes (Grundker et
al., 2001)




Gi, Gs Gonadotrope PTX-sensitive IP production, CTX-enhanced LH release. CTX and PTX
decreased GnRHR binding.





Gi, not Gs Ovarian cancer cells PTX inhibits induction of apoptosis and PP2A redistribution. CTX does not
affect this pathway.
No (Imai et al.,
2006)
Gq T3 IP3 and DAG production No (Poulin et al.,
1996)
Gq T3 Gq/11 antibody inhibits PLC activity No (Hsieh and
Martin, 1992)
Gq In vivo Gq and G11
knockout mice
LH and steroid (testosterone and estradiol) production affected, but not
abolished in mouse knockouts of either Gq or G11.
No (Stanislaus et
al., 1998a)
Gq Pituitary cells Laser-scanning microscopy and immunohistochemistry reveal redistribution
of Gq/11 in response to a GnRHR agonist















Cell type Method used to infer G protein involvement Direct
method
Reference
Gq Purified gonadotrope Phosphoinositide hydrolysis and DAG formation. No (Andrews and
Conn, 1986)
Gq Rat pituitary cell cultures,
GGH3
Palmitoylation labelling of the Gq/11. IP production. Downregulated
expression of Gq/11 in response to a GnRH agonist.
No (Stanislaus et
al., 1997)
Gq, Gs COS-7 cAMP and IP production. No (Arora et al.,
1998)
Gq, Gs CV-1 cells IP and cAMP production. No (Oh et al.,
2003)
Gq, Gs GGH3 GnRHR third intracellular loop peptide competitively inhibited IP and cAMP




Gq, Gs GGH3 IP production, cAMP accumulation. No (Awara et al.,
1996)
Gq, Gs Sf9 insect cells IP and cAMP production. No (Delahaye et
al., 1997)








Gq, Gs, Gi GT1-7 neurons Measurement of cAMP (stimulation at low agonist concentrations and
inhibition at high agonist concentrations), Ca2+ and IP production, and






Rat pituitary cells, GGH3 Receptor-stimulated palmitoylation of Gi and Gs protein types. Enhanced or
decreased cAMP production when Gs or Gi are overexpressed. IP production





GGH3 Gq and Gs involvement in MAPK signalling suggested by PKC- and PKA-





LT2 ERK, c-fos and LHinduction are PTX-insensitive, but affected by
interference with Gq and Gs action. Gq and Gs protected from trypsin
digestion in presence of GnRH agonist and GTP analogue.
No (Liu et al.,
2002)
Gq, not Gi T3 MAPK activation is not sensitive to PTX, thus suggest Gq. No (Reiss et al.,
1997)




T3, CHO-K1, COS-7 IP production and Gq protein GTP photolabelling. Lack of photolabelling of
all other G protein types. IP, Ca2+ release and ERK signalling are PTX-
insensitive. No cAMP or cAMP response element responses.




















T3 Time and dose-dependent downregulation of G proteins Gq and G11 in





Gs GGH3 PRL release in a cAMP-dependent manner. No (Stanislaus et
al., 1996)
Gs GGH3 PRL release facilitated by cAMP production, which is mimicked by CTX. No (Kuphal et al.,
1994)
Gs Ovarian tumour cells cAMP production. cAMP analogues induce ERK activation. No (Chamson-
Reig et al.,
2003)
Gs, not Gi GGH3 cAMP production. cAMP analogues and CTX enhance GnRHR gene








Not Gs Primary rat culture
pituitary cells
No effect of CTX or cAMP potentiating agents or analogues on LH release. No (Conn et al.,
1979)
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1.6.2 GPCR-mediated G protein-independent signalling and regulation of
phosphotyrosine signalling
Regulation of phosphotyrosine signalling is an important signal transduction mechanism
that regulates a wide variety of essential physiological processes, including proliferation,
migration, adhesion and differentiation (Ostman et al., 2006; Stoker, 2005). The
phosphotyrosine content of a cell is tightly regulated by the opposing actions of protein
tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). This equilibrium is
frequently dysregulated in cancer cells. Consistent with this, PTKs are able to transform
cells while PTPs often exhibit tumour suppressor activity (Ostman et al., 2006).
Historically, receptor-activated phosphotyrosine signalling as considered to be
exclusively mediated by receptor tyrosine kinases (RTKs) and receptor tyrosine
phosphatases (RTPs). However, emerging data indicates that GPCRs also regulate
tyrosine phosphorylation cascades (Gavi et al., 2006; Lowes et al., 2002; Luttrell and
Luttrell, 2004). Specifically, GPCRs have been shown to initiate transactivation of
receptor tyrosine kinases (RTKs), activation of the cytoplasmic tyrosine kinase, src, and
activation of PTPs (Florio, 2008; Luttrell and Luttrell, 2004). Interestingly, while some
GPCRs activate these pathways downstream of G protein signalling, recent experimental
evidence suggests that certain GPCRs are able to directly interact with and activate
PTKs/PTPs, independently of G proteins (Florio, 2008; Sun et al., 2007b). The ability of
GPCRs to interact with and/or activate PTK/PTP molecules, independently of G
proteins, presents the possibility that the structural requirements for activation of the two
distinct pathways may differ. Thus investigation of the molecular determinants which
facilitate activation of the PTK/PTP pathway and the differential capacity of different
ligands to activate this pathway, when compared to G protein signalling, may facilitate
the understanding of LiSS at the GPCR. In this review, I will focus on the molecular
mechanisms that are proposed to facilitate GPCR direct interactions with two types of
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1.6.2.1 GPCRs can bind directly to src
Src is a member of the src family of protein tyrosine kinases (SFKs). These proteins play
important roles in the regulation of cell growth, differentiation, cell shape, migration and
survival (Parsons and Parsons, 2004). Consistent with this, src activity is frequently
upregulated in many cancers and is considered an oncogene (Parsons and Parsons,
2004). SFKs are critical and well-established downstream signalling partners of growth
factor receptors/RTKs (Bromann et al., 2004). However, src activation by GPCRs is
now also well-established and is proposed to facilitate the effects of GPCRs on cell
proliferation, cytoskeleton remodelling and in GPCR trafficking (Luttrell and Luttrell,
2004).
Src consists of an N-terminal domain, followed by an SH3, an SH2, a kinase domain and
a short C-terminal tail (Boggon and Eck, 2004). Inactive src exists in an autoinhibited
conformation where the SH3 and SH2 domains fold back against the kinase domain
making intramolecular interactions that lock the kinase in an inactive conformation. An
interaction that stabilises this conformation is binding of the SH2 domain to an
autoinhibitory phosphorylated tyrosine residue in the C-terminal tail (Boggon and Eck,
2004). Src activation is initiated by engagement of its SH2 and/or SH3 domains with
appropriate motifs or by dephosphorylation of the autoinhibitory tyrosine residue in its
C-terminal tail. These events enable autophosphorylation of a tyrosine residue within the
kinase domain and activation of src (Boggon and Eck, 2004).
There are a number of ways in which GPCRs can form direct complexes with src. One
mechanism of GPCR-src interaction involves utilisation of -arrestin as a scaffold. The
ability of GPCRs to form a complex with -arrestin and src, thereby facilitating MAPK
activation, has been suggested for several GPCRs, including the 2-adrenergic and
angiotensin (AT1A) receptors (Luttrell et al., 1999; Sun et al., 2007b; Wei et al., 2003). A
second mechanism for GPCR-src interactions involves GPCR engagement of the src
SH2 domain (Fan et al., 2001). The 2-AR is suggested to recruit src by a canonical
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in its C-terminal tail (Fan et al., 2001). This interaction enables activation of src and is
believed to facilitate GPCR desensitisation and internalisation, in addition to the
activation of MAPK cascades (Fan et al., 2001). GPCRs are also able to interact directly
with src SH3 domains. Indeed, the serotonin 5-HT6 receptor C-terminal tail binds to the
SH3 domain of a SFK member, fyn, thereby initiating MAPK signalling (Yun et al.,
2007). Furthermore, the 3-AR exhibits SH3-binding proline rich (PxxP) motifs in its
third intracellular loop and C-terminal tail, which are proposed to directly interact with
src (Cao et al., 2000). Finally, a splice variant of the CCK2 receptor is able to bind to
and directly activate src via a 69 amino acid insertion in its third intracellular loop by an,
as yet, undefined mechanism (Olszewska-Pazdrak et al., 2004).
Thus numerous GPCRs are able to bind to src, either using -arrestin as a scaffold or by
direct engagement of the SH2 or SH3 domains of src, thereby facilitating src activation.
These mechanisms of src activation can occur in a G protein-independent manner (Sun
et al., 2007b). For example, an angiotensin II analogue is able to recruit -arrestin and
initiate MAPK activation without activation of G protein signalling (Wei et al., 2003).
This implies that -arrestin recruitment and G protein signalling can occur
independently of each other, suggesting that src activation via interaction with the
GPCR--arrestin complex could also occur independently of G protein signalling.
Additionally, expression of a peptide of the third intracellular domain of a CCK2 splice
variant was able to bind to and activate src, suggesting that the mechanism of src
activation by this receptor is G protein-independent (Olszewska-Pazdrak et al., 2004).
Sun et al. have provided convincing evidence that the 2-AR is also able to activate src
independently of G proteins (Sun et al., 2007a). They show that that the 2-AR can
initiate src-dependent MAPK activation in Gs knockout cells in the presence of PTX,
eliminating the possibility that Gs and Gi are involved in this pathway (Sun et al.,
2007a). Furthermore, it was shown that the 2-AR can activate src in a purified in vitro
system in the absence of G proteins (Sun et al., 2007a). The molecular mechanisms for
src activation by this receptor appear to be cell type specific, as utilisation of -arrestin,
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to mediate src activation by the 2-AR in different cell types (Fan et al., 2001; Luttrell et
al., 1999; Sun et al., 2007a).
The GnRH receptor is also able to activate src in many different cell systems, utilising
varied mechanisms, including transactivation of the epidermal growth factor receptor
(EGFR) or via activation downstream of PKC, depending on the cell context (Dobkin-
Bekman et al., 2006; Kraus et al., 2001; Kraus et al., 2006; Naor et al., 2000). Notably,
in T3 cells, a PKC inhibitor was only partially effective in inhibiting src activation
leading to the suggestion that src activation by the GnRH receptor has a Gq-independent
component (Benard et al., 2001). A Gscavenger and -arresti dominant negative
construct were unable to reduce GnRH-induced ERK activation, suggesting that these
proteins do not contribute to src activation by the GnRH receptor in T3 cells (Benard et
al., 2001). This raises the possibility that the GnRH receptor may facilitate direct
activation of src. Indeed, in chapter 4, I show that the GnRH receptor forms a complex
with src, as detected by immunoprecipitation experiments, and propose a mechanism to
explain how this interaction occurs.
1.6.2.2 GPCRs can bind directly to SHPs
In addition to direct interactions with src PTKs, GPCRs form direct interactions with a
family of cytoplasmic PTPs, the SHPs. Historically, SHPs were identified as signalling
partners of immunoreceptors, binding to these receptors via immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) and thereby facilitating the negative regulatory signals
of these receptors (Barrow and Trowsdale, 2006; Coggeshall et al., 2002; Underhill and
Goodridge, 2007; Unkeless and Jin, 1997). Early identification of SHP-binding ITIMs
suggested that the consensus sequence was V/IxpYxxL/V (where pY is a phosphorylated
tyrosine residue and x is any amino acid) (Unkeless and Jin, 1997). However,
subsequent studies have suggested a much broader motif specificity, particularly at the
-2 position relative to the essential phosphorylated tyrosine residue of the motif (Imhof
et al., 2006; Sweeney et al., 2005; Wavreille et al., 2007). This broad specificity
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receptors, including growth factor receptors and GPCRs (Florio, 2008; Wang et al.,
2006).
SHPs are involved in the regulation of many cell processes, including differentiation,
cell proliferation, survival and apoptosis, cytoskeletal maintenance and chemotaxis
(Chong and Maiese, 2007; Stein-Gerlach et al., 1998). They mediate these effects by
influencing a number of signalling pathways, including the PI3K/Akt, JAK/STAT and
MAPK cascades (such as ERK and JNK) and NF-B (Chong and Maiese, 2007). SHP-1
is mainly involved in negative regulation of these pathways (Chong and Maiese, 2007).
In contrast, SHP-2 signalling can be either positive or negative depending on the cell
context (Chong and Maiese, 2007). Furthermore, SHP-1 is predominantly expressed in
haematopoietic cells, while SHP-2 is ubiquitously expressed (Chong and Maiese, 2007;
Neel et al., 2003).
The basic structure of the SHPs consists of two SH2 domains, denoted the N-terminal
SH2 (N-SH2) and C-terminal SH2 (C-SH2) domains, which are followed by the
phosphatase domain and a C-terminal tail which contains two tyrosine phosphorylation
sites (Neel et al., 2003; Poole and Jones, 2005). Reminiscent of src, in the inactive state,
the N-SH2 domain of SHP is folded over and engages with the catalytic cleft of the
phosphatase domain. The C-SH2 domain is unaffected by this interaction and is
proposed to function as sensor for phosphorylated docking sites for the protein (Neel et
al., 2003). There are two proposed mechanisms for activation of the SHPs (Neel et al.,
2003). The first mechanism involves engaging the N- and C-SH2 domains with
appropriately phosphorylated motifs. The second mechanism requires phosphorylation
of the two tyrosine residues pY536/pY542 and pY564/pY580 in the C-terminal tail of
SHP-1/SHP-2 (Neel et al., 2003). These residues bind to the N-SH2 and C-SH2 domains
respectively, relieving inhibition of the phosphatase and facilitating its activation.
SHPs are activated downstream of a number of GPCRs, including the chemokine
CXCR4 (Chernock et al., 2001; Fernandis et al., 2004; Hoff and Brunner-Weinzierl,
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type A endothelin-1 (Bisotto and Fixman, 2001), angiotensin AT1 (Fernstrom et al.,
2005; Godeny et al., 2007; Marrero et al., 1998), somatostatin (Florio, 2008) and
bradykinin B2 receptors (Duchene et al., 2002). Within these receptor systems, SHPs
have been implicated in the regulation of migration, chemotaxis, cytoskeletal
remodelling, proliferation and apoptosis. Interestingly, some GPCRs have been shown to
bind directly to SHPs by exhibiting ITIM-like sequences within ICL3 or its TM7/C-
terminal tail, which enable binding of SHP SH2 domains. Using co-immunoprecipitation
and surface plasmon resonance experiments, direct interactions have been shown
between the sst2 somatostatin receptor and SHP-2 (Ferjoux et al., 2003), the bradykinin
B2 receptor and SHP-2 (Duchene et al., 2002) and the CCK2 receptor and SHP-2
(Vatinel et al., 2006). Additionally, glutathione s-transferase (GST) pulldown assays
suggest that an ITIM-like (YIPP) motif in the angiotensin AT1 receptor facilitates SHP-2
binding (Marrero et al., 1998). Furthermore, co-immunoprecipitation experiments
suggest that the sst2 somatostatin receptor and SHP-1 form a complex (Lopez et al.,
1997). These interactions were necessary for agonist-induced activation of the relevant
SHPs by the GPCRs.
It is difficult to extract a common mechanism of GPCR-induced SHP activation from the
literature due to the paucity of existing data and because, analogous to src activation, the
mechanism of SHP activation is often receptor and cell-context dependent. The GPCRs
for which the most experimental evidence for receptor-induced SHP activation exists,
are the somatostatin receptors (Florio, 2008). In this receptor system, SHP activation
requires src/PTK activity, which in turn requires Gi activation (Florio, 2008), probably
because the dissociated Gsubunits activate src activity (Ferjoux et al., 2003). Thus the
mechanism of src activation (G protein dependent or independent) may dictate the
mechanism of SHP activation and is expected to differ for different GPCRs.
Activation of the GnRH receptor has been shown to induce PTP activity (Grundker et
al., 2001; Imai et al., 1996a; Imai et al., 1996b). It is also known to antagonise the
phosphorylation and signalling of two growth factor receptors, the EGFR and the
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1999; Moretti et al., 1996; Rose et al., 2004). These effects are proposed to enable the
anti-proliferative effects of this receptor (Imai et al., 1996a). However, activation of
SHP-1 and SHP-2 by the GnRH receptor has not been evaluated. Considering the anti-
proliferative activity of the GnRH receptor and its ability to upregulate PTP activity, in
chapter 4, I investigate GnRH receptor activation of the SHPs and whether this
activation can be mediated by direct interactions with the receptor, independently of G
proteins.
1.6.2.3 Physiological relevance of G protein-independent signalling
A key issue is whether GPCR-mediated G protein-independent signalling has
physiological relevance or whether this phenomenon is simply a result of the
overexpression of the receptors in heterologous recombination systems. This question
was addressed by a group which created transgenic mice specifically expressing a
wildtype or mutant angiotensin AT1 receptor in the heart (Zhai et al., 2005). The mutant
AT1 receptor (denoted AT1-i2m) exhibited an altered second intracellular loop that
prevented activation of the downstream G proteins, Gq and Gi, but which did not
interfere with G protein-independent signalling, involving activation of src and ERK
(Zhai et al., 2005). This study revealed that the mutant receptor was able to induce
cardiac hypertrophy and other alterations in cardiac function, suggesting that certain
effects of the receptor can be mediated by G protein-independent mechanisms in vivo
(Zhai et al., 2005).
Thus, assuming that G protein-independent signalling has physiological significance,
what are the determining factors for induction of G protein-independent signalling by a
GPCR? Sun et al. observed a dose-dependent switch in the coupling of the 2-AR from
G protein-dependent signalling at low agonist concentrations to G protein-independent
signalling at high agonist concentrations (Sun et al., 2007a). Furthermore, Rajagopal et.
al. observe that the biochemical effects mediated by the AT1-i2m receptor mutant
parallel the downstream effects of the GRK/-arrestin-mediated signals at this receptor
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may be initiated by the desensitisation machinery of the cell. However, as many of these
GPCR-protein interactions occur independently of -arrestins, this may not represent a
general mechanism for activation of this type of signalling.
1.6.2.4 GPCR dimerisation and signalling
Thus GPCRs are able to interact directly with src and SHP, proteins which were
previously considered restricted to the realm of cytokine and RTK signalling. A key
element of cytokine and RTK-mediated signalling is receptor dimerisation (Brooks et
al., 2007). However, the impact of dimerisation on the signalling of GPCRs is less clear.
FRET and BRET (fluorescence and bioluminescence resonance energy transfer
respectively) experiments suggest that GPCRs dimerise in the ER following synthesis
(Terrillon and Bouvier, 2004). Other evidence, which has also been shown for the GnRH
receptor, is that misrouted mutants exert a dominant negative effect on the expression of
wildtype receptors at the cell surface, retaining the receptors in the ER and supporting
the proposal that dimerisation of receptors occurs early in the trafficking pathway
(Brothers et al., 2004; Knollman et al., 2005; Terrillon and Bouvier, 2004). Furthermore,
FRET assessment of GPCR dimerisation in the plasma membrane suggests that the
GnRH receptors, like other GPCRs, exist as dimers at the cell surface (Cheung and
Hearn, 2003; Terrillon and Bouvier, 2004). While early BRET and FRET studies
suggested that GPCR dimerisation may be regulated by ligands, it is now currently
accepted that GPCRs exist as constitutive dimers at the cell surface (Milligan et al.,
2003). While heterodimerisation of GPCRs has been shown to affect the signalling of
the constituent receptors, the role of homodimerisation in GPCR signalling is still a
matter of debate (Terrillon and Bouvier, 2004). This is particularly pertinent following
the observation that purified monomeric 2-ARs can couple efficiently to Gs in a
reconstituted lipid bilayer system (Whorton et al., 2007). Nevertheless, a role for 2-AR
dimerisation has been suggested to facilitate receptor-induced G protein-independent
activation of src (Sun et al., 2007a). However, this proposal lacks experimental support.
Interestingly, dimerisation is proposed to play a key role in enabling JAK/STAT
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Future work will hopefully provide insight into the broader implications of this
phenomenon on GPCR signalling.
1.6.3 Summary
GPCRs have had their signalling repertoire extended to include activation of multiple G
protein classes and activation of signalling via G protein-independent mechanisms. This
has relevance to LiSS as the structural requirements for activation of these different
pathways may be distinct, suggesting that structurally distinct ligands may be able to
selectively target desirable signalling pathways. Thus elucidation of the capacity of
ligands to activate these pathways and the receptor conformations that facilitate specific
signalling is required. Comprehensive understanding of LiSS offers the exciting
possibility that GPCR drugs may be developed that have improved specificity at target
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2.4.8 Homologous binding with the antagonist, Cetorelix, and expression of Tyr6.58-
mutated GnRH receptors
For technical reasons, 125I-[His5, D-Tyr6]GnRH I was the preferred label in the above
assays as 125I-Cetorelix exhibits high non-specific binding. However, the peptide
antagonist, Cetorelix exhibited unchanged affinity for the Tyr6.58-mutated receptors
(Fig.2.3). Thus, the Cetorelix label is useful to assess the affects of Tyr6.58 mutation
on GnRH receptor expression. Homologous binding assays with Cetorelix were
performed (Fig.2.3). The IC50 value for Cetorelix at the wildtype receptor was 5.7 ±
1.9 nM, which was similar to that observed at the mutant receptors (Fig.2.3).
Mutation of Tyr6.58 to Ala did not alter GnRH receptor expression (Rexp = 102 ± 5 %
of wildtype). However, mutation of the Tyr6.58 to Phe and Leu, which have
hydrophobic side chains but lack functional groups with hydrogen bonding abilities,
decreased receptor expression to 30 ± 5 (p<0.01) and 32 ± 3 % (p<0.01) of the
wildtype level respectively (Fig.2.3). In contrast, mutation of Tyr6.58 to Gln increased
receptor expression to 228 ± 13 % (p<0.01). These data show that receptors with
hydrophobic residues in position 6.58, namely the Tyr6.58Phe and Tyr6.58Leu
receptors, have decreased expression. In contrast, receptors which have a side chain
that can make hydrogen bonding interactions, specifically the wildtype and
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Figure 2.3. Homologous competition binding with Cetorelix at wildtype and Tyr6.58-mutated
receptors. A, binding curves showing homologous competitive binding of the peptide antagonist
Cetorelix at the wildtype and Tyr6.58 mutant receptors transiently expressed in COS-7 cells. Results are
representative experiments, which were repeated at least three times with similar results. B,
normalised binding curves which show no significant differences in receptor affinity for cetorelix at
the wildtype and mutant receptors. , wildtype; ▼, Tyr6.58Phe; , Tyr6.58Ala; , Tyr6.58Leu; ▲, 
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2.4.9 Functional responses of Tyr6.58-mutated receptors
To evaluate the effects of Tyr6.58 mutation on GnRH receptor activation, GnRH-
elicited IP responses were determined (Table 2.3). Stimulation of the wildtype GnRH
receptor with GnRH I or GnRH II resulted in robust IP responses with Emax values
approximately 5-fold higher than basal IPs (Fig.2.4). The EC50 values for GnRH I
and GnRH II at the wildtype receptor were 0.9 ± 0.2 nM and 9.6 ± 2 nM respectively
(Table 2.3). Mutation of Tyr6.58 to Phe increased EC50 values by 57- and 26-fold for
GnRH I and GnRH II respectively (p<0.01). However, the signalling efficiencies
(Q), which consider receptor expression, ligand affinity, potency and Emax values, of
the Tyr6.58Phe receptor for GnRH I and GnRH II were 82 % and 144 % of the
wildtype levels respectively (Table 2.3). This suggests that the Tyr6.58Phe receptor is
as effective, possibly even more effective for GnRH II, in mediating receptor
activation than the wildtype receptor. These data indicate the para-OH group of
Tyr6.58 is not important for receptor activation. Mutation of Tyr6.58 to Ala produced
an even larger decrease in potency with increases in EC50 values of 1916- and 202-
fold for GnRH I and GnRH II respectively (p<0.01). Furthermore, the signalling
efficiency of the Tyr6.58Ala receptor in response to GnRH I and GnRH II was 23 and
46 % of the wildtype level respectively. This result shows that the Tyr6.58Ala receptor
is compromised in its ability to mediate receptor activation and suggests that the
aromatic ring of Tyr6.58 is important for activation of the GnRH receptor by GnRH I
and GnRH II. To confirm the validity of these suggestions, the responses of the
Tyr6.58Phe and Tyr6.58Ala receptors were determined in response to [His5,D-
Tyr6]GnRH I, as it was reasoned that the smaller changes in IC50 values for this
peptide would yield more accurate results. The signalling efficiencies of the
Tyr6.58Phe and Tyr6.58Ala receptors in response to [His5,D-Tyr6]GnRH I were 94 %
and 20 % respectively. Thus, these data are consistent with the previous results,
showing that the Tyr6.58Phe receptor was able to mediate efficient receptor activation,
while the Tyr6.58Ala receptor was appreciably compromised. This further supports
the proposal that the aromatic ring, but not OH group, of Tyr6.58 is important in
mediating GnRH-elicited receptor activation.
To investigate the proposed molecular requirements of Tyr6.58 in receptor activation
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activation in response to GnRH I and GnRH II was evaluated. Tyr6.58Leu mutation
abolished IP signalling in response to GnRH I (Table 2.3; Fig.2.4). This receptor has
similar affinity for GnRH I as the Tyr6.58Ala receptor (Table 2.1), which has a
signalling efficiency of 23% in response to GnRH I. Thus the inability of the
Tyr6.58Leu receptor to respond to GnRH I is not due to the low affinity of this peptide
at the receptor, but is more likely due to the participation of Tyr6.58Leu in
intramolecular interactions that prevent formation of the active receptor
conformations mediating Gq/11 coupling. In contrast, GnRH II induced an Emax of 85
± 10 % and a signalling efficiency of 116% at the Tyr6.58Leu receptor (Table 2.3;
Fig.2.4). Thus the Tyr6.58Leu receptor has a higher signalling efficiency than the
Tyr6.58Ala receptor (46%) in response to GnRH II. This shows that Leu in position
6.58 of the GnRH receptor can make compensatory interactions that facilitate
efficient receptor activation in response to GnRH II, but not GnRH I. Together, these
data show that GnRH I requires an aromatic, rather than hydrophobic, residue in
position 6.58, while GnRH II requires a residue with hydrophobic properties for
efficient activation.
The Tyr6.58Gln receptor had increased Emax values relative to the wildtype receptor in
response to GnRH I (156 ± 7 %; p<0.01) and GnRH II (167 ± 24 %; p<0.05), likely
due to the increased expression of this receptor. In contrast, the signalling
efficiencies of Tyr6.58Gln receptor in response to GnRH I and GnRH II were 35 %
and 31 % respectively. These are similar to the signalling efficiencies observed at the
Tyr6.58Ala receptor (Table 2.3). These results indicate that a Gln in position 6.58 is
unable to reconstitute the molecular requirements of Tyr6.58 necessary for efficient
receptor activation. This further supports the data obtained with the Tyr6.58Phe
receptor which suggests that the hydrogen bonding capabilities of the para-OH of
Tyr6.58 are not necessary to mediate receptor activation. Thus, taken together, these
data suggest that Tyr6.58 is important in mediating receptor activation in response to
both GnRH I and GnRH II. The H-bonding properties of this residue are not
important for receptor activation mediated by GnRH I or GnRH II. However, while
GnRH I absolutely requires an aromatic ring in position 6.58 for receptor activation,
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Table 2.3. GnRH-elicited IP responses of the wildtype and Tyr6.58-mutated receptors.
Forty-eight hours following transient transfection of COS-7 cells with wildtype and Tyr6.58 mutant receptor constructs and overnight myo-[3H]inositol labelling, IP
responses to GnRHs were assessed. Signalling efficiencies (Q) of the receptors were determined as described in Experimental Procedures.




























Wildtype 100 0.9 ±
0.2
1.0 100 100 9.6 ± 2 1.0 100 100 0.7 ±
0.1
1.0 100
Tyr6.58Phe 94 ± 7 51 ±
10**
57 82 87 ± 12 254 ±
27**
26 144 107 ± 3 4.7 ±
0.4**
6.7 94
Tyr6.58Ala 72 ± 6** 1724 ±
146**
1916 23 82 ± 18 1940 ±
175**
202 46 88 ± 6 73 ±
10**
104 20












a Data are the mean ± S.E. of at least three independent experiments performed in triplicate.
ud, undetectable IP response.





























Figure 2.4. GnRH-elicited IP responses at the wildtype and Tyr6.58Leu mutant receptors. Forty-
eight hours following transient transfection of COS-7 cells with wildtype (/) and Tyr6.58Leu (♦/◊)
receptors and overnight [3H]-myo-inositol labelling, IP responses to GnRH I (solid symbols /♦) and 
GnRH II (open symbols /◊) were determined and sigmoidal dose-response curves fitted (solid and
dashed lines respectively). This figure is representative of three independent experiments performed in














An exciting emerging field of GPCR research is directed towards the understanding
of the molecular requirements underlying the ability of structurally distinct ligands to
induce different receptor active conformations that have distinct downstream
signalling capabilities (Perez and Karnik, 2005; Urban et al., 2007; Weinstein, 2005).
This enquiry of research has therapeutic relevance in the rational design of GPCR
drugs with increased specificity for desired signalling pathway and reduced side-
effects. The two endogenous ligands, GnRH I and GnRH II, have been identified as
having differential signalling abilities at the human GnRH receptor (Lu et al., 2005;
Millar et al., 2008). The GnRHs differ at positions 5, 7 and 8 in the decapeptide
sequence. Here, a comprehensive study was performed to investigate the differential
ligand-receptor molecular interactions between Tyr5 of GnRH I and His5 of GnRH II,
and Tyr6.58 of the GnRH receptor. Furthermore, the importance of Tyr6.58 in receptor
expression and activation was determined.
2.5.1 Tyr5 of GnRH I is proposed to interact with Tyr6.58 of the GnRH receptor
Sequential substitution of Tyr5 with Phe- and Ala-substituted GnRH I analogues
produced 2- and 127-fold decreases in affinity of the peptide for the wildtype
receptor respectively, indicating the importance of the aromatic ring, but not the
para-OH group, of Tyr5 in GnRH I binding to the GnRH receptor (Table 2.1).
Mutation of Tyr6.58 to Phe and Ala induced 4.9- and 332-fold decreases in affinity for
GnRH I revealing the importance of both the OH and aromatic ring of Tyr6.58 in
GnRH I binding (Table 2.1). Evaluation of the affinities of position 5-substituted
GnRH I analogues for Tyr6.58-mutated receptors have led to the proposal that the OH
and aromatic ring of Tyr6.58 interact with the aromatic ring of Tyr5 of GnRH I. This is
suggested from the experimental data indicating that Tyr6.58Phe and Tyr6.58Ala
receptors exhibited smaller affinity decreases for Ala5-substituted GnRH I analogues
relative to native GnRH I (25- and 3.2-fold respectively) compared with the wildtype
receptor (127-fold). The interaction of Tyr6.58 and Tyr5 of GnRH I suggested by these
experimental data support the predictions of independently constructed molecular
models of the GnRH receptor, based on the structure of rhodopsin, which
incorporated previously delineated GnRH I binding interactions (Hovelmann et al.,
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In our molecular model of the GnRH receptor, Tyr6.58 and Tyr5 are arranged in a T-
shaped aromatic stacking interaction, where the OH and aromatic ring of Tyr6.58
point towards the aromatic ring of Tyr5 of GnRH I (Fig.2.2). This specialised
aromatic interaction is proposed to consist of van der Waals, hydrophobic and
electrostatic forces, where the relative contribution may depend on the geometry of
the aromatic rings relative to each other (Waters, 2002; Waters, 2004). The aromatic
nature of the interaction between Tyr6.58 and Tyr5 proposed by the molecular model
is supported by the experimental data where the Tyr6.58Leu receptor, which has a
hydrophobic, but not aromatic, side chain in position 6.58, had similar affinity for
GnRH I as the Tyr6.58Ala receptor and considerably lower affinity than the Tyr6.58Phe
receptor, supporting the importance of an aromatic ring at this position in the
receptor in GnRH I binding.
2.5.2 His5 of GnRH II is proposed to interact with Tyr6.58 of the GnRH receptor
While the above experimental data supports an interaction between Tyr5 of GnRH I
and Tyr6.58 of the GnRH receptor, it was considered likely that the interactions of
His5 of GnRH II would differ from those of GnRH I. Nevertheless, similar to the data
obtained with GnRH I, mutation of Tyr6.58 to Phe and Ala induced an 8- and 82-fold
decrease in affinity for GnRH II respectively (Table 2.2), indicating that the OH
group and aromatic ring of Tyr6.58 are also important for GnRH II binding. Similarly,
substitution of His5 of GnRH II with Ala produced a large decrease (177-fold) in
affinity for the wildtype receptor showing that position 5 of GnRH II, like GnRH I, is
important for high affinity binding interactions. The interaction of the His5 side chain
with the OH group and aromatic ring of Tyr6.58 is suggested by the experimental
results indicating that the Tyr6.58Phe and Tyr6.58Ala receptors exhibited smaller
changes in affinity for [Ala5]GnRH I (14- and 4.5-fold respectively) than the
wildtype receptor (177-fold). Thus these results suggest that His5 of GnRH II, like
Tyr5 of GnRH I, also interacts with Tyr6.58 of the GnRH receptor. This supports the
proposal that receptor binding contacts for GnRH II overlap with those of GnRH I
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In our molecular model of GnRH II docked to the GnRH receptor, His5 of GnRH II,
like Tyr5 of GnRH I, also forms an aromatic interaction with Tyr6.58 of the GnRH
receptor. The involvement of His5 of GnRH II in an aromatic interaction is supported
by the observation that substitution of His5 of GnRH II with Tyr, which also exhibits
aromatic properties, retained high affinity peptide binding (Table 2.2). Further
support is that the Tyr6.58Leu receptor did not have comparable affinity for GnRH II
as the Tyr6.58Phe receptor, emphasising the importance of an aromatic ring in this
position for high affinity GnRH II binding (Table 2.2). A notable difference between
GnRH I and GnRH II binding, proposed by the molecular model, is that His5 of
GnRH II and Tyr6.58 form a parallel offset stacking interaction that differs from the
T-shaped stacking interaction observed in the GnRH I interaction between Tyr5 and
Tyr6.58. This orientation of residues in an aromatic interaction has increased
components of van der Waals and hydrophobic interactions (Waters, 2002).
Interestingly, this arrangement is supported by the experimental data where the
hydrophobic characteristics of the Tyr6.58Leu mutation enabled some reconstitution
of GnRH II binding affinity compared with the Tyr6.58Ala receptor. In contrast, this
partial rescue of peptide affinity by the Tyr6.58Leu receptor was not observed with
GnRH I. This shows that the molecular requirements of GnRH I and GnRH II
interaction with Tyr6.58, while similar, are distinct as there is a greater hydrophobic
component to the interaction of position 5 of GnRH II with Tyr6.58 of the receptor,
compared with GnRH I. This thus supports the predictions of the molecular model
where Tyr5 and His5 interact with different rotamer conformations of Tyr6.58 by
aromatic interactions with distinct geometries. The differential interactions of Tyr5 of
GnRH I and His5 of GnRH II with Tyr6.58 are also supported by the observation that
Tyr6.58Ala mutation induced larger decreases in affinity for GnRH I (332-fold) than
for GnRH II (82-fold).
2.5.3 Tyr6.58 mutation induces large decreases in affinity for GnRH I and GnRH II,
but not [His5, D-Tyr6]GnRH I
Aromatic interactions are biologically relevant forces that contribute to stabilisation
of protein structure and direct the specificity of intramolecular interactions thereby
facilitating protein folding into the required protein conformation (Waters, 2002;
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single isolated interaction pair would not be expected to significantly effect the
interaction between two proteins/peptides (Waters, 2002; Waters, 2004). In contrast,
my experimental data show that removal of the aromatic ring at Tyr6.58 led to large
changes in affinity for GnRHs. Specifically, when Tyr6.58 was mutated to Ala this led
to a 332-fold and 82-fold reduction in affinity for GnRH I and GnRH II respectively.
One explanation for these large effects on ligand affinity is that Tyr6.58 makes
interactions with other residues in the ligand or in the receptor, in addition to its
partnered interaction with position 5 of the GnRH. However, the experimental results
show that the Tyr6.58 mutation exhibited only relatively small changes in affinity for
Ala5-substituted GnRH I and GnRH II analogues (8.3-fold and 2.1-fold respectively).
This suggests that the large decrease in affinity for GnRH I and GnRH II (of 332-
and 82-fold respectively) induced by Tyr6.58 mutation to Ala is primarily due to the
loss of its interaction with position 5 of the GnRH.
A second explanation for the large decrease resulting from the loss of the interaction
between Tyr6.58 and position 5 of the GnRH is that this interaction contributes to the
formation of subsequent GnRH-receptor contacts. Recent studies suggest that ligand-
GPCR interactions occur in a sequential manner and that initial interactions
synergistically contribute to subsequent ligand-receptor contacts (Del Carmine et al.,
2004; Kobilka, 2007). Experimental data which provides mechanistic insight into
how this may occur in the GnRH receptor is the observation that [His5, D-
Tyr6]GnRH I exhibited smaller changes in affinity for Tyr6.58-mutated receptors than
the other GnRH analogues (Table 2.1; Table 2.2). The Tyr6.58Phe had similar affinity
for [His5, D-Tyr6]GnRH I as the wildtype receptor, while the Tyr6.58Ala, Tyr6.58Leu
and Tyr6.58Gln receptors all exhibited small ~10-fold decreases in affinity. Thus
[His5, D-Tyr6]GnRH I is less reliant on the interaction of position 5 of the ligand
with Tyr6.58 than other GnRH analogues. An important distinguishing feature of
[His5, D-Tyr6]GnRH I compared with other GnRHs is that this peptide is already
constrained in the high affinity peptide conformation required for GnRH binding to
the receptor (Barran et al., 2005). GnRHs are proposed to bind to the receptor in a
II’-type turn conformation (Barran et al., 2005). However, in solution GnRH
peptides are able to assume a multitude of conformations. Thus initial ligand-
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configuration of the ligand into the high affinity conformation that facilitates
subsequent ligand-receptor contacts. [His5, D-Tyr6]GnRH I, which is intrinsically
constrained in the high affinity conformation, would thus be less dependent on this
interaction for high affinity binding. This proposal is further supported by previous
experimental data which showed that mutation of Asp7.32 of the GnRH receptor,
which is proposed to interact with Arg8 of GnRH I, also induced considerably
smaller decreases in affinity for a range of constrained GnRH analogues compared
with other GnRH peptides (Fromme et al., 2001). This phenomenon is specific to
these residues in the mid-region of the GnRH peptide as mutation of Asp2.61 and
Asn2.65, which interact with His2 and Gly-NH2 in the N- and C-termini of the peptide
respectively, exhibit similar decreases in affinity for native and constrained GnRH
analogues (Davidson et al., 1996; Flanagan et al., 2000). Thus these results support a
binding scheme where one end/terminus of the GnRH peptide binds to the receptor,
followed by receptor interactions with residues in the mid-region of the ligand that
facilitate configuration of the bioactive conformation of the ligand, thereby enabling
subsequent interactions of the opposite terminus of the peptide with the receptor.
2.5.4 The peptide antagonist, Cetorelix, exhibited unchanged affinity for the Tyr6.58
mutant receptors
The peptide antagonist, Cetorelix, also has a Tyr in position 5. However, it had
unchanged affinity for the Tyr6.58 mutant receptors compared with the wildtype
receptor (Fig.2.3). This result shows that Tyr5 of Cetorelix does not interact with
Tyr6.58. Thus position 5 of Cetorelix binds differentially to the GnRH receptor
compared with the agonists, GnRH I and GnRH II. This result is not surprising as
Cetorelix is only 50% homologous with GnRH I and is thus likely to bind to the
receptor in a different conformation (Millar et al., 2004). The ability of the agonists,
GnRH I and GnRH II, to bind to Tyr6.58, but not the antagonist, Cetorelix, is
consistent with the proposed role of this residue in receptor activation, as measured
by IP assays, discussed below.
2.5.5 Tyr6.58 of the GnRH receptor is important for receptor expression
In addition to its importance in GnRH I and GnRH II binding, mutation of Tyr6.58










Chapter 2: The role of Tyr6.58 of the GnRH receptor in GnRH binding and receptor
activation
110
expression, mutation to residues with hydrophobic side chains, Phe and Leu,
decreased receptor expression to ~30% of the wildtype level (Fig.2.3). These data
suggest that hydrophobic residues in position 6.58 destabilise receptor structure
thereby preventing efficient receptor trafficking to the cell surface. The higher
relative expression of the wildtype receptor suggests that this effect is corrected by
the presence of a functional group that can make H-bonds at this position. Thus, the
OH of Tyr6.58 is likely to make intramolecular interactions that stabilise receptor
conformation. This is further supported by the observation that the Gln receptor,
which does not have a hydrophobic destabilising influence, but retains the H-bonding
abilities at position 6.58, had 228 ± 13 % increased expression relative to the
wildtype receptor.
2.5.6 Tyr6.58 of the GnRH receptor is important for receptor activation
The ability of Tyr6.58 intramolecular interactions to alter receptor conformation,
suggested by the above data exploring receptor expression, is further supported by
the experimental data which shows that Tyr6.58 is important for receptor activation,
which requires a conformational change in receptor structure. The effects of Tyr6.58
on receptor activation were determined using IP assays, which provide a measure of
Gq/11 activation by the GnRH receptor. Mutation of Tyr6.58 to Phe produced
signalling efficiencies of 82 % and 144 % of the wildtype levels for GnRH I and
GnRH II respectively (Table 2.3). This suggests that the OH group of Tyr6.58 is not
important for receptor activation in response to GnRH I and GnRH II. However,
mutation of Tyr6.58 to Ala induced a large change in signalling efficiencies to 23 %
and 46 % of wildtype levels in response to both GnRH I and GnRH II (Table 2.3).
Thus, the aromatic ring of Tyr6.58 is important in facilitating receptor activation by
both GnRH I and GnRH II. Interestingly, while the Tyr6.58Leu receptor has similar
affinity as the Tyr6.58Ala receptor for GnRH I, Tyr6.58Leu mutation abolished IP
signalling in response to GnRH I (Fig.2.4). This result suggests that Tyr6.58Leu
makes intramolecular interactions in the GnRH I-stabilised receptor conformation
that prevent formation of an active Gq/11-coupled conformation. In contrast, GnRH
II-elicited IP signalling was improved at the Tyr6.58Leu receptor (116 %) compared
with the Tyr6.58Ala receptor (46%). Together, these results suggest that Tyr6.58Leu
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active conformations in response to GnRH I and GnRH II. This supports the above
proposal that GnRH I and GnRH II bind to different rotamer conformations of Tyr6.58
of the receptor. How different rotamer conformations of Tyr6.58 differentially affect
receptor conformation and downstream signalling requires further investigation.
However, one suggestion is that the rotamer configuration of Tyr6.58 affects the
conformations of other residues in TM6 by a “domino efect”, which may 
differentially affect the rotamer toggle switch and thus the active conformation of the
receptor (Schwartz et al., 2006; Shi et al., 2002).
In summary, the experimental results suggest that the OH and aromatic ring of
Tyr6.58 of the human GnRH receptor interact with the aromatic rings of Tyr5 of
GnRH I and His5 of GnRH II. Our molecular models, supported by the experimental
results, indicate that position 5 of GnRH I and GnRH II engages with distinct
rotamer conformations of Tyr6.58, by different aromatic stacking interactions. The
experimental data show that Tyr6.58 mutation altered receptor expression and thus
must be spatially positioned to make intramolecular interactions that can alter
receptor conformation. Furthermore, Tyr6.58 is important in facilitating receptor
activation. The differential responses of the Tyr6.58Leu receptor to GnRH stimulation
suggest that the interactions of Tyr6.58, necessary for receptor activation, differ for
GnRH I and GnRH II. These data thus support the proposal that GnRH I and GnRH
II stabilise different receptor active conformations that may contribute to the distinct
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In reproductive cancer cells, the GnRH receptor mediates anti-proliferative signalling
that does not correlate with activation of classical Gq/11 signalling. Several reports have
suggested the involvement Gi in these effects. This has led to the proposal that the GnRH
receptor mediates anti-proliferative signalling by direct coupling to Gi. However,
experimental verification is required. In the present study, direct activation of Gi by the
GnRH receptor was investigated using the [35S]GTPS binding assay. Using the
[35S]GTPS assay with rapid filtration, GnRH receptor-mediated activation of Gi was
not detected, despite robust agonist-stimulated Gi coupling observed at the CCR5
receptor. Next, using the more sensitive [35S]GTPS binding assay, the Scintillation
Proximity Assay (SPA), GnRH receptor-Gi coupling was also not observed. Detection of
agonist-stimulated Gi activation by the M2 muscarinic receptor and Gq/11 activation by
the GnRH receptor provided verification of the functionality of the SPA. Finally, a
reconstituted baculovirus-infected system enabling high expression of the GnRH
receptor and Gi in a cell background of low endogeneous G proteins also failed to
facilitate detection of GnRH receptor-mediated Gi activation. In this system, detection of
Gi activation by CCR5 verified that the assay was operational. These results show that
the GnRH receptor is not able to directly activate Gi and thus negates the proposal that
the proximal receptor-mediated events of GnRH receptor anti-proliferative signalling are
mediated by GnRH receptor-Gi coupling.
3.2 Introduction
The GnRH receptor mediates anti-proliferative and proapoptopic signalling in
reproductive cancer cells (Grundker and Emons, 2003; Grundker et al., 2001; Kraus et
al., 2006; Maiti et al., 2005; Maudsley et al., 2004). However, activation of this pathway
does not correlate with activation of classical Gq/11 signalling by the GnRH receptor.
Specifically, GnRH I and GnRH II exhibit a reversal of potency at the two pathways and
classical GnRH receptor antagonists, which do not activate Gq/11, are able to induce anti-
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2008). These data suggest that another GnRH receptor-mediated pathway is responsible
for these anti-proliferative effects. Several researchers have reported the importance of
Gi signalling in GnRH receptor-mediated anti-proliferative signalling and thus it has
been proposed that the anti-proliferative effects of the GnRH receptor are mediated by
its ability to couple to this alternative Gi, rather than Gq/11, protein family (Grundker and
Emons, 2003; Grundker et al., 2001; Limonta et al., 1999; Millar et al., 2004; Millar et
al., 2008).
However, there is disparity concerning whether the GnRH receptor is able to couple
directly to Gi proteins. Most studies have used analysis of second messenger generation
and pertussis toxin to infer the involvement of Gi in GnRH receptor signalling (Kimura
et al., 1999; Limonta et al., 1999; Maudsley et al., 2004; Sim et al., 1995). As these
methods of analysis investigate signalling distal to receptor-G protein coupling and are
subject to signal cross-talk (Birnbaumer, 2007), they do not provide conclusive evidence
for a direct GnRH receptor-Gi interaction. Other methods used to infer GnRH receptor
activation of Gi have included receptor-G protein cross-linking studies (Grundker et al.,
2001), agonist-stimulated palmitoylation and G protein release (Krsmanovic et al., 2003;
Stanislaus et al., 1998) and agonist-stimulated protection of Gi from PTX-catalysed ADP
ribosylation (Limonta et al., 1999). In contrast, a study of GnRH receptor-induced
photolabelling of Gq and Gi with [-32P]GTP azidoanilide detected only agonist-induced
labelling of Gq and not Gi, suggesting that the GnRH receptor does not directly couple to
Gi (Grosse et al., 2000).
In the present study, to address this dispute regarding GnRH receptor-Gi coupling, the
[35S]GTPS binding assay was performed with GnRH receptor-expressing membranes.
This assay measures the most proximal step of receptor-G protein coupling, specifically
the receptor-stimulated exchange of GDP for GTP on the Gprotein (Harrison and
Traynor, 2003; Lazareno, 1999; Milligan, 2003; Weiland and Jakobs, 1994).
Membranes, containing the GPCR and G proteins, are incubated with the radioactively-
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agonist. Agonist stimulation leads to receptor-induced GDP/GTP exchange and the
activated G proteins are thus labelled with [35S]GTPS. The non-hydrolysable nature of
the analogue prevents the loss of signal by the intrinsic G protein GTPase activity. This
well-established method for measurement of GPCR-G protein coupling has a number of
advantages. Firstly, in addition to providing a direct measure of G protein activation, the
assay is performed in membranes and thus the signal cannot result from downstream
signalling cross-talk. Furthermore, the assay provides a quantitative measure of receptor-
induced G protein activation.
Several variations of the [35S]GTPS binding assay were explored. These methods
confer different advantages and vary in the mechanism whereby, following the initial
incubation step, the G protein-bound [35S]GTPS is separated from the unbound
molecules (Fig.3.1). The simplest method involves capture of the membranes
(containing G protein-bound [35S]GTPS) by rapid filtration through glass fibre filters.
This is the least sensitive of the assays, but is cost-effective and technically
undemanding. A second method involves capture of the G proteins by
immunoprecipitation. This assay has the advantage of enabling the use of G protein
subtype-specific antibodies, thus providing a more specific, in addition to more
sensitive, signal. The Scintillation Proximity Assay (SPA) involves a further
modification of the immunoprecipitation method (DeLapp et al., 1999). Here, a
scintillation bead is targeted to the antibody bound-G protein. If the G protein is bound
to [35S]GTPS, the proximity of the radioactive molecule to the scintillation bead
facilitates the generation of light. This assay therefore precludes the necessity to separate
bound and unbound [35S]GTPS and is thus particularly amenable to high throughput
assays.
Optimisation of the [35S]GTPS binding assay requires variation of a number of factors
relevant to the assay incubation conditions and optimal conditions will differ depending
on the GPCR, G protein subtype and cell line investigated (Harrison and Traynor, 2003;
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investigation. Additionally, the effects of altering Mg2+, Na+ and GDP concentrations
need to be assessed. Mg2+ ions promote [35S]GTPS binding by enabling the GDP/GTP
exchange on the G protein (Birnbaumer, 2007; Harrison and Traynor, 2003). In contrast,
both Na+ ions and GDP improve the signal-to-noise ratio by decreasing basal
[35S]GTPS binding (Harrison and Traynor, 2003). Na+ is proposed to facilitate this
effect by reducing GPCR constitutive activity, while GDP binds with higher affinity to
the inactive, versus active, G protein (Harrison and Traynor, 2003). Furthermore, the
most effective antibody concentration needs to be assessed when performing
immunoprecipitation/SPA experiments. In this study, an exhaustive investigation of
differing assay conditions was performed in order to investigate the ability of the GnRH
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Figure 3.1. Schematic representation of the principles and variations of the [35S]GTPS binding
assay. Membranes (M) containing the GPCR (R) and G proteins (G) of interest are incubated with
radioactively-labelled [35S]GTPS in the presence or absence of the GPCR ligand (L). Ligand-induced
activation of the GPCR facilitates GDP/GTP exchange on the G protein and thus [35S]GTPS becomes
bound to the activated G protein, providing a measure of GPCR-mediated G protein activation. Separation
of G protein-bound, from unbound, [35S]GTPS can be performed in several ways (1-3). Firstly, it can
occur by rapid filtration through GF/C glass fibre filters (F) (1). To obtain a more sensitive and specific
signal, G proteins can be isolated using G protein-specific antibodies (2-3). The antibody-bound G
proteins can then be separated with Protein G-sepharose (PG) (2). Alternatively, use of the SPA bead (S)
precludes the necessity to separate bound and unbound [35S]GTPS, because the bead only emits a signal















Gi1-3 constructs in pcDNA3 and antibodies against the C-termini of Gi1/2 and Gi3 were
generated and generously provided by Dr. Graeme Milligan. GnRH receptor constructs
in pcDNA3.1 were constructed in our laboratory. The CCR5 construct was generously
provided by Dr. Vanessa Hayes. The Gq/11(C-19) antibody was from Santa Cruz
Biotechnology. Anti-IgG-coated SPA beads and Protein G sepharose were obtained
from Amersham, pansorbin cells from Calbiochem and Complete EDTA-free Protease
inhibitor cocktail tablets from Roche Applied Sciences. G418/Geneticin and carbachol
were purchased from Sigma. Sf21 cells were from ATCC. Components (vectors (see
below) and DH10Bac cells) for generation of baculovirus constructs were from
Invitrogen. [35S]GTPS (1000-1250 Ci/mmol) was purchased from Amersham.
3.3.2 Cloning
In order to generate baculoviruses, the following constructs were subcloned into the
appropriate vectors using PCR. The CCR5 and human and rat GnRH receptors were
subcloned into the pFastbac vector. Additionally, the different Gprotein subunits (Gi1,
Gi2 and Gi3) were also subcloned into pFastbac1. The G1 and G2 subunits were cloned
into the pFastbacDual vector so that all cells infected with the virus would always
express both subunits. The constructs were verified by dideoxy sequencing.
3.3.3 Cell culture and generation of stable cell lines
Cell culture of mammalian cells was performed as described in chapter 2. SCL60 cells,
HEK293 cells stably expressing the rat GnRH receptor, were generated in our laboratory
previously (Maudsley et al., 2004). CHO-M2 muscarinic receptor stable cell lines were
obtained by Zhi-liang Lu from his previous laboratory. HEK293 cells were transfected
with the CCR5 receptor and the human GnRH receptor using Fugene6 (Roche) and
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Sf21 insect cells were grown in suspension culture at 27oC in Sf900II medium with L-
glutamine (Gibco) containing 10%FBS (Delta Bioproducts) in the presence of Penicillin
and Streptomycin (2 mg/ml streptomycin sulphate; 4000 U/ml Benzylpenicillin).
3.3.4 Generation of baculovirus
Baculoviruses were generatedaccording to manufacturer’s instructions(Gibco). Viruses
were amplified and viral titres were determined by end-point dilution as described
previously (O'Reilly et al., 1994).
3.3.5 Preparation of membranes for binding and GTPS assays
Either stably-transfected cells or baculovirus-infect d cells were used for membrane
preparations. For Sf21 cells, baculoviruses were allowed to infect cells at a multiplicity
of infection (MOI) of 3:6:6 for receptor:G:G12. However, various MOI ratios were
investigated to determine this optimal concentration. Cells were allowed to express
protein for 48h and membranes were harvested in the following way. Cells were
collected in a harvesting buffer (20mM HEPES; 100mM EDTA; pH 7.5) and ruptured
with 20 strokes of a glass dounce homogeniser. Nuclei and unbroken cells were
separated with a low speed centrifugation step of 200g for 15 minutes. The resultant
supernatant was then subjected to a high speed spin at ~40 000g for 45 minutes and
resuspended in the appropriate buffer depending on assay. To ensure optimal assay
conditions, membranes were freshly prepared rather than stored at -80oC as it is our
experience that the GnRH receptor is not stable under these conditions (Colleen
Flanagan, unpublished observations). Membrane concentrations were determined by the
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3.3.6 Iodination of MIP-1
A 7.8µg/10µl aliquot of macrophage inflammatory protein 1-beta (MIP-1) (Cytolab
Ltd) was mixed with 10µl of 1mCi Na125I (Amersham) and 15µl of 0.5M phosphate
buffer (pH 7.4). Chloramine T (10µl of 1mg/mL in 0.5M phosphate buffer) was added
and the reaction allowed to proceed for 1 minute. The reaction was stopped by adding
50μl of sodium metabisulfide (1mg/mL in phosphate buffer). The reaction mixture was
applied onto a G-25 column and eluted with PBS containing 0.1% BSA. Fractions were
collected after every 90sec. The first peak of eluted fractions was aliquotted and stored.
The GnRH label was produced as described in chapter 2.
3.3.7 Radioligand binding assays for CCR5 and the GnRH receptor
Membranes expressing the appropriate receptor were incubated in a binding buffer
(GnRH receptor binding buffer (10mM HEPES; 1mM EDTA; pH 7.4; 0.1%BSA);
CCR5 binding buffer (50mM HEPES; pH 7.4; 1mM CaCl2; 5mM MgCl2)), the
appropriate radiolabel of 50 000cpm per tube (125I-MIP-1or 125I[His5,D-Tyr6]GnRH I)
and various concentrations of competing cold ligand. Tubes were incubated at 4oC for
16h (for the GnRH receptor) or 27oC for 1h (CCR5). Incubated tubes were filtered
through GF/C filters (Whatman) using a Brandel Harvester. The GF/C filters were pre-
soaked in 1%BSA (for CCR5) or 1%PEI (for the GnRH receptor). Filters were washed
twice with ice-cold washing buffer (0.01%PEI for GnRH; 50mM HEPES, 1mM CaCl2,
5mM MgCl2 and 0.5M NaCl for CCR5). Thereafter filters were counted with a gamma
counter.
3.3.8 [35S]GTPS binding assays
Membranes expressing the receptor of interest (~75µg of protein/well for SPA and
similar concentrations for other experiments) were incubated in the presence or absence
of ligand and 0.2nM/100nCi [35S]GTPS in a GTPS assay buffer (5mM MgCl2;
100mM NaCl; 20mM HEPES; 1mM EDTA; 1mM dithiothreitol) for various times at
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their effects on the reaction. Figure legends provide information of the concentrations of
these factors specific to that experiment. The reaction was stopped by addition of a
stopping buffer (which was Buffer A (ice-cold water) for rapid filtration experiments
and Buffer B (5mM MgCl2; 100mM NaCl; 20mM HEPES; pH 7.4) for
immunoprecipitation experiments). For rapid filtration experiments, the reaction mix
was filtered through GF/C filters, which were washed twice with ice-cold water as
described previously (Lazareno, 1999). The filters were counted using liquid
scintillation counting. For immunoprecipitation experiments, the reaction mix was
centrifuged (14 000rpm for 15 minutes) and membranes were solubilised in a
solubilisation buffer (100mM Tris-HCl; 200mM NaCl; 1mM EDTA; 1.25% NP-40; pH
7.4 and a Protease inhibitor cocktail tablet) at 4oC for 1 hour. Samples were precleared
with pansorbin cells for 1 hour and immunoprecipitated with an appropriate antibody
conjugated to protein G sepharose overnight. The immunoprecipitated complexes were
washed twice with solubilisation buffer and counted using liquid scintillation
spectrometry. For SPA, the assay (performed in 96-well plates) proceeded as described
previously (DeLapp et al., 1999). Briefly, membranes were solubilised with a 0.3% NP-
40 solution for 30 minutes. Thereafter, antibodies (used at concentrations ranging from
1/440 for Gi1/2 antibody to 1/1100 for Gq/11 antibody- optimal concentration needs to be
determined for each antibody) and SPA beads were added and incubated for a further 3
hours. Plates were centrifuged at 3000rpm for 10 minutes and counted in a beta-counter.














3.4.1 Investigation of GnRH receptor-Gi coupling using the [35S]GTPS binding assay
with rapid filtration
HEK293 cells stably expressing the rat GnRH receptor (SCL60 cells) were selected for
use in the [35S]GTPS binding assay. The reasons were two-fold. Firstly, this cell line
expresses high levels of the GnRH receptor, as determined by radioligand binding assays
(data not shown). This criterion is important in order to ensure a robust signal, as G
protein activation is not subject to the amplification observed at more distal signalling
molecules. Secondly, previous studies in this cell line reported potent and efficacious
induction of anti-proliferative signalling by the GnRH receptor, which is proposed to be
mediated by Gi (Maudsley et al., 2004). HEK293 cells stably-expressing the chemokine
CCR5 receptor, which is an established Gi–coupled receptor (Mueller et al., 2002), were
generated in order to serve as a positive control and cell surface expression of CCR5 was
determined and verified using radioligand binding assays (data not shown).
Membranes containing the GnRH or CCR5 receptors were used in the [35S]GTPS
binding assay with rapid filtration. Due to the low sensitivity of this assay, only Gi
activation is detected, as this G protein subtype is well-expressed and has a high rate of
nucleotide exchange (Harrison and Traynor, 2003). Basal [35S]GTPS binding curves, in
the presence of varied concentrations of MgCl2, were biphasic at both the GnRH
receptor and CCR5-containing membranes (Fig.3.2), consistent with previous reports
(Harrison and Traynor, 2003). Furthermore, the levels of basal binding at the two sets of
membranes were similar, indicating that comparable levels of membrane proteins were
present in the assay. In the presence of the CCR5 agonist, MIP-1, a significant increase
(p<0.01) in [35S]GTPS binding relative to basal levels was observed at 5, 10, 20 and
50mM MgCl2 (Fig.3.2A). This result demonstrates that this assay is able to detect
GPCR-induced activation of Gi and is thus functional. In contrast, the GnRH receptor-
containing membranes did not exhibit an agonist-stimulated increase in [35S]GTPS
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investigation of other optimising factors, discussed above, also failed to enable detection
of GnRH receptor-Gi coupling (data not shown). This result thus suggests that the GnRH
receptor is not able to induce robust activation of Gi.





































Figure 3.2. The [35S]GTPS Assay with rapid filtration in the presence of varied MgCl2
concentrations measuring receptor-stimulated Gi activation. The assay was performed with HEK293
cells stably expressing the CCR5 receptor (A) or the GnRH receptor (B). Membranes were incubated in
the presence (Stim) or absence (Basal) of the indicated ligand for 30 minutes prior to addition of the
reaction mix containing [35S]GTPS. This step was included to allow the ligand-receptor interaction to
reach equilibrium. Thereafter, membranes were incubated in a buffer containing 50mM HEPES (pH 7.4),
1mM EDTA, 0.1%BSA, 100mM NaCl, 10μM GDP, 0.2nM [35S]GTPS and varied MgCl2 concentrations
at 30oC for 30 minutes. G protein-bound [35S]GTPS was collected by filtration through GF/C filters as
described in the experimental procedures. Data are the mean ± S.E. of triplicate points. This figure is
representative of numerous similar experiments investigating various optimising factors of the assay. **,
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3.4.2 Investigation of GnRH receptor-Gi coupling using the Scintillation Proximity
Assay (SPA)
As the GnRH receptor is classically a Gq/11-coupled receptor, its activation of Gi may not
be robust and thus detection could require an assay with increased sensitivity. To this
end, the SPA was performed. This assay has increased sensitivity, but also specificity, as
it involves the use of G protein-subtype-specific antibodies (DeLapp et al., 1999). Here,
membranes containing the GnRH receptor and the M2 Muscarinic receptor (another
well-established Gi-coupled GPCR) were used. Detection of [35S]GTPS bound by Gi1/2
proteins using SPA showed decreased basal [35S]GTPS binding in the presence of
increasing concentrations of GDP, as expected (Fig.3.3A). The M2 muscarinic receptor
mediated a significant (p<0.01) agonist-induced increase in [35S]GTPS binding by Gi1/2
at all GDP concentrations (Fig.3.3A). The ability of the M2 muscarinic receptor to
facilitate Gi1/2 activation and thus GTPS binding is verification of the functionality of
the assay. However, the GnRH receptor did not show an agonist-induced increase in
[35S]GTPS binding at any of the GDP concentrations investigated (Fig.3.3B). Further
investigation of various optimising factors and using a Gi3-specific antibody also failed
to detect GnRH receptor-Gi coupling (data not shown).
To confirm that the integrity of the GnRH receptor-containing membranes was intact,
the ability of the GnRH receptor to couple to Gq was assessed. Using a Gq-specific
antibody, basal and agonist-stimulated [35S]GTPS binding to Gq was determined
(Fig.3.4A). In the presence of another GnRH receptor agonist, GnRH II, a significant
(p<0.01) increase in [35S]GTPS binding to Gq was detected at 5, 10, 20 and 50mM
MgCl2 concentrations, relative to basal levels (Fig.3.4A). This result provides evidence
that the membranes have functional GnRH receptors at sufficiently high levels to detect
GnRH receptor-G protein coupling. The membranes prepared for this assay were also
used for detection of Gi coupling, but GnRH II-elicited GnRH receptor-Gi coupling was
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Figure 3.3. The Scintillation Proximity Assay with varying GDP concentrations measuring receptor-
stimulated Gi activation. CHO and HEK293 cells stably expressing the M2 Muscarinic receptor (A) or
the GnRH receptor (B) respectively were incubated in the presence (Stim) or absence (Basal) of the
indicated ligand for 60 minutes at 25oC. The assay buffer conditions included 20mM HEPES pH7.4, 5mM
MgCl2, 100mM NaCl, 0.2nM [35S]GTPS and varied GDP concentrations as indicated. Antibodies to Gi1/2
subunits were added and anti-IgG-coated SPA beads facilitated capture of antibody-bound G proteins.
Gi1/2 proteins with radioactive [35S]GTPS bound stimulated the SPA beads to emit light, which was
detected by liquid scintillation counting. Data are the mean ± S.E. of triplicate points. This figure is
representative of numerous similar experiments investigating various optimising factors of the assay. **,
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Figure 3.4. The Scintillation Proximity Assay with varying MgCl2 concentrations measuring GnRH
receptor-stimulated Gi and Gq activation. HEK293 cells stably expressing the GnRH receptor were
incubated with the assay buffer (containing 20mM HEPES pH7.4; 100mM NaCl; 1.25mM [35S]GTPS
and the indicated MgCl2 concentrations) in the presence (Stim) or absence (Basal) of GnRH II for 60
minutes at 25 oC. G protein subtype-specific antibodies were then used to determine activation of Gq (A)
and Gi (B) by the GnRH receptor. Data are the mean ± S.E. of triplicate points. This figure is
representative of numerous similar experiments investigating various optimising factors of the assay. **,
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3.4.3 Investigation of GnRH receptor-Gi coupling using a reconstituted baculovirus-
infected system
In a final attempt to detect GnRH receptor-Gi coupling, a baculovirus-infected
reconstituted system enabling overexpression of both GnRH receptors and Gi proteins in
insect cell membranes was developed for use in the [35S]GTPS binding assay. This
system has successfully enabled expression of a large number of GPCRs, including the
GnRH receptor, and has a number of advantages (Akermoun et al., 2005; Cheung and
Hearn, 2003; Delahaye et al., 1997; Grunewald et al., 1996; McIntire et al., 2002; Neill
et al., 1997). Firstly, high levels of functional GnRH receptor and Gi proteins can be
achieved in a background of the low endogeneous G proteins expressed by the insect
cells (Windh and Manning, 2002). Furthermore, alterations in the ratio of receptor:G
protein is easily achieved by changing the multiplicity of infection (MOI) of the
constructed viruses. By manipulating the system thus, the detection of even small signals
would be achieved. Furthermore, Gi would not have to compete with Gq for coupling to
the GnRH receptor.
Baculoviruses, enabling expression of the GnRH and CCR5 receptors and various G
and Gprotein subunits, were constructed. Radioligand binding assays confirmed that
the GnRH and CCR5 receptors were functionally expressed in this system (data not
shown). Furthermore, using the CCR5 receptor as a positive control, the functionality of
the G protein subunits was demonstrated (Fig.3.5A). A negative control of membranes
containing the CCR5 receptor alone did not exhibit agonist-induced [35S]GTPS
binding, as expected (Fig.3.5A). With the addition of Gi2, basal [35S]GTPS binding
was increased (p<0.01) showing that the Gi2 protein was able to bind the GTP
analogue. Additionally, in these membranes containing CCR5 and Gi2, MIP-1
induced a small, but significant (p<0.01), increase in [35S]GTPS binding, relative to the
basal levels (Fig.3.5A). This result shows the ability of CCR5 to mediate activation of
Gi2 and indicates that both CCR5 and the Gsubunit are functional. In membranes
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basal [35S]GTPS binding was observed. Gsubunits promote association of the G
protein with the receptor. Thus the increased association of Gwith CCR5 and the
known constitutive activity of CCR5 (Arias et al., 2003) are likely to be responsible for
this increased signal. This provides evidence to support the functionality of the G
subunits. Additionally, a further small, but significant (p<0.01), increase in [35S]GTPS
binding was observed in response to agonist in these membranes, showing that this
system enables detection of functional agonist-induced GPCR-mediated G protein
coupling (Fig.3.5A). It is likely that the signal-to-noise ratio of this response would be
improved by optimisation of assay conditions (such as increasing the Na+ and GDP
concentrations), but CCR5 was not the focus of this study and was thus not pursued.
Extensive investigation of various optimising factors and assay conditions was explored
for the GnRH receptor, but failed to detect GnRH receptor-Gi coupling. Fig.3.5B is a
representative figure of these experiments showing that no GnRH receptor coupling to













































































Figure 3.5. The [35S]GTPS Assay with rapid filtration with baculovirus-infected cell membranes.
Sf21 cells were infected with baculoviruses inducing expression of the CCR5 (A) and GnRH receptors (B)
and the indicated G protein subunits. The cells were infected at an MOI of 3:6:6 for receptor:G:G.
Forty-eight hours following infection, membranes were harvested and the GTPS assay with rapid
filtration was performed as described in the experimental procedures. The assay conditions for the reaction
included 20mM HEPES pH7.4, 100mM NaCl, 5mM MgCl2 and 1μM GDP for 30 minutes at 27 oC in the
presence or absence (NS, non-stimulated) of the indicated ligands. Data are the mean ± S.E. of triplicate
points. This figure is representative of numerous similar experiments investigating various optimising
















Classical pituitary GnRH receptor signalling involves Gq/11 coupling (Pawson and
McNeilly, 2005). However, the anti-proliferative effects of this receptor on cancer cells
are suggested to be mediated by alternative coupling of the GnRH receptor to Gi proteins
(Grundker and Emons, 2003; Grundker et al., 2001; Limonta et al., 1999; Millar et al.,
2004; Millar et al., 2008). The suggestion that the anti-proliferative effects of the GnRH
receptor are mediated by an alternative pathway to classical Gq/11 signalling is supported
by the ability of classical antagonists to activate this pathway, as well as the reversal of
efficacy of GnRH I and GnRH II at these pathways (Grundker and Emons, 2003; Millar
et al., 2008; Yano et al., 1994). Thus, it has been proposed that different GnRH ligands
stabilise distinct active conformations of the GnRH receptor and thus differ in their
ability to activate Gq/11 and Gi (Maudsley et al., 2004; Millar et al., 2004). Within this
framework, ligands which preferentially stabilise the Gi-coupled GnRH receptor
conformation are proposed to facilitate the anti-proliferative effects of the receptor.
Nevertheless, the ability of the GnRH receptor to directly couple to Gi is disputed
(Grosse et al., 2000) and has not been verified experimentally. In the present study, the
ability of the GnRH receptor to directly couple to Gi was investigated using the
[35S]GTPS binding assay. The data presented here show that GnRH receptor-Gi
coupling could not be detected in any of the [35S]GTPS binding assays performed.
Indeed, even in a reconstituted environment of high concentrations of the GnRH
receptor and Gi proteins, coupling was not observed (Fig.3.5). In contrast, for the well-
established Gi-coupled GPCRs, CCR5 and the M2 muscarinic receptor, agonist-
stimulated Gi activation was detected, thus confirming the functionality of the assay
systems. This result shows that the GnRH receptor is not able to couple directly to the Gi
family of G proteins.
The inability of the GnRH receptor to couple directly to Gi is supported by a previous
study which reported exclusive GnRH receptor-mediated labelling of Gq/11 with [-
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these results contradict other reports proposing GnRH receptor-Gi coupling. Some
conclusions of Gi coupling resulted from experimental observations of GnRH receptor-
induced inhibition of cAMP accumulation (Krsmanovic et al., 2003; Maudsley et al.,
2004). Thus, an alternative explanation for these data is that Ca2+, generated downstream
of Gq/11 activation, facilitates inhibition of certain adenylate cyclase isoforms
(Birnbaumer, 2007). However, some studies have specifically implicated GnRH
receptor-mediated Gi activation by showing inhibition of GnRH receptor signalling with
pertussis toxin (Imai et al., 2006; Kimura et al., 1999; Sim et al., 1995), Gi
palmitoylation and release from the membrane in response to GnRH analogues
(Krsmanovic et al., 2003; Stanislaus et al., 1998) and protection of pertussis toxin-
mediated ADP ribosylation of Gi in the presence of GnRH analogues (Grundker et al.,
2001; Imai et al., 1996). For these results to be consistent with the data presented in this
chapter, these signalling events must occur downstream of initial receptor-mediated
events. There are several mechanisms whereby this could occur. One suggestion is that
GnRH receptor-Gi coupling occurs following phosphorylation event which enables a
switch in G protein coupling. Indeed, PKA-mediated phosphorylation of the 2-
adrenergic receptor (Daaka et al., 1997; Zamah et al., 2002) and prostacyclin receptor
(Lawler et al., 2001), downstream of Gs activation, was required to observe Gi activation
by these receptors. A second suggestion follows the observation of Gi coupling to RTKs
(Delcourt et al., 2007; Kreuzer et al., 2004). It follows that GnRH receptor-mediated
RTK transactivation could be responsible for the downstream effects on Gi (Kraus et al.,
2001; Shah et al., 2003). Thus, it is proposed that the involvement of Gi in GnRH
receptor signalling occurs downstream of initial receptor-mediated events. The
demonstration that high agonist concentrations are required to facilitate Gi signalling
mediated by the GnRH receptor further supports the conclusion that GnRH receptor-Gi
coupling is not a proximal signalling event (Krsmanovic et al., 2003).
In conclusion, the experimental results presented here, show that the GnRH receptor is
not able to couple directly to Gi. This result is significant as it negates the proposal that
the proximal signalling event initiating the anti-proliferative effects of the GnRH
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receptor does not require Gq/11 activation, this suggests that an alternative pathway is
responsible. In light of the therapeutic implications for the treatment of reproductive
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4.1 Abstract
GnRH receptor activation mediates anti-proliferative effects, associated with an
increase in PTP activity, in cancer cells. In the present study, the ability of the GnRH
receptor to activate the PTPs, SHP-1 and SHP-2 was explored. While unable to
detect SHP-1 phosphorylation, GnRH I elicited a robust 2-fold increase in SHP-2
phosphorylation on Tyr542 in a time- and dose-dependent manner, illustrating specific
and potent (EC50 = ~1nM) activation of this phosphatase. SHP-2 phosphorylation
was detected in the presence of EGFR, Gq and Gi inhibitors, as well as excess G
subunits, indicating that this pathway is activated independently of G proteins and
EGFR transactivation. Furthermore, Gq/11-uncoupled Tyr7.53Ala and Asp7.49Ala
GnRH receptors induced SHP-2 activation, as did a classical GnRH receptor
antagonist, Ant135-18, supporting the proposal that distinct GnRH receptor
conformations mediate SHP-2 and Gq/11 activation. In view of the G protein-
independence of SHP-2 activation, the GnRH receptor sequence was analysed to
determine if a direct SHP-2 binding motif could be identified. Analysis and
immunoprecipitation experiments enabled identification of a canonical SH2-binding
motif, pYxxL, at the bottom of TM7 of the GnRH receptor, which is constitutively
phosphorylated and proposed to facilitate SHP-2 activation. GnRH I-elicited SHP-2
phosphorylation is mediated by src, as the src inhibitor, PP2, prevented the
phosphorylation event. Furthermore, immunoprecipitation experiments reveal that
src forms a direct binding complex with the GnRH receptor. A SHP-2 dominant
negative construct, SHP-2(c/s) enabled identification of the contribution of SHP-2
signalling to GnRH I-elicited ERK and Akt regulation and thus this pathway may be
associated with the anti-proliferative effects induced by the GnRH receptor.
4.2 Introduction
The GnRH receptor is central to mammalian reproduction (Pawson and McNeilly,
2005). In the pituitary, classical GnRH receptor signalling involves activation of the
Gq/11 family of G proteins and consequent LH and FSH release, which, in turn,
regulate gametogenesis and steroidogenesis at the gonads (Pawson and McNeilly,
2005). In contrast, GnRH receptors expressed in peripheral reproductive cancers
have been shown to induce anti-proliferative signalling (Grundker and Emons, 2003;
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The endogenous GnRHs, GnRH I and GnRH II exhibit a reversal of potency at these
two pathways. GnRH I has higher potency for Gq/11 signalling, while GnRH II is
more potent at the anti-proliferative pathway (Grundker and Emons, 2003; Millar et
al., 2008). In addition, certain GnRH receptor antagonists, classified due to their
inability to facilitate Gq/11 activation, are able to induce anti-proliferative signalling at
GnRH receptor (Maudsley et al., 2004; Yano et al., 1994). These data support the
proposal that Gq/11 and anti-proliferative signalling at the GnRH receptor occur via
distinct signalling pathways.
Efforts to identify the proximal events of the Gq/11-independent anti-proliferative arm
of GnRH receptor signalling have suggested that the GnRH receptor couples to a
second G protein family, the Gi proteins (Grundker et al., 2001; Imai et al., 2006;
Imai et al., 1996b). However, our previous work (see chapter 3) and the work of
others (Grosse et al., 2000) show that the GnRH receptor is unable to directly couple
to Gi, suggesting that, if Gi is involved, its participation is downstream of other
receptor-mediated events.
Emerging experimental evidence supports the ability of GPCRs to interact directly
with src PTKs and/or SHP PTPs (Cao et al., 2000; Duchene et al., 2002; Fan et al.,
2001; Ferjoux et al., 2003; Lopez et al., 1997; Sun et al., 2007a; Vatinel et al., 2006),
facilitating coupling of the GPCR to phosphotyrosine signalling cascades.
Interestingly, the GnRH receptor has been shown to induce PTP activity in peripheral
cancer cells and furthermore, antagonises the proliferative signalling of the EGF and
IGF-I receptors in certain cell types (Grundker et al., 2001; Imai et al., 1996a; Imai et
al., 1996b; Marelli et al., 1999; Moretti et al., 1996). These signalling events are
proposed to underlie the anti-proliferative effects of the GnRH receptor, therefore
providing the impetus to investigate GnRH receptor-elicited PTP activity further. In
this chapter, I sought to determine whether the GnRH receptor was able to activate
the SH2 domain-containing phosphatases, SHP-1 and SHP-2 and whether this
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The src kinase specific inhibitor PP2, the PDGF receptor inhibitor AG1296, the EGF
receptor inhibitor AG1478 and the SHP-2 inhibitor, NSC-87877 were all obtained
from Calbiochem. Pertussis toxin was obtained from Sigma. The Gq/11 inhibitor,
YM254890, was generously donated by Dr. Jun Takasaki. The cDNAs for SHP-2
(wild-type) (#12283) and the SHP-2 dominant negative construct SHP-2(c/s)
(#12284) were acquired from Addgene (www.addgene.org) (Kolli et al., 2004).
GnRH I and GnRH II were purchased from Sigma and Bachem respectively. The
antagonists Antagonist 135-25, Antagonist 135-18 and Cetorelix were synthesised in
our laboratory as described previously (Mamputha et al., 2007). cDNAs of the
wildtype and mutant receptors were constructed previously (see below) and the
vector control DNA was pcDNA3.1 (Invitrogen).
4.3.2 Cell culture and transfection
MCF-7 cells (obtained from ATCC) were transiently transfected with 15μg of DNA
in a 0.4cm cuvette (containing 1.5X107 cells per 0.7ml of Optimem Media (Gibco))
using electroporation. Cells were pulsed at 320V and 960 μFusing a Bio-Rad Gene
Pulser. After transfection, cells were plated into 10cm dishes and grown in DMEM
(Gibco) supplemented with 10% fetal calf serum, 2% glutamine, 1% penicillin
(10 000units/ml)/streptomycin (10 000mg/ml) at 37oC in a humidified 5% CO2
atmosphere. MCF-7 cells exhibit a high level of transfection efficiency following
electroporation, which is demonstrated by the high levels of receptor expression that
are observed with radioligand binding assays (Fig.S1).
Cell stimulations were performed 48h following transfection. Sixteen hours prior to
stimulations, cells were incubated in serum-free media (DMEM, 2% glutamine, 1%
penicillin/streptomycin, 10mM HEPES). Agonist stimulations were performed in
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4.3.3 Immunoprecipitation and immunoblotting
Following ligand stimulation, cells were placed on ice and washed with ice-cold
Dulbecco’s Phosphate-Buffered Saline (DPBS). The cells were then incubated with a
NP-40-based Lysis Buffer (250mM NaCl, 50mM HEPES, 0.5% NP-40, 10%
glycerol, 2mM EDTA, pH 8.0, supplemented with 1mM sodium orthovanadate,
1mM phenylmethylsulfonyl fluoride and 1μg/ml leupeptin). Solubilised lysates were
sonicated for 5 seconds and clarified by centrifugation at 20 000g for 15 min at
which point the lysate was either mixed with an equal volume of 2XLaemli Buffer or
subjected to overnight immunoprecipitation at 4oC with constant agitation.
For immunoprecipitation of the HA-tagged GnRH receptors, 2μg of mouse anti-HA
12CA5 monoclonal antibody (Roche Applied Science) and 25μl of a 30% protein
A/protein G agarose preconjugate slurry (Calbiochem) were incubated with cell
lysates as described above. Immunoprecipitation of tyrosine phosphoproteins was
achieved by incubating the lysate with 20μl of a 50% anti-PY20-agarose
preconjugate slurry (Santa Cruz Biotechnology). Endogeneous src was
immunoprecipitated with 20μl of a 50% preconjugated anti-src antibody slurry (c-
src(N-16); Santa Cruz Biotechnology). Immune complexes were collected with a 5
min centrifugation step at 20 000Xg and washed twice with the NP-40-based lysis
buffer described above. After washing, 20μl of 2XLaemli Buffer was added to the
collected immune complex pellet. The samples were heated to 95oC for 5 min prior
to loading onto the gels.
Samples were run by SDS-PAGE on 4-20% Tris-Glycine gels (Invitrogen) and
transferred to Immobilon-FL 0.45μm polyvinylidene difluoride membranes
(Millipore) using a Biorad Semi-dry transfer apparatus. Membranes were blocked
with Odyssey Blocking buffer (Li-Cor Biosciences).
For immunodetection of relevant proteins, the following antibodies were used. To
detect phosphorylated SHP-1, anti-SHP-1 (pTyr536) (ECM Biosciences) was used at a
1:500 dilution. Anti-SHP-2 (pTyr452) (Calbiochem) was used to detect
phosphorylated SHP-2 at a 1:1000 dilution. The anti-HA 12CA5 monoclonal
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1:500 dilution. Activation of src was detected using a Tyr416 phospho-specific src
antibody (Cell signalling). pERK (phospho-p44/42 MAP Kinase (Thr202/Tyr204)
rabbit antibody), ERK (p42 MAP Kinase (3A7) mouse monoclonal antibody) and
pAkt (Phospho (Ser473) rabbit monoclonal antibody) were all obtained from Cell
Signalling and used at 1:1000 dilution. Primary antibodies were detected with Goat
IRDye800 conjugated anti-mouse antibodies (Rockland) and Goat Alexa Fluor
680/700 conjugated anti-rabbit antibodies (Invitrogen Molecular Probes) at a 1:5000
dilution for all primaries with the exception of ERK and pERK which was a 1:10 000
dilution. The membranes were visualised and quantified using the Odyssey Li-Cor
infrared imaging system and application software version 2.1.12.
4.3.4 Data analysis
Data were plotted and analysed using Graphpad Prism 4.0 (Graphpad Software Inc.).
Sigmoidal dose-response curves were fitted to the relevant data and the EC50 value
determined. Statistical analysis was performed using a Students t test or a one-way
ANOVA with a Dunnett’s multiple comparison test.
4.4 Results
4.4.1 Determination of GnRH I-elicited SHP-1 and SHP-2 activation
In the inactive state, SHP-1 and SHP-2 exist in an autoinhibited conformation where
the N-terminal SH2 domain folds back against the phosphatase domain and inhibits
its activity (Neel et al., 2003). Phosphorylation of SHP-1 and SHP-2 on Tyr536 and
Tyr542 in their C-terminal tails, respectively, provides a site for engagement of the N-
terminal SH2 domain of the SHP, relieving the inhibition of the phosphatase and
enabling its activation (Neel et al., 2003; Poole and Jones, 2005). Thus, in order to
investigate whether the human GnRH receptor activates SHP-1 and SHP-2, MCF-7
cells transiently expressing the GnRH receptor were stimulated with GnRH I and the
phosphorylation status of these SHP Tyr residues assessed.
Stimulation of the transfected MCF-7 cells with GnRH I led to a robust statistically
significant (p<0.01) 2-fold increase in SHP-2 phosphorylation on Tyr542 (Fig.4.1).
The induction of SHP-2 phosphorylation in response to GnRH I was rapid, with
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GnRH I-elicited SHP-2 phosphorylation was achieved by 5 minutes and the
phosphorylation status remained protracted over 60 minutes of GnRH I stimulation
(Fig.4.1). Untransfected MCF-7 cells did not induce SHP-2 activation, indicating that
this effect is specifically mediated by the human type I GnRH receptor (Fig.S2).
Thus, in response to GnRH I, the GnRH receptor is able to induce robust and rapid
activation of SHP-2 in a time-dependent manner in MCF-7 cells.
To assess the potency of GnRH I-elicited SHP-2 activation, transiently transfected
MCF-7 cells were stimulated with various concentrations of GnRH I. GnRH I-
elicited SHP-2 phosphorylation occurred in a dose-dependent manner (Fig.4.2).
Analysis of the fitted dose-response curve of SHP-2 phosphorylation indicates that
GnRH I had an EC50 value of ~1.0nM (Fig.4.2). This result shows that SHP-2 is
specifically and potently phosphorylated in response to GnRH I. Interestingly, SHP-2
detection on western blots is a wide band (Fig.4.1), that consists of two bands (see
Fig.4.2). These two bands may represent an extended linear conformation of the
protein (which will run slower) and a folded conformation where the C terminal
phosphorylated tyrosine is bound by the N-SH2 domain of the protein (Neel et al.,
2003). Alternatively, they may represent SHP-2 forms with differential modifications
(Poole and Jones, 2005).
In contrast to SHP-2, neither basal nor GnRH I-induced phosphorylation of SHP-1
on Tyr536 was detected (Fig.S3) despite reports that SHP-1 expression occurs in these
cells (Thangaraju et al., 1999). Taken together, these results indicate that, while we
were unable to detect GnRH I-induced phosphorylation of SHP-1 on Tyr536, GnRH I
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Figure 4.1. Time-course of GnRH I-elicited SHP-2 activation. Forty-eight hours following
transient transfection with the human GnRH receptor and overnight serum starvation, cells were
treated with 100nM GnRH I for the indicated time points. Phosphorylated proteins were
immunoprecipitated with the PY20 antibody and SHP-2 phosphorylation on Tyr542 was detected. Data
represent the mean ± S.E. of three independent experiments. **, p<0.01, significantly different from
control (NS (non-stimulated) cells); one-way ANOVA with Dunnet’s multiple comparison test.
Figure 4.2. Dose-response curve of GnRH I-elicited SHP-2 phosphorylation. MCF-7 cells were
prepared as described above, treated with various concentrations of GnRH I for 5 minutes and SHP-2
phosphorylation detected. A sigmoidal dose-response curve was fitted to the data and the EC50 for
SHP-2 phosphorylation by GnRH I determined as ~1.0nM. Data represent the mean ± S.E. of three
independent experiments. *, p<0.05, **, p<0.01, significantly different from control (NS cells); one-
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4.4.2 Effects of the EGFR inhibitor, AG1478, on GnRH I-elicited SHP-2 activation
Tyrosine kinase receptors, such as the EGF receptor, mediate SHP-2 activation
(Araki et al., 2003; Bennett et al., 1994; Chong and Maiese, 2007; Wang et al.,
2006). Thus, considering the ability of the GnRH receptor to induce transactivation
of the EGFR in several cell lines (Dobkin-Bekman et al., 2006; Kraus et al., 2001;
Shah et al., 2003), it was necessary to determine if this represents the mechanism for
SHP-2 activation in response to GnRH I. To establish this, cells were preincubated
with a specific inhibitor to the EGF receptor, AG1478, prior to GnRH I stimulation.
The results show that GnRH I elicited statistically significant (p<0.05) SHP-2
activation in the presence of the EGFR inhibitor, comparable to the stimulation
obtained in the absence of the inhibitor (Fig.4.3). This shows that GnRH I-elicited
SHP-2 activation does not occur by transactivation of the EGFR and indicates that
another pathway must be responsible.
4.4.3 The role of G protein signalling in GnRH I-elicited SHP-2 activation
The major pathway of GPCR signalling involves coupling to G proteins. Thus, an
investigation of the effects of inhibition of this signalling pathway on GnRH I-
elicited SHP-2 activation was performed. Classical GnRH receptor signalling
involves activation of the Gq/11 family of G proteins (Kraus et al., 2001; Naor et al.,
2000; Pawson and McNeilly, 2005). Additionally, GnRH receptor coupling to the Gi
family of G proteins has been suggested to mediate GnRH-induced activation of PTP
activity in ovarian cancer cells (Grundker et al., 2001). Thus to assess whether the G
proteins, Gq or Gi, mediate the coupling of the GnRH receptor to SHP-2, specific
inhibitors to the Gq/11 and Gi proteins, YM254890 and PTX respectively, were
preincubated with the cells prior to GnRH I stimulation. Furthermore, overexpression
of the G1 and G2 subunits was performed to determine the effects of these G
protein subunits on GnRH I-elicited SHP-2 activation.
In the presence of 100nM of the Gq/11 inhibitor, YM254890, which completely
inhibits the GnRH receptor-mediated IP responses (Fig.S4), GnRH I induced
statistically significant (p<0.05) phosphorylation of SHP-2 (Fig.4.4). This result
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protein. Nevertheless, compared with control cells, SHP-2 phosphorylation in
response to GnRH I was reduced in the presence of YM254890, showing that this
inhibitor partially inhibits the phosphorylation event. In the presence of the Gi
inhibitor, PTX, GnRH I elicited robust statistically significant (p<0.05) SHP-2
activation, comparable with control levels (Fig.4.4). This result shows that GnRH
receptor-mediated SHP-2 phosphorylation does not occur via activation of the Gi
family of G proteins. Following overexpression of the G12 subunits, which
associate with and thereby inhibit the activity of the Gsubunits, the GnRH receptor
also induced statistically significant (p<0.05) phosphorylation of SHP-2 (Fig.4.4).
This result suggests that GnRH I-elicited SHP-2 activation can occur independently
of all G protein subtypes. However, compared with control cells, in the presence of
excess Gsubunits GnRH I-elicited SHP-2 phosphorylation was partially inhibited,
similar to the inhibition observed with YM254890. Taken together, these results
suggest that SHP-2 activation in response to GnRH I exhibits partial Gq/11 protein
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Figure 4.3. The effect of the EGFR inhibitor, AG1478, on GnRH I-elicited SHP-2
phosphorylation. Serum-starved transiently transfected MCF-7 cells expressing the GnRH receptor
were incubated with DMSO (control) or with AG1478 (100nM) for 30 minutes prior to GnRH I
stimulation. Cells were stimulated with 100nM GnRH I (filled bars) or with vehicle control (open
bars) for 5 minutes. The data represent the mean ± S.E. of 2-3 independent experiments. *, p<0.05, **,
p<0.01, significantly different from NS control; Students t test.
Figure 4.4. The effects of inhibitors to Gq and Gi and Goverexpression on GnRH I-elicited
SHP-2 phosphorylation. MCF-7 cells were transiently transfected with the GnRH receptor and a
vector control (for control and inhibitor-treated cells) or G12 (equal concentrations of each) at a 1:1
ratio. Forty-eight hours following transfection and overnight serum-starvation, cells were treated with
PTX (200ng/ml; 16 hours), YM254890 (100nM; 30 minutes) or DMSO as a control (30 minutes).
Filled and open bars represent cells stimulated with 100nM GnRH I or vehicle control for 5 minutes
respectively. The data represent the mean ± S.E. of at least three independent experiments. *, p<0.05,
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4.4.4 Investigation of SHP-2 activation in response to GnRH II and three classical
GnRH receptor antagonists
Considering that the above results suggest a G protein-independent mechanism of
GnRH-induced SHP-2 activation, I was interested in determining if classical
antagonists of GnRH receptor-mediated Gq/11 signalling could induce SHP-2
activation. Furthermore, the ability of the second endogenous GnRH receptor
agonist, GnRH II, to facilitate SHP-2 activation at the GnRH receptor, was in
question. Thus cells were stimulated, for 5 minutes, with GnRH I as a control, GnRH
II and three GnRH receptor antagonists, Ant135-25, Cetorelix and Ant135-18, and
the SHP-2 phosphorylation responses assessed. GnRH II induced robust statistically
significant (p<0.01) SHP-2 phosphorylation, comparable with GnRH I-elicited SHP-
2 phosphorylation (Fig.4.5). Thus, both the endogenous GnRH agonists, GnRH I and
GnRH II, are able to mediate SHP-2 activation at the GnRH receptor. Evaluation of
the ability of the selected antagonists to mediate SHP-2 activation revealed that
Ant135-18 elicited statistically significant (p<0.05) SHP-2 phosphorylation of ~30%
the level induced by GnRH I. This result shows that classical GnRH receptor
antagonists can activate SHP-2 and supports the proposal that GnRH receptor-
mediated SHP-2 activation can occur in a Gq/11-independent manner. Furthermore, it
suggests that GnRH receptor conformational requirements that mediate SHP-2
activation differ from those that facilitate Gq/11 activation. In contrast, 5 minute
stimulation with Ant135-25 and Cetorelix did not induce discernible SHP-2
phosphorylation, suggesting that these antagonists stabilise different receptor
conformations to Ant135-18. In summary, these data support the proposal that the
GnRH receptor is able to adopt multiple receptor conformations with distinct
signalling profiles at the Gq/11 and SHP-2 signalling pathways.
4.4.5 Investigation of SHP-2 activation by Gq/11-uncoupled mutant GnRH receptors
In order to investigate the GnRH receptor conformational requirements for SHP-2
activation, the ability of three previously characterised GnRH receptor mutants, the
Ala6.29Lys, Asp7.49Ala and Tyr7.53Ala receptors, to facilitate SHP-2 phosphorylation
was evaluated. Each of these mutations induces uncoupling of the GnRH receptor
from Gq/11 signalling (Arora et al., 1996; Flanagan et al., 1999; Lu et al., 2005;
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Ala6.29Lys mutation occurs within the third intracellular loop, below TM6, and is
thought to facilitate Gq/11 uncoupling by sterically hindering G protein association
with the receptor (Myburgh et al., 1998). In contrast, the Asp7.49Ala and Tyr7.53Ala
mutations occur in the TM domains of the receptor, specifically within the highly
conserved D/NPxxY motif. These residues are proposed to make intramolecular
interactions in both the inactive and active states of GPCRs (Fritze et al., 2003;
Palczewski et al., 2000; Prioleau et al., 2002; Urizar et al., 2005). Thus, the
Asp7.49Ala and Tyr7.53Ala mutations are suggested to induce Gq/11 uncoupling by
preventing formation of intramolecular interactions that stabilise the active receptor
conformation. Furthermore, mutation of both Asp7.49 and Tyr7.53 has been implicated
in facilitating different conformational states of GPCRs and activation of non-G
protein signalling pathways (Flanagan et al., 1999; Kalatskaya et al., 2004; Mitchell
et al., 1998; Prioleau et al., 2002).
The Ala6.29Lys mutant receptor was not able to induce SHP-2 phosphorylation in
response to GnRH I (Fig.4.6). This result suggests that the steric constraint imposed
by this mutation on Gq/11 protein coupling also hinders SHP-2 activation. Thus the
molecular requirements for Gq/11 coupling and SHP-2 activation may overlap. In
contrast, the Asp7.49Ala mutation did not prevent SHP-2 phosphorylation and GnRH
I-elicited SHP-2 activation at this receptor was statistically significant (p<0.05)
(Fig.4.6). This result further supports the proposal that SHP-2 activation occurs
independently of Gq/11 activation and that the conformational requirements for SHP-2
and Gq/11 activation are distinct. This is also supported by the ability of the Tyr7.53Ala
mutation to mediate statistically significant (p<0.05) SHP-2 phosphorylation
comparable with wildtype receptor levels, despite being uncoupled from Gq/11
signalling. Interestingly, the Tyr7.53Ala mutant receptor exhibited elevated basal
SHP-2 phosphorylation relative to the wildtype receptor (Fig.4.6), suggesting that
this mutation induces constitutive activity at the SHP-2 signalling pathway. This is
consistent with previous reports suggesting that Tyr7.53 induces selective constitutive
activity in other GPCRs and that this residue represents a receptor conformational
molecular switch (Kalatskaya et al., 2004; Prioleau et al., 2002). The ability of this
mutation of the GnRH receptor to induce constitutive activity at the SHP-2 signalling
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active conformational requirements of the GnRH receptor differ for the two
pathways. Thus, together, these data suggest that the molecular requirements of the
GnRH receptor that facilitate Gq/11 and SHP-2 coupling overlap, but are governed by
distinct receptor conformations.
Figure 4.5. The effects of different ligands on GnRH receptor-mediated SHP-2 phosphorylation.
MCF-7 cells transiently expressing the GnRH receptor (48 hrs) were serum-starved (overnight) and
treated for 5 min with 100nM of GnRH I or GnRH II or 1μM of Ant135-25, Cetorelix or Ant135-18.
NS cells were treated with vehicle control for 5 min. Data are the mean ± S.E. of three independent
experiments. *, p<0.05, **, p<0.01, significantly different from NS control; Students t test.
Figure 4.6. Determination of SHP-2 phosphorylation by the Gq/11-uncoupled Tyr7.53Ala,
Ala6.29Lys and Asp7.49Ala GnRH receptor mutants. The indicated receptors were transiently
transfected into MCF-7 cells. Serum-starved cells were stimulated with 100nM GnRH I (filled bars)
or with vehicle control (open bars) for 5 minutes. Data are the mean ± S.E. of 2-3 independent
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4.4.6 GnRH receptor expression and tyrosine phosphorylation
The above experimental results provided clues for identification of a putative GnRH
receptor motif that facilitates SHP-2 activation. Firstly, the ability of GnRH I-elicited
SHP-2 activation to occur independently of G proteins suggests that SHP-2 may
form a direct binding complex with the GnRH receptor. Secondly, the increased
basal activity of the Tyr7.53Ala receptor is illuminating as Tyr7.53 interactions are
proposed to alter the conformation of TM7 and the C-terminal tail of GPCRs
(Weinstein, 2005). As the GnRH receptor lacks a C-terminal tail, this suggests that
the motif important for SHP-2 activation may occur in TM7 of the GnRH receptor.
Analysis of the amino acid sequence of the GnRH receptor reveals a putative SH2-
binding domain, YxxL, located within the four terminal amino acids of TM7 of the
GnRH receptor (Fig.4.7). Indeed, similar SH2-binding motifs have been identified in
a few other GPCRs and were necessary to observe the activation of SHPs by these
receptors (Duchene et al., 2002; Ferjoux et al., 2003; Vatinel et al., 2006). However,
in order for this domain to represent a canonical SH2 binding site, the tyrosine
residue within this motif must be phosphorylated (Pawson, 2004). Thus, it was
necessary to investigate whether tyrosine phosphorylation of the GnRH receptor
could be detected. The Tyr7.53Ala mutation was included in these experiments as this
residue, with the exception of the Tyr within the YxxL motif, is the only additional
tyrosine accessible on the intracellular surface of the receptor (see Fig.4.7). Thus if
Tyr phosphorylation of this mutant GnRH receptor could be detected, this would
imply that the Tyr7.55 of the YxxL motif is Tyr phosphorylated.
First, wildtype and Tyr7.53Ala GnRH receptors, which contain HA-tags at their N-
termini, were transiently transfected into MCF-7 cells and expression of the receptors
evaluated. Four distinct GnRH receptor bands were detected (Fig.4.8), consistent
with previous reports (Sedgley et al., 2006). Three of these bands were ~32, ~34 and
~36KDa in size. These bands are likely to represent GnRH receptors with differential
modifications, like glycosylation and/or phosphorylation. The fourth band was larger
and wider and was ~60-70kDa in size. This band may represent receptor dimers. The
most intense GnRH receptor band was ~36KDa in size and thus represents the most
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exhibited a similar distribution of GnRH receptor bands and had comparable receptor
expression with the wildtype receptor (Fig.4.8).
Next, tyrosine phosphorylation of the GnRH receptors was determined (Fig.4.9). A
distinct band of ~32KDa was detected following immunoprecipitation of tyrosine
phosphorylated proteins and detection of the GnRH receptor HA tag. This band was
not observed in untransfected MCF-7 cells indicating that this band is specific for the
GnRH receptor (Fig.4.9). This shows that the wildtype GnRH receptor undergoes
tyrosine phosphorylation. The absence of bands corresponding to other GnRH
receptor isoforms (see Fig.4.8) suggests that the population of GnRH receptors are
heterogeneous, with some receptors tyrosine phosphorylated, while others are not.
Both the wildtype receptor and Tyr7.53Ala receptor exhibited comparable tyrosine
phosphorylation (Fig.4.9). This suggests that the GnRH receptor is tyrosine
phosphorylated, but that the phosphorylation site is not Tyr7.53. As the only additional
Tyr accessible at the intracellular surface of the receptor is Tyr7.55 of the YxxL motif,
I propose that this is the tyrosine phosphorylation site of the receptor. Interestingly,
tyrosine phosphorylation of the GnRH receptor was constitutive and increased only
slightly following agonist stimulation (Fig.4.9). Indeed, time-course studies revealed
very little change in the tyrosine phosphorylation status of the GnRH receptor even
after stimulation for time points up to 60 minutes (Fig.S5).
These data suggest that the human GnRH receptor is constitutively phosphorylated
on Tyr of the YxxL motif in TM7, suggesting that this motif represents a canonical
pYxxL SH2-binding domain. This motif thus represents a putative mechanism for
SHP-2 recruitment to the GnRH receptor independently of G proteins, which may
facilitate SHP-2 phosphorylation in response to GnRH I. However, attempts to co-
immunoprecipitate the GnRH receptor and SHP-2 (with and without agonist
stimulation) to confirm a direct interaction between the two proteins were
unsuccessful (data not shown). This suggests that SHP-2 interaction with the GnRH
receptor may be dynamic, low affinity or alternatively, the antibodies in the
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Figure 4.7. Secondary structure representation of the human GnRH receptor. This figure is a
two-dimensional representation of the human GnRH receptor revealing the 7 transmembrane-spanning
regions and intra- and extracellular loops. The most highly conserved residues in the rhodopsin family
of GPCRs are indicated in yellow. Residues that are mutated and cause Gq/11 uncoupling (see section
4.4.5) are in blue. Amino acids that constitute the YxxL motif are in green and residues that make up
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Figure 4.8. Expression of the GnRH receptor in MCF-7 cells. MCF-7 cells were transfected with
HA-tagged (at the N-terminus) wildtype and Tyr7.53Ala GnRH receptors. Untransfected (UT) cells
were used as a negative control. Cells were serum-starved overnight and stimulated with 100nM
GnRH I or with vehicle for 5 minutes. GnRH receptors were immunoprecipitated with an anti-HA
antibody and immunoblotted with the same antibody. Four GnRH receptor bands are present and are
indicated with arrows and approximate sizes in kilodaltons (kDa). The most prominent GnRH
receptor band is indicated with the largest arrow. The heavy chain IgG band from the antibody used to
immunoprecipitate the receptor is also indicated. This figure is representative of three independent
experiments.
Figure 4.9. Tyrosine phosphorylation of the wildtype and Tyr7.53Ala GnRH receptors. MCF-7
cells were transfected with the HA-tagged wildtype and Tyr7.53Ala GnRH receptors. UT cells were
used as a negative control. Cells were serum-starved overnight and stimulated with 100nM GnRH I or
with vehicle for 5 minutes. Tyrosine phosphorylated proteins were immunoprecipitated with the PY20
antibody and GnRH receptors detected with an anti-HA antibody. The specific GnRH receptor band
detected is indicated with a large arrow and its approximate size in KDa. This figure is representative
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4.4.7 Determination of src binding to the GnRH receptor
Assuming that the pYxxL motif represents the mechanism whereby SHP-2 interacts
with and is activated by the GnRH receptor, it was necessary to address how SHP-2
undergoes Tyr phosphorylation following its recruitment to the receptor in response
to agonist. Previous experimental evidence led to the investigation of the role of the
cytoplasmic tyrosine kinase, src, in this phosphorylation event. Firstly, src has been
shown to phosphorylate SHP-2 on Tyr542 in other cell lines (Li et al., 2006).
Furthermore, in other GPCR systems, such as the somatostatin receptors, SHP-2
activation required src activation (Ferjoux et al., 2003; Florio, 2008).
Thus, to determine if src is responsible for the GnRH I-elicited phosphorylation of
SHP-2, receptors were stimulated with GnRH I following preincubation in the
presence or absence of the src inhibitor, PP2. Compared with control cells, PP2
preincubation significantly (p<0.01) decreased basal SHP-2 phosphorylation
(Fig.4.10). This suggests that src is primarily responsible for SHP-2 phosphorylation
on Tyr542 in MCF-7 cells. Furthermore, PP2 prevented GnRH I-elicited SHP-2
phosphorylation (Fig.4.10), suggesting that src is required for GnRH receptor-
mediated phosphorylation of SHP-2. These data thus suggest that src phosphorylates
SHP-2 on Tyr542 in response to GnRH I.
As src is suggested to phosphorylate SHP-2 and GnRH I-elicited SHP-2
phosphorylation occurs independently of G proteins, it was reasoned that src activity
may also be regulated by direct interaction with the GnRH receptor. Indeed,
activation of src by direct engagement with other GPCRs has been shown previously
(Cao et al., 2000; Fan et al., 2001; Sun et al., 2007a). Furthermore, multimeric src-
SHP complexes have been shown to occur at the somatostatin GPCRs (Arena et al.,
2007; Ferjoux et al., 2003). Thus, the ability of src to form a direct binding complex
with the GnRH receptor was assessed. Src was immunoprecipitated from MCF-7
cells transiently transfected with the HA-tagged wildtype GnRH receptor, and co-
immunoprecipitation of the GnRH receptor determined. The results show that src
pulled down four GnRH receptor bands (Fig.4.11) corresponding to all the isoforms
of the GnRH receptor expressed in these cells (see Fig.4.8). These bands were not
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the GnRH receptor. These results show that src is able to form a binding complex at
the GnRH receptor and that, like tyrosine phosphorylation of the GnRH receptor, this
association is constitutive and does not increase considerably upon GnRH I
stimulation (Fig.4.11). Furthermore, the results showed that src is able to associate
with all four GnRH receptor isoforms. Interestingly, compared with detection of
GnRH receptor expression where the most intense band was ~36KDa (Fig.4.8), the
most prominent GnRH receptor associated with src corresponds to ~32KDa, the
isoform of the GnRH receptor which is tyrosine phosphorylated (see Fig.4.9). This
result suggests that, while src association with the receptor does not require Tyr
phosphorylation, src is preferentially associated with the Tyr phosphorylated isoform
of the GnRH receptor. This may be because src has a higher affinity for the
phosphorylated GnRH receptor isoform and/or because src is responsible for GnRH
receptor phosphorylation.
There are various mechanisms that enable GPCRs to form a direct complex with src,
including engagement of the SH2 or SH3 domains of the kinase or by formation of a
GPCR--arrestin-src binding complex (Cao et al., 2000; Fan et al., 2001; Luttrell et
al., 1999). The above result shows that the pYxxL motif is not critical for src
association as src associates with all four GnRH receptor isoforms. This suggests that
src does not associate with the GnRH receptor via its SH2 domain (Fig.4.11).
Additionally, robust GnRH receptor-mediated SHP-2 phosphorylation was detected
in COS-7 cells which have low endogeneous -arrestins (Fig.S6) and previous
evidence in the literature, as indicated by internalisation and signalling studies,
suggest that the human GnRH receptor does not interact with -arrestins (Caunt et
al., 2006; McArdle et al., 1999). This suggests that it is unlikely that src utilises a -
arrestin scaffold for interaction with the GnRH receptor. Thus, together, these results
suggest that src associates with the GnRH receptor via its SH3 domain. Analysis of
the GnRH receptor amino acid sequence for putative SH3 binding motifs was
undertaken. Sequence analysis of the GnRH receptor revealed the presence of three
(R/K)xx(K/R) motifs in ICL1 (Fig.4.7), which represent putative SH3 binding
domains (Li, 2005; Seet et al., 2007). Thus it is proposed that the GnRH receptor
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Figure 4.10. The effect of the src inhibitor, PP2, on GnRH I-elicited SHP-2 phosphorylation.
MCF-7 cells were transiently transfected with the GnRH receptor and serum-starved as described
previously. Prior to stimulations, cells were pretreated with 5µM PP2 or DMSO (for control cells) for
30 minutes. Cells were stimulated with GnRH I (filled bars) or vehicle (NS controls) (open bars) for 5
minutes. Data represent the mean ± S.E. of three independent experiments. *, p<0.05, **, p<0.01,
bracketed bars significantly different; Students t test.
Figure 4.11. Determination of src association with the GnRH receptor. Serum-starved transiently
transfected MCF-7 cells were stimulated with 100nM GnRH I or vehicle (NS control) for 5 minutes.
Src was immunoprecipitated with an antibody which recognises its N-terminus and associated GnRH
receptors were detected with an anti-HA antibody. Four GnRH receptor bands are present and are
indicated with arrows and the approximate sizes in kDa. The most prominent GnRH receptor band is
indicated with a larger arrow. Untransfected (UT) MCF-7 cells served as a negative control. This
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4.4.8 Effects of GnRH I-elicited SHP-2 activation on downstream ERK activation
In order to establish the downstream signalling targets of SHP-2 activation in
response to GnRH I and thereby begin to determine the functional and physiological
significance of this novel pathway, known targets/pathways of SHP-2 that overlap
with established GnRH receptor signalling pathways were examined. Both the GnRH
receptor and SHP-2 are well-established activators of the MAPK pathway and ERK
signalling (Caunt et al., 2006; Chong and Maiese, 2007). The activation of ERK
plays a role in a number of important cellular processes, such as cell growth and
proliferation (Kimura et al., 1999; Meloche and Pouyssegur, 2007) and transcription
(Caunt et al., 2006; Maudsley et al., 2007). Thus the role of GnRH I-elicited SHP-2
activation on downstream ERK signalling was investigated.
MCF-7 cells were transfected with the GnRH receptor and a vector control or SHP-2
dominant-negative construct, SHP-2(c/s), which has a non-functional phosphatase
domain (Kolli et al., 2004), and the ability of the GnRH receptor to elicit ERK
activation was evaluated (Fig.4.12). In control cells, GnRH I induced robust
statistically significant ERK activation that was maximal at 10 minutes (p<0.01) and
decreased at the subsequent 30 and 60 minute time points, but was still elevated
above basal levels at 60 minutes of GnRH I stimulation. The kinetics of this ERK
response is comparable with that observed in several other cell lines (Benard et al.,
2001; Caunt et al., 2006). In cells transfected with the dominant-negative SHP-2(c/s)
construct, basal ERK phosphorylation was reduced (Fig.4.12) consistent with the
established role of SHP-2 in ERK signalling (Chong and Maiese, 2007).
Nevertheless, the increase in GnRH I-elicited ERK phosphorylation in the presence
of the SHP-2(c/s) construct was robust and exhibited similar kinetics to that observed
with the control cells (Fig.4.12). This result shows that SHP-2 does not make a major
contribution to the robust ERK response induced by the GnRH receptor and is
consistent with previous reports showing that the GnRH receptor-mediated ERK
activation occurs mainly via a PKC-dependent mechanism in several cell lines
(Benard et al., 2001; Caunt et al., 2006; Kraus et al., 2001; Naor et al., 2000).
However, interestingly, while the difference is small, the increase in GnRH I-elicited
ERK activation at the 30 and 60 minute time points were consistently lower in the
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statistically significant difference (p<0.01 and p<0.05 for 30 and 60 minute time
points respectively). This result shows that SHP-2 activation contributes to ERK
activation by the GnRH receptor at 30 and 60 minutes and thus SHP-2 facilitates a
more sustained ERK response by the GnRH receptor.
4.4.9 Effects of GnRH I-elicited SHP-2 activation on downstream Akt
phosphorylation
Another signalling pathway that is regulated by both the GnRH receptor and SHP-2
is the Akt signalling pathway (Chong and Maiese, 2007; Kraus et al., 2004; Rose et
al., 2004). Akt signalling is important for several fundamental cellular functions,
including transcription, proliferation, growth and survival (Hawkins et al., 2006;
Osaki et al., 2004). Previous reports suggest that the GnRH receptor inhibits Akt
phosphorylation on Ser473, and thus activation of Akt, in several cell lines (Kraus et
al., 2004; Rose et al., 2004). In contrast, SHP-2 has been shown to activate or inhibit
Akt signalling under different cellular conditions (Chong and Maiese, 2007). Thus,
the effect of GnRH I-elicited SHP-2 activation on Akt signalling was examined.
Activation of Akt by phosphorylation on Ser473 in response to GnRH I was assessed
in the presence of expression of a vector control or the dominant negative SHP-2(c/s)
construct. In the control cells, the GnRH receptor induced a small transient increase
in Akt phosphorylation on Ser473 that was maximal at 10 minutes and decreased at
the subsequent 30 and 60 minute time points (Fig.4.13). However, this response was
not statistically significant. In contrast, in the SHP-2(c/s)-expressing cells, the
phosphorylation of Akt on Ser473 was enhanced and was statistically significant at 10
(p<0.01) and 30 (p<0.05) minutes of GnRH I stimulation (Fig.4.13). This result
suggests that activation of SHP-2 by the GnRH receptor may contribute to the
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Figure 4.12. The effects of a SHP-2 dominant negative construct, SHP-2(c/s), on GnRH I-elicited
ERK activation. MCF-7 cells were transfected with the GnRH receptor and a vector control (for
control cells) or SHP-2(c/s) at a 1:1 ratio. Cells were serum-starved overnight and then stimulated
with 100nM GnRH I for the indicated time points. Bars represent phosphorylated ERK (pERK)
normalised for total ERK (which serves as a loading control) and following removal of basal pERK
values. Points are the mean ± S.E. of at three independent experiments. *, p<0.05, **, p<0.01,
significantly different from NS controls (one-way ANOVA with Dunnet’s multiple comparison test) 
or comparison of bracketed bars (Students t test).
Time (min) 0 10 30 60 0 10 30 60
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Figure 4.13. The effect of a SHP-2 dominant negative construct, SHP-2(c/s) on Ser473
phosphorylation of Akt in response to GnRH I. MCF-7 cells were transfected with the GnRH
receptor and a vector control or SHP-2(c/s) at a 1:1 ratio. Cells were serum-starved and stimulated
with 100nM GnRH I for the indicated times. Akt phosphorylation on Ser473 was detected with a
phosphospecific antibody. Bars represent phosphorylated Akt (pAkt) normalised for total ERK (which
serves as a loading control) and following removal of basal pAkt values. Points are the mean ± S.E. of
at three independent experiments. *, p<0.05, **, p<0.01, significantly different from NS controls; one-
way ANOVA with Dunnet’s multiple comparison test.
Time (min) 0 10 30 60 0 10 30 60
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4.5 Discussion
The GnRH receptor exhibits anti-proliferative and proapoptopic effects in
reproductive cancer cells (Grundker and Emons, 2003; Grundker et al., 2001; Kraus
et al., 2004; Maiti et al., 2005; Maudsley et al., 2004). Activation of the GnRH
receptor stimulates PTP activity and has been shown to interfere with the
proliferative activity of several RTKs (Grundker et al., 2001; Imai et al., 1996a; Imai
et al., 1996b; Marelli et al., 1999; Moretti et al., 1996). This effect is believed to
facilitate the anti-proliferative effects mediated by this receptor. Interestingly, anti-
proliferative signaling mediated by the GnRH receptor doesn’t correlate with 
activation of the classical Gq/11 signalling pathway (Grundker and Emons, 2003;
Millar et al., 2008), suggesting that another pathway is responsible for these effects.
In light of emerging evidence suggesting that GPCRs are able to make direct
interactions with the PTPs, SHP-1 and SHP-2 (Duchene et al., 2002; Ferjoux et al.,
2003; Lopez et al., 1997; Vatinel et al., 2006), the present study aimed to investigate
whether the GnRH receptor was able to mediate activation of these PTPs.
4.5.1 GnRH I elicits SHP-2 phosphorylation at the GnRH receptor in a time- and
dose-dependent manner
To ascertain if the GnRH receptor was able to activate the PTPs, SHP-1 and SHP-2,
tyrosine phosphorylation of their C-terminal tails on Tyr536 and Tyr542 respectively,
in response to GnRH I, was assessed. Determination of SHP-1 activation, by
evaluating its phosphorylation on Tyr536, was unsuccessful. Neither basal nor GnRH
I-elicited SHP-1 phosphorylation was detected (Fig.S3), despite reports that SHP-1 is
expressed in these cells (Thangaraju et al., 1999). It may be that the antibody used
has low affinity or that phosphorylation of this residue is a rare event, as SHPs can be
activated by other mechanisms in addition to phosphorylation on the C-terminal tail
(Neel et al., 2003). Thus this result does not preclude the possibility that the GnRH
receptor can activate SHP-1.
In contrast, the results show that GnRH I elicited a robust and specific
phosphorylation of SHP-2 on Tyr542 in a time- and dose-dependent manner in MCF-7
cells (Fig.4.1 and Fig.4.2). Analysis of the kinetics of SHP-2 phosphorylation shows
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Furthermore, the protracted activation over 60 minutes indicates that this signalling
pathway is not readily downregulated. GnRH I had a high potency for the activation
of SHP-2 with an EC50 value of ~1nM. Together, the robust, rapid and high potency
of the GnRH I-elicited SHP-2 response suggest that this pathway is likely to
represent a physiologically relevant signalling event.
4.5.2 GnRH I-elicited SHP-2 phosphorylation occurs independently of EGFR
transactivation and is only partially dependent on G protein signalling
To investigate the mechanism whereby the GnRH receptor mediates SHP-2
activation, several signalling pathways were examined. First, considering that the
EGF receptor is a well-established activator of SHP-2, the possibility that the GnRH
receptor activates SHP-2 by transactivation of the EGF receptor, was investigated.
The results show that the GnRH receptor was able to induce robust SHP-2 activation
in the presence of an EGFR inhibitor (Fig.4.3). Thus, it was concluded that the
ability of the GnRH receptor to activate SHP-2 in the MCF-7 cells is not via
transactivation of the EGFR.
Next, the role of G protein signalling in GnRH receptor-mediated SHP-2 activation
was explored. Several experimental results show that SHP-2 activation by the GnRH
receptor can be mediated independently of G proteins. Firstly, inhibitors of the G
proteins, Gq/11 and Gi, did not completely prevent SHP-2 activation in response to
GnRH I (Fig.4.4). Furthermore, overexpression of the G subunits, which
effectively switch off the activity of the Gsubunits (Cabrera-Vera et al., 2003), did
not completely prevent SHP-2 activation (Fig.4.4) supporting the proposal that this
pathway can be activated independently of G proteins. Additional evidence is the
ability of the Gq/11-uncoupled Tyr7.53Ala and Asp7.49Ala mutant GnRH receptors to
induce robust SHP-2 phosphorylation comparable with the wildtype receptor
(Fig.4.6). Furthermore, a classical GnRH receptor antagonist at the Gq/11 signalling
pathway, Ant135-18, was able to induce SHP-2 phosphorylation at the GnRH
receptor (Fig.4.5). Taken together, these results show that the GnRH receptor can
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An important observation is that the Gq/11 inhibitor and the Gsubunits, while
unable to prevent SHP-2 phosphorylation, nevertheless reduced the SHP-2 response
and the extent of the inhibition was comparable (Fig.4.4). This suggests that there is
a partial dependence on Gq/11 for SHP-2 activation by the GnRH receptor.
Nevertheless, a second explanation exists. The Gq/11 inhibitor is proposed to inhibit
Gq/11 signalling by preventing GDP/GTP exchange, but doesn’t afect the ability of
Gq/11 to interact with the receptor (Takasaki et al., 2004). Thus the inhibitor may
inhibit SHP-2 activation by preventing G protein dissociation from the receptor,
thereby precluding access of SHP-2 to the receptor. The Gsubunits, which
promote association of the Gsubunits with the receptor (Cabrera-Vera et al., 2003),
may thus inhibit SHP-2 activation in a similar manner. This proposal is supported by
the observation that the steric constraint imposed by the Ala6.29Lys mutation
inhibited both Gq/11 and SHP-2 activation, suggesting that Gq/11 and SHP-2 may
interact with an overlapping region/domain of the GnRH receptor and thus that their
binding is mutually exclusive.
Classically, GPCRs, as their name suggests, are thought to require activation of G
proteins in order to activate intracellular signalling cascades. However, emerging
evidence in several GPCRs has revealed that this family of receptors may also utilise
G protein-independent signalling mechanisms, particularly in the activation of
phosphotyrosine signalling pathways (Sun et al., 2007a; Sun et al., 2007b).
Furthermore, this mechanism of GPCR signalling is gaining recognition as a
physiologically relevant pathway in vivo (Zhai et al., 2005). My results show that the
GnRH receptor is able to activate SHP-2 in a G protein-independent manner, thus
presenting another example of a GPCR which can signal via non-classical signalling
mechanisms and extending the number of GPCRs that exhibit G protein-independent
signalling. In the context of other GPCRs which signal by G protein-independent
mechanisms, these results provide further support for the proposal that G protein-
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4.5.3 The GnRH receptor conformations that mediate SHP-2 and Gq/11 activation
are distinct
A further implication inherent in the above results is that the GnRH receptor is able
to adopt multiple active conformations and that these conformations have distinct
abilities to activate the Gq/11 and SHP-2 signalling pathways. For example, the ability
of Ant135-18 to activate SHP-2, but not Gq/11 signalling, suggests that this ligand
stabilises a receptor conformation that can facilitate SHP-2, but not Gq/11, activation.
Furthermore, alanine mutagenesis of Tyr7.53 and Asp7.49 revealed that these residues
are required to make intramolecular interactions necessary for a receptor
conformation that enables Gq/11 signalling (Arora et al., 1996; Flanagan et al., 1999;
Lu et al., 2005), but the results presented here show that they are not important for
GnRH receptor-mediated SHP-2 activation (Fig.4.6). Thus these data also support
the proposal that the GnRH receptor can adopt distinct active conformations with
different signalling capabilities. The ability of the GnRH receptor to adopt multiple
receptor conformations with distinct signalling capabilities has important therapeutic
implications as it presents the exciting possibility that drugs can be developed to
specifically target desired signalling pathways, without activating signalling which
causes adverse effects.
4.5.4 The GnRH receptor exhibits a constitutively tyrosine-phosphorylated
canonical SH2-binding pYxxL motif
The ability of the GnRH receptor to activate SHP-2 independently of G proteins
suggests that SHP-2 is activated by direct interaction with the GnRH receptor.
Indeed, SHP-2 has been shown to interact directly with SH2-binding motifs in a few
other GPCRs, including the bradykinin, somatostatin and chemokine CCK2 receptors
(Duchene et al., 2002; Ferjoux et al., 2003; Vatinel et al., 2006). Analysis of the
GnRH receptor amino acid sequence identified a putative SH2-binding YxxL motif
at the C-terminal end of TM7 (Fig.4.7) and further examination of tyrosine
phosphorylation of the wildtype and Tyr7.53Ala GnRH receptors revealed that Tyr7.55
within this YxxL motif is phosphorylated indicating that this motif has the hallmarks
of a canonical SH2-binding domain (Fig.4.9). It is thus proposed that SHP-2 interacts
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There are several other important observations regarding the tyrosine
phosphorylation of the GnRH receptor. Firstly, tyrosine phosphorylation of the
GnRH receptor was constitutive and, while four GnRH receptor isoforms were
expressed in the MCF-7 cells (Fig.4.8), only one of these isoforms was tyrosine
phosphorylated (Fig.4.9). This suggests that, in the basal state, GnRH receptors exist
as a heterogeneous population of differentially Tyr phosphorylated states. An
important consequence of the identification of a subpopulation of GnRH receptors
that exhibit constitutive tyrosine phosphorylation is the possibility that the
distribution of GnRH receptors in the phosphorylated state may vary in different
tissues. Expression of the GnRH receptor in cancerous tissues, where the activity of
tyrosine kinases, such as src, is elevated, may contribute to a higher proportion of
phosphorylated receptors and thus facilitate tissue-specific signalling of the receptor
(Maudsley et al., 2005; Nelson and Challiss, 2007). Indeed, the M3-muscarinic
receptor is differentially phosphorylated by casein kinase 2 (CK2) in different cell
types (Torrecilla et al., 2007) and CK2 phosphorylation of this receptor inhibits its
activation of Jun-kinase signaling, but doesn’t afect ERK activation or receptor 
internalisation (Torrecilla et al., 2007). Thus, the tissue-specific expression,
localisation and regulation of kinases can differentially affect the signalling outcome
of receptor activation in different cell types.
The effects of tyrosine phosphorylation on GnRH receptor signalling have not been
explored. However, it has been reported that tyrosine phosphorylation of the GnRH
receptor may regulate receptor conformation (Liebow et al., 1991). Specifically, it
has been shown that tyrosine phosphorylation of the human GnRH receptor alters the
binding of the GnRH agonist, [D-Trp6]GnRH (Liebow et al., 1991). In the presence
of EGF and ATP, phosphorylation of the GnRH receptor was observed and
correlated with an increase in [D-Trp6]GnRH binding. Similarly, incubation with
somatostatin analogue, RC-160, facilitated dephosphorylation of the GnRH receptor
and induced a decrease in [D-Trp6]GnRH binding. However, no change in GnRH
receptor affinity was observed and as these experiments were performed on
pancreatic cancer cell membranes, altered receptor trafficking or protein synthesis
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allosteric mechanism, where phosphorylation alters receptor conformation, shifting
the receptor conformational equilibrium to favour the high affinity binding state.
This suggests that phosphorylation of the GnRH receptor could alter the potency of
GnRH receptor signalling by increasing the number of high affinity receptors.
Thus, these results show that the human GnRH receptor exhibits constitutive tyrosine
phosphorylation in MCF-7 cells. This introduces a new level of complexity and may
contribute to tissue-specific signalling observed at the GnRH receptor. Furthermore,
Tyr7.55 has been identified as the Tyr residue which is phosphorylated and thus
indicates that the pYxxL motif in TM7 of the GnRH receptor represents a canonical
SH2-binding domain. This site thus represents the proposed mechanism whereby
SHP-2 interacts directly with the GnRH receptor and is activated independently of G
proteins.
4.5.5 Tyr7.53 of the D/NPxxY motif constitutes a molecular switch that regulates
SHP-2 activation
The suggestion that the pYxxL motif is important for SHP-2 activation is consistent
with the experimental data observed at the Tyr7.53Ala mutant receptor. This receptor
exhibited elevated basal SHP-2 phosphorylation levels compared with the wildtype
receptor, suggesting that this receptor has constitutive activity at the SHP-2
signalling pathway (Fig.4.6). This further supports the proposal that the GnRH
receptor conformations that mediate SHP-2 and Gq/11 signalling are distinct, as this
mutant is not constitutively active at the Gq/11 signalling pathway. Additionally, this
result suggests that Tyr7.53 interactions contribute to a molecular switch that
constrains a functional domain which facilitates SHP-2 activation. I have proposed
that the functional domain that facilitates SHP-2 activation is the pYxxL at the C-
terminal end of TM7 of the GnRH receptor. Previous reports suggest that the
analogous Tyr participates in a conformational switch that specifically alters the
conformation of the functional domain constituting the C-terminal tail in other
GPCRs (Kalatskaya et al., 2004; Prioleau et al., 2002; Weinstein, 2005). For
example, alanine mutagenesis of the equivalent residue in the B2 Bradykinin receptor
led to constitutive phosphorylation and internalisation of the receptor, but did not
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a similar way, alanine mutagenesis of Tyr7.53 in the GnRH receptor disrupts a
molecular switch, which constrains the position of the pYxxL motif at the bottom of
TM7, thereby enabling constitutive activation of SHP-2, but not Gq/11 signalling.
4.5.6 Src forms a direct and constitutive binding complex with the GnRH receptor
and is necessary for GnRH I-elicited SHP-2 activation
Tyrosine phosphorylation of the GnRH receptor and SHP-2 in response to GnRH I
supported the involvement of a tyrosine kinase in this signalling pathway. Due to the
reported regulation of SHP-2 by src (Li et al., 2006), it was considered feasible to
investigate the participation of src in this signalling pathway. The results presented
here show that the src inhibitor, PP2, decreased both basal SHP-2 phosphorylation
and GnRH I-elicited SHP-2 phosphorylation (Fig.4.10). Thus it was concluded that
src is responsible for SHP-2 phosphorylation in MCF-7 cells.
The involvement of src in the SHP-2 signalling pathway introduced a further
mechanistic challenge regarding how this protein is regulated by the GnRH receptor
independently of G proteins. Nevertheless, recent reports suggest that GPCRs are
also able to directly interact with src either via a -arrestin scaffold, or by interaction
with the SH2 or SH3 domains of src (Cao et al., 2000; Fan et al., 2001; Luttrell et al.,
1999). Indeed, immunoprecipitation experiments revealed that src associated with all
four GnRH receptor isoforms expressed in the MCF-7 cells (Fig.4.11). The
experimental data excluded the possibility that src associates with the GnRH receptor
via its SH2 domain as tyrosine phosphorylation of the GnRH receptor was not an
absolute requirement for src association (Fig.4.11). Furthermore, the ability to detect
robust SHP-2 phosphorylation in COS-7 cells with low endogeneous -arrestins
suggested that src does not associate with the GnRH receptor via a -arrestin
scaffold. Analysis of the GnRH receptor sequence revealed the presence of three
(R/K)xx(K/R) motifs in ICL1 (Fig.4.7) which represent putative SH3 binding
domains (Li, 2005; Seet et al., 2007). Thus, it is proposed that src associates via its
SH3 domain with (R/K)xx(K/R) motifs in ICL1 of the GnRH receptor.
There are two other important observations regarding src association with the GnRH
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of src with the GnRH receptor was constitutive. Secondly, while src bound to all four
GnRH receptor isoforms, it was preferentially associated with the phosphorylated
receptor state (Fig.4.11). This result shows that phosphorylation of the receptor is not
required for src binding, but is nevertheless highly correlated with this event. A
proposed mechanism which explains this phenomenon is that src is responsible for
the tyrosine phosphorylation of the GnRH receptor. Thus src binding to the GnRH
receptor may facilitate its activation thereby enabling phosphorylation of the GnRH
receptor.
4.5.7 Proposed model of GnRH receptor-mediated SHP-2 activation
Thus from the above results, I propose the following model for GnRH I-elicited
SHP-2 activation at the GnRH receptor (Fig.4.14). In the basal state, src associates
with ICL1 of the GnRH receptor via its SH3 domain. This event facilitates activation
of src and enables src to phosphorylate Tyr7.55 of the YxxL motif in TM7 of the
GnRH receptor, creating a docking site for SHP-2. SHP-2 either constitutively
associates with this motif or ligand binding and a receptor conformational
rearrangement is required in order for SHP-2 to access the site. Upon GnRH I
stimulation, the GnRH receptor undergoes a conformational change involving
disruption of the constraining interactions of Tyr7.53 of the D/NPxxY motif. This
conformational change either allows SHP-2 access to the pYxxL motif or facilitates a
change in the relative conformation of src and SHP, thus enabling src
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Figure 4.14. Schematic representation of the proposed mechanism of SHP-2 activation by the
GnRH receptor in response to GnRH I. In the basal state (A), src binds to ICL1 of the GnRH
receptor via its SH3 domain. This facilitates activation of the kinase and enables src phosphorylation
of Tyr7.55 of the YxxL motif in TM7 of the GnRH receptor, creating a docking site for SHP-2. SHP-2
either binds to this motif in the basal state or ligand-induced receptor conformational changes are
required to allow SHP-2 access to this site. Following GnRH I binding (B), the GnRH receptor
undergoes a conformational change involving disruption of the constraining interactions made by
Tyr7.53 of the D/NPxxY motif. This either facilitates SHP-2 binding or changes the relative position of
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This unusual scheme of GnRH receptor signalling is more reminiscent of cytokine
activation of the JAK/STAT pathway than the classical GPCR G protein signalling
(Haan et al., 2006). However, the number of GPCRs for which direct interactions
with src and/or SHP-2 have been demonstrated is increasing, suggesting that this
non-classical GPCR signalling may represent a more broadly utilised signalling
mechanism (Cao et al., 2000; Duchene et al., 2002; Fan et al., 2001; Ferjoux et al.,
2003; Marrero et al., 1998; Olszewska-Pazdrak et al., 2004; Sun et al., 2007a; Sun et
al., 2007b).A key question is how the “switch” from G protein-dependent signalling
to this G protein-independent mechanism of signalling occurs. It was previously
proposed that the G protein-independent activation of src by the 2-adrenergic
receptor involved a dose-dependent switch, where low agonist concentrations
activated G proteins, while high agonist concentrations activated the G protein-
independent signalling mode (Sun et al., 2007a). However, the low EC50 value of
~1nM for GnRH I-elicited SHP-2 activation suggests that this explanation is not
sufficient in the GnRH receptor signalling context. I propose a second possible
explanation. Specifically, that tyrosine phosphorylation of the GnRH receptor
mediates the switch in coupling. This suggestion is supported by the previous
observation, discussed above, that phosphorylation of the GnRH receptor alters the
number of high affinity GnRH receptors (Liebow et al., 1991), which would thus
increase the potency of GnRH receptor signalling. Indeed, PKA phosphorylation of
the 2-adrenergic has been shown to mediate a switch in G protein signalling, from
Gs to Gi activation (Daaka et al., 1997). Furthermore, phosphorylation of GPCRs by
GRKs mediates a switch from G protein to -arrestin-mediated signalling (Lefkowitz
et al., 2006). Thus the localisation, expression and activity of src and thus
phosphorylation of the GnRH receptor in different tissues may dictate the potency of
the GnRH receptor G protein-independent signalling to SHP-2.
4.5.8 SHP-2 contributes to GnRH receptor regulation of ERK and Akt signalling
In order to determine the effects of GnRH receptor-mediated SHP-2 activation on
downstream signalling, the effects of a SHP-2 dominant negative construct, SHP-
2(c/s) on GnRH I-elicited ERK and Akt signalling was assessed. The results show
that, in the presence of the SHP-2 dominant negative construct, the ERK response










Chapter 4: Investigation of the coupling of the GnRH receptor to the SH2 domain-
containing phosphatase 2, SHP-2
168
GnRH I stimulation (Fig.4.12). This result suggests that activation of SHP-2 by the
GnRH receptor may increase the magnitude and contribute to a more sustained ERK
response. The definitive relevance of this to GnRH receptor signalling requires
further investigation, but, in the context of previously performed experimental data,
it is possible to speculate that this pathway may contribute to the anti-proliferative
signalling mediated by the GnRH receptor. Firstly, ERK activation has been
implicated previously in the anti-proliferative signalling of the GnRH receptor
(Kimura et al., 1999; Kraus et al., 2006), as well as other GPCRs (Florio et al., 2000;
Lahlou et al., 2003). The magnitude and duration of the ERK response, specifically a
robust and prolonged activation, facilitates cell cycle arrest by upregulation of
cyclin-dependent kinase (Cdk) inhibitors (Meloche and Pouyssegur, 2007). Thus
SHP-2 activation may facilitate the anti-proliferative effects of the GnRH receptor by
enhancing the magnitude and duration of the ERK response.
Next, the effect of the SHP-2(c/s) on GnRH receptor regulation of Akt activation was
assessed. In control cells, Akt activation, as measured by the increase in its
phosphorylation on Ser473, was elicited in response to GnRH I, but the response was
small and not statistically significant. This small signalling response may be
mediated by GnRH receptor transactivation of the EGFR. Interestingly, in the
presence of the SHP-2 dominant negative construct, GnRH I-elicited Akt activation
was enhanced and the response became statistically significant. This result suggests
that SHP-2 may be involved in the inhibition of Akt activation. The Akt signalling
pathway plays a central role in the regulation of cell-cycle progression and survival
(Hawkins et al., 2006; Osaki et al., 2004). Furthermore, GnRH receptor inhibition of
Akt activation has been proposed previously to enable the anti-proliferative effects of
the GnRH receptor (Kraus et al., 2004; Rose et al., 2004). Thus, SHP-2 activation by
the GnRH receptor contributes to the inhibition of Akt activation and may therefore
facilitate the anti-proliferative effects of the GnRH receptor. Thus, together, GnRH
receptor-mediated SHP-2 activation, which the results show enables a more robust
and prolonged ERK response and facilitates inhibition of Akt signalling, may
contribute to the anti-proliferative effects mediated by the GnRH receptor. This is
consistent with the involvement of SHP activation in the regulation of cell
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sst1 and sst2 somatostatin (Ferjoux et al., 2003; Florio, 2008; Florio et al., 2000;
Lopez et al., 1997) and CCK2 chemokine receptors (Vatinel et al., 2006).
The above results show that GnRH I-elicited GnRH receptor activation induced both
activation and inhibition of Akt signalling, as inferred from Akt phosphorylation on
Ser473. This suggests that there are two pathways emanating from the GnRH receptor,
a proliferative signalling pathway and an anti-proliferative pathway. Interestingly,
while, as discussed, the GnRH receptor exerts anti-proliferative effects in certain
cancer cell lines, proliferative effects on other cell lines have been observed
(Enomoto et al., 2004). A similar phenomenon has been observed at the B2
bradykinin receptor, where activation of the receptor results in proliferative or anti-
proliferative signalling depending on the experimental conditions (Duchene et al.,
2002). In the bradykinin receptor, it has been proposed that the proliferative effects
of the receptor are mediated by activation of the Gq/11 protein, while the anti-
proliferative effects are mediated by SHP-2 activation (Duchene et al., 2002). As my
results suggest that SHP-2 activation is involved in anti-proliferative signalling of the
GnRH receptor, it is tempting to speculate that this Gq/11-coupled receptor is subject
to a similar signalling scheme.
One set of data that is difficult to reconcile with the proposed anti-proliferative
effects of SHP-2 activation by the GnRH receptor, is the inability to detect SHP-2
activation in response to Ant135-25 and Cetorelix, which have been shown to
mediate anti-proliferative signalling in certain cancer cell lines (Grundker and
Emons, 2003; Maudsley et al., 2004). However, the effects of these ligands may be
cell-context dependent as other researchers have reported an inability to detect cell
death in response to Cetorelix in prostate cancer cells (Maiti et al., 2005). Thus this
result does not preclude the possibility that SHP-2 activation by the GnRH receptor
facilitates anti-proliferative signalling.
4.5.9 Summary
In summary, the results presented in this chapter show that the GnRH receptor is able
to mediate robust time- and dose-dependent activation of SHP-2 in response to
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and represents a novel mechanism of GnRH receptor signalling. This signalling
pathway contributes to GnRH receptor-mediated ERK and Akt regulation and may
thus be involved in the anti-proliferative effects of the GnRH receptor. Of particular
interest, SHP-2 activation is mediated by a subset of receptor conformations that are
distinct from those that mediate Gq/11 signalling. Understanding the molecular nature
of ligand-receptor interactions and receptor activation relevant to these signalling
pathways will create an opportunity for the tailored development of drugs targeted at
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4.6 Supplementary figures
Figure S1. MCF-7 cells exhibit efficient transfection following electroporation. MCF-7 cells were
electroporated with 15g of the wildtype GnRH receptor (■) or control (●) DNA and subjected to 
whole cell radioligand binding assays 48 hours post transfection (see materials and methods). Control-
transfected cells did not exhibit specific binding for the GnRH receptor label, 125I-[His5,D-
Tyr6]GnRH. However, cells transfected with the wildtype GnRH receptor showed high specific
binding of the label indicating efficient transfection and expression of the GnRH receptor in the MCF-
7 cells. Furthermore, the IC50 value for GnRH I at these receptors was 4nM, which is consistent with
that observed in other cell lines (see chapter 2).
Figure S2. SHP-2 activation in the MCF-7 cells is specifically mediated by the type I GnRH
receptor. MCF-7 cells were transfected with control DNA or with the wildtype type I human GnRH
receptor. Forty-eight hours following transient transfection and overnight serum starvation, cells were
treated with 100nM GnRH I as indicated. Phosphorylated proteins were immunoprecipitated with the
PY20 antibody and SHP-2 phoshorylation on Tyr542 was detected. Cells transfected with control DNA
did not show GnRH I-elicited SHP-2 activation. However, cells transfected with the wildtype receptor
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Figure S3. Basal and GnRH I-induced SHP-1 phosphorylation could not be detected in MCF-7
cells. MCF-7 cells were transiently transfected with the wildtype GnRH receptor. Forty-eight hours
following transfection and overnight serum starvation, cells were treated with 100nM GnRH I as
indicated. Phosphorylated proteins were immunoprecipitated with the PY20 antibody and SHP-1
phoshorylation on Tyr536 was detected. The expected molecular weight of SHP-1 is 68KDa. A band of
this size could not be detected in these cells using this antibody. M, protein marker; UT, untransfected
cells; NS, non-stimulated.
Figure S4. The Gq/11 inhibitor, YM254890, inhibits GnRH I-elicited inositol phosphate responses
at the wildtype GnRH receptor. MCF-7 cells were transiently transfected with the wildtype GnRH
receptor. Forty-eight hours following transfection and overnight myo-D-[3H]inositol labelling, cells
were pre-incubated in the presence of DMSO (■) or 100nM YM254890 (●)for 30 minutes and the
GnRH I-elicited inositol phosphate responses were assessed (see materials and methods in chapter 2).
Compared with the DMSO control, YM254890 efficiently inhibits GnRH I-elicited inositol phosphate
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Figure S5. Time-course of GnRH receptor tyrosine phosphorylation in MCF-7 cells. MCF-7 cells
were transiently transfected with the HA-tagged wildtype GnRH receptor. Untransfected (UT) cells
were used as a negative control. Cells were serum-starved overnight and stimulated with 100nM
GnRH I as indicated (forty-eight hours following transfection). Tyrosine phosphorylated proteins
were immunoprecipitated with the PY20 antibody and the GnRH receptor was detected with an anti-
HA antibody. The specific GnRH receptor band detected is indicated with a large arrow and its
approximate size in KDa. The phosphorylation status of the GnRH receptor does not change
considerably over a 60 minute time interval.
Figure S6. GnRH I elicits robust SHP-2 activation in COS-7 cells. COS-7 cells were transfected
with the wildtype GnRH receptor (see materials and methods in chapter 2). Forty-eight hours
following transient transfection and overnight serum starvation, cells were treated with 100nM GnRH
I as indicated. Phosphorylated proteins were immunoprecipitated with the PY20 antibody and SHP-2
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GnRH receptors are expressed in the pituitary where they regulate reproduction by
signalling via Gq/11 proteins to enable the biosynthesis and release of LH and FSH
(Cheng and Leung, 2005; Pawson and McNeilly, 2005). In peripheral reproductive
cancer cells, ligand-induced activation of GnRH receptors exerts anti-proliferative
effects, which do not correlate with Gq/11 activation (Grundker and Emons, 2003;
Kraus et al., 2006; Limonta et al., 2003). We propose that different ligands stabilise
distinct receptor active conformations at the GnRH receptor, which have differential
capacity for activation of these downstream signalling pathways and have termed this
concept LiSS (Millar et al., 2004; Millar et al., 2008).
Several different types of experimental evidence can be used to support the existence
of LiSS at the GnRH receptor. Firstly, evidence supporting the ability of different
ligands to stabilise different receptor active conformations are consistent with LiSS
at the receptor. Furthermore, showing that different GnRH receptor conformations
(induced by ligands or receptor mutations) have differential capacity for activation of
downstream signalling pathways can also be used as evidence to support LiSS at the
GnRH receptor. In this dissertation, several types of experimental support for LiSS at
the GnRH receptor were presented.
In chapter 2, I investigated the ligand-receptor contacts and role of Tyr6.58 in
facilitating receptor activation in response to GnRH I and GnRH II. Previous reports
and our molecular model of GnRH I docked at the GnRH receptor suggested that
Tyr5 of GnRH I interacts with Tyr6.58 of the receptor, but this required experimental
validation. GnRH II differs from GnRH I at positions 5, 7 and 8 and has a His in
position 5. The importance of Tyr6.58 in GnRH II binding also required investigation.
My experimental results show that Tyr6.58Ala mutation induced large changes in
affinity for both GnRHs, but not the Ala5-substituted GnRHs, indicating that Tyr6.58
interacts with Tyr5 of GnRH I and His5 of GnRH II. The Tyr6.58Leu and Tyr6.58Gln
mutant receptors, which mimic the hydrophobic and H-bonding abilities of Tyr6.58
respectively, were unable to mediate comparable high affinity binding as observed at
the Tyr6.58Phe receptor. This emphasises the importance of the aromatic nature of
Tyr6.58 in the high affinity binding of GnRHs. Thus the results suggest that Tyr6.58










Chapter 5: Concluding discussion
176
importance in ligand binding, mutation of Tyr6.58 to Phe and Ala yielded GnRH-
induced signalling efficiencies of 82-144% and 23-46% respectively, indicating the
importance of the aromatic ring, but not OH group, in receptor activation. The
importance of Tyr6.58 in receptor activation suggests that this residue participates in
intramolecular interactions, in addition to the ligand-receptor contacts, that contribute
to the active receptor conformation.
Interestingly, despite the utilisation of Tyr6.58 by both GnRH I and GnRH II for
ligand binding and receptor activation, the results suggest that the mechanism differs.
Firstly, while GnRH I has similar affinity at the Tyr6.58Leu and Tyr6.58Ala receptors,
GnRH II has higher affinity for the Tyr6.58Leu receptor, indicating that the Leu side
chain at position 6.58 can make compensatory interactions with GnRH II, but not
GnRH I. This result is supported by our molecular models of GnRH I and GnRH II
docked at the GnRH receptor, which shows that position 5 of the decapeptides
interact with Tyr6.58 by aromatic interactions with distinct geometries. In the model
of GnRH I docked at the receptor, Tyr5 makes a T-shaped stacking interaction with
Tyr6.58, while His5 of GnRH II interacts with Tyr6.58 by a parallel offset stacking
interaction. This arrangement may thus facilitate the ability of the Tyr6.58Leu to
interact with His5 of GnRH II, but not with Tyr5 of GnRH I. Additionally, the
experimental results show that the Tyr6.58Leu receptor cannot mediate receptor
activation in response to GnRH I, despite a signalling efficiency of 23% at the
Tyr6.58Ala receptor. This difference is not due to decreased affinity, as the Leu and
Ala receptors have similar affinity for GnRH I. Thus this result suggests that
Tyr6.58Leu makes intramolecular interactions that prevent formation of the active
receptor conformation achieved by the Tyr6.58Ala receptor. In contrast, the Tyr6.58Leu
receptor has higher signalling efficiency (116%) in response to GnRH II than the
Tyr6.58Ala receptor (46%). This suggests that Tyr6.58Leu makes different
intramolecular interactions in the GnRH I- compared with the GnRH II-stabilised
active receptor conformations. This is also consistent with our molecular models,
which show that GnRH I and GnRH II interact with different rotamer conformations
of Tyr6.58, which thereby enables the formation of the aromatic interactions with
distinct geometries discussed above. Thus, together, these data support the proposal
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provide evidence that is consistent with LiSS at the GnRH receptor. Furthermore, the
results provide valuable verification of the accuracy of our molecular models, which
can be used to predict other ligand-receptor and receptor intramolecular interactions
that are useful in the understanding of LiSS.
In chapters 3 and 4, I wished to examine the ability of the GnRH receptor to signal to
differential downstream signalling pathways that mediate the anti-proliferative
signalling effects of the GnRH receptor and are distinct from Gq/11 activation. This
required identification of the most proximal signalling event that mediates the anti-
proliferative signalling effects of the GnRH receptor. Previous proposals have
suggested that the GnRH receptor mediates anti-proliferative signalling by coupling
to the alternative G protein, Gi. Thus, I established a series of [35S]GTPS binding
assays to determine GnRH receptor-Gi coupling. My results show that the GnRH
receptor is not able to activate Gi, even in a reconstituted environment of high
concentrations of the GnRH receptor and Gi proteins. In contrast, I have identified a
novel signalling partner of the GnRH receptor, the SH2 domain-containing
phosphatase 2 (SHP-2), which I propose is responsible for the anti-proliferative
signalling effects, by forming a direct interaction with the GnRH receptor. The
GnRH receptor-induced SHP-2 activation occurred in the presence of a Gq/11
inhibitor indicating that SHP-2 activation can be activated independently of Gq/11.
Furthermore, the results show that SHP-2 can be activated by the GnRH receptor in
response to a classical GnRH receptor antagonist at the Gq/11 signalling pathway.
Thus ligands that are antagonists at the Gq/11 signalling pathway, can act as agonists
at the SHP-2 pathway, suggesting that the two pathways are activated by distinct
receptor active conformations and providing further support for LiSS at the GnRH
receptor. Additionally, two GnRH mutants, the Tyr7.53Ala and the Asp7.49Ala
receptors, which are uncoupled at the Gq/11 signalling pathways, were able to mediate
activation of SHP-2. These residues are in the TM domains of the receptor and are
not proposed to make direct interactions with Gq/11 or SHP-2, but are rather required
to make intramolecular interactions that stabilise the active receptor conformations.
Thus the ability of these mutants to mediate differential signalling suggests that these
receptors are able to achieve an active receptor conformation that can activate SHP-
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conformations compared with the wildtype receptor is further supported by the
observation that the Tyr7.53Ala receptor exhibits constitutive activity at the SHP-2
signalling pathway, but is not constitutively active at the Gq/11 signalling pathway.
Together these results support the proposal that the GnRH receptor is able to adopt
multiple distinct receptor active conformations (stabilised by different ligands or
induced by receptor mutations) that have differential capacity for activation of
downstream signalling pathways.
The results presented here provide convincing evidence to support LiSS at the GnRH
receptor. Furthermore, I have identified a novel signalling pathway, involving
activation of SHP-2, which is activated independently of Gq/11. Delineation of the
molecular mechanisms governing LiSS and the signalling proteins activated
independently of each other at the GnRH receptor provides valuable information for
the development of therapeutics designed to specifically activate desired signalling
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